



LUND UNIVERSITY

THE ROLE OF BMP SIGNALING AND ENDOGLIN IN REGULATION OF HEMATOPOIESIS

Singbrant, Sofie

2009

[Link to publication](#)

Citation for published version (APA):

Singbrant, S. (2009). *THE ROLE OF BMP SIGNALING AND ENDOGLIN IN REGULATION OF HEMATOPOIESIS*. [Doctoral Thesis (compilation), Division of Molecular Medicine and Gene Therapy]. Department of Molecular Medicine and Gene Therapy, Lund University.

Total number of authors:

1

General rights

Unless other specific re-use rights are stated the following general rights apply:

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Read more about Creative commons licenses: <https://creativecommons.org/licenses/>

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

LUND UNIVERSITY

PO Box 117
221 00 Lund
+46 46-222 00 00

THE ROLE OF BMP SIGNALING AND ENDOGLIN IN REGULATION OF HEMATOPOIESIS

SOFIE SINGBRANT SÖDERBERG

Department of Molecular Medicine and Gene Therapy
Institute for Laboratory Medicine
Faculty of Medicine, Lund University

With the approval of the Lund University Faculty of Medicine, this thesis
will be defended on February 26, 2009, at 9.00 in the Segerfalk lecture hall,
Wallenberg Neurocentrum, Sölvegatan 17, Lund.

Supervisor: Professor Stefan Karlsson

Faculty Opponent:
Professor Frank JP Staal
Department of Immunology
Erasmus University Medical Center
Rotterdam, The Netherlands



LUND

Organization LUND UNIVERSITY Department of Molecular Medicine and Gene Therapy Institute for Laboratory Medicine		Document name DOCTORAL DISSERTATION	
		Date of issue 26th of February 2009	
Author(s) Sofie Singbrant Söderberg		Sponsoring organization	
Title and subtitle THE ROLE OF BMP SIGNALING AND ENDOGLIN IN REGULATION OF HEMATOPOIESIS			
Abstract Hematopoiesis, the formation of blood cells, ultimately depends on a rare population of hematopoietic stem cells (HSCs), which can both self-renew to maintain the HSC pool, and differentiate into all mature blood lineages. HSC fate decisions are governed by a complex combination of numerous signals, although the molecular mechanisms are not fully understood. This thesis describes the role of two important regulatory candidates, Bone Morphogenetic Proteins (BMP) and Endoglin in adult hematopoiesis. Several publications have described the importance of BMP signaling in specification of hematopoietic tissue in developing embryos. In Article I and II, we investigate the full role of BMP signaling in adult mice, using single and double Cre-based conditional knockout mice for the BMP signaling mediators Smad1 and Smad5. We demonstrate that BMP signaling deficient bone marrow (BM) competes normally with wild-type cells and display unperturbed self-renewal and differentiation capacity when transplanted into lethally irradiated recipients. Thus, despite its crucial role in initial patterning of hematopoiesis, BMP signaling is not required to maintain adult hematopoiesis. Endoglin is a TGF- β accessory receptor recently demonstrated to identify functional long-term HSCs, although little is known regarding its function in these cells. We have investigated the role of endoglin in hematopoiesis by both knocking down, and over-expressing its levels using viral vectors. Interestingly, our study suggests a pivotal role for endoglin in adult erythropoietic development. However, transplantation of transduced BM stem and progenitor cells reveals that neither endoglin suppression nor over-expression affects the ability of HSCs to long-term repopulate recipient marrow.			
Key words: Smad-signaling, BMP, Endoglin, Hematopoiesis, Hematopoietic Stem Cell, Conditional Knockout, Viral-mediated gene expression			
Classification system and/or index terms (if any):			
Supplementary bibliographical information:		Language English	
ISSN and key title: 1652-8220		ISBN 978-91-86253-02-8	
Recipient's notes	Number of pages 162	Price	
	Security classification		

Distribution by (name and address)

I, the undersigned, being the copyright owner of the abstract of the above-mentioned dissertation, hereby grant to all reference sources permission to publish and disseminate the abstract of the above-mentioned dissertation.

 Signature 

Date 19th of January 2009

"Knowledge is proud that he has learned so much
Wisdom is humble that he knows no more"
William Cowper

© Sofie Singbrant Söderberg

ISSN 1652-8220

ISBN 978-91-86253-02-8

Lund University, Faculty of Medicine Doctoral Dissertation Series 2009:15

Printed by: Media-Tryck, Lund 2009

TABLE OF CONTENTS

LIST OF PUBLICATIONS	7
ABBREVIATIONS	9
SVENSK SAMMANFATTNING	13
PREFACE	15
BACKGROUND TO THIS THESIS	17
HEMATOPOIESIS	17
The Function of the Blood & Immune System	17
The Hematopoietic Hierarchy	18
The Discovery of Hematopoietic Stem Cells	21
Identification of Hematopoietic Stem & Progenitor Cells	21
Fate Options	22
Regulation of Hematopoietic Stem Cells	24
i) Intrinsic Factors	25
ii) Extrinsic Factors	28
The Hematopoietic Stem Cell Niche	33
Engraftment & Homing To the Niche	34
DEVELOPMENT OF THE HEMATOPOIETIC SYSTEM	37
CLINICAL USE OF HEMATOPOIETIC STEM CELLS	40
Bone Marrow Transplantations	40
Gene Therapy	40
Cell Sources	41
ASSAYS & METHODS	43
Functional Biological Assays Evaluating HSCs	43
Assays Evaluating Committed Progenitors	44
MOLECULAR BIOLOGY OF TGF-β SIGNALING	46
Ligands, Receptors & Smads	46
Target Gene Selection & Transcriptional Control	47
Features of the Smad Proteins	50
Smad-dependent & Smad-independent Signaling Crosstalk	50
THE ROLE OF THE TGF-β FAMILY SIGNALING IN HEMATOPOIESIS AND DISEASE	52
TGF- β	52

Activins	56
BMP	56
Endoglin	59
<u>SPECIFIC AIMS OF THIS THESIS</u>	61
<u>SUMMARY OF RESULTS</u>	63
ARTICLE I	63
ARTICLE II	64
ARTICLE III	65
<u>GENERAL DISCUSSION</u>	67
LOSS OF FUNCTION	67
Conditional Knockout Mice	67
shRNA	68
GAIN OF FUNCTION	69
Retroviral Over-expression	69
REDUNDANCY IN THE SMAD SIGNALING PATHWAY	70
ONTOGENIC DIFFERENCES	71
BMP SIGNALING IN THE COLON	72
ENDOGLIN IN HEMATOPOIESIS	74
<u>CONCLUSIONS</u>	77
<u>FUTURE DIRECTIONS</u>	79
Double Knockout for Smad1 and Smad5 in Fetal Liver Hematopoiesis	79
The Role of BMP Signaling in Human Cord Blood Hematopoiesis	79
Interactions Between BMP Signaling and Other Regulatory Pathways	80
Complete Knockout of Endoglin	81
<u>PUBLICATIONS NOT INCLUDED IN THE THESIS</u>	83
<u>ACKNOWLEDGEMENTS</u>	85
<u>REFERENCES</u>	89

LIST OF PUBLICATIONS

- Article I** **Smad5 is dispensable for adult murine hematopoiesis.** Singbrant S, Moody J.L, Blank U, Karlsson G, Zwijsen A, Umans L, Karlsson S. *Blood* 108(12): 3707-12 (2006)
- Article II** **BMP signaling is essential to preserve colon architecture, but is dispensable for hematopoietic stem cell function in adult mice.** Singbrant S, Karlsson G, Ehinger M, Jaako P, Zwijsen A, Stadtfeld M, Graf T, Karlsson S. *Manuscript* (2008)
- Article III** **Endoglin is not critical for hematopoietic stem cell engraftment and reconstitution but regulates adult erythroid development.** Moody J.L, Singbrant S, Karlsson G, Blank U, Aspling M, Flygare J, Bryder D, Karlsson S. *Stem Cells* 25(11): 2809-19 (2007)

ABBREVIATIONS

5-FU	5-fluorouracil
ActRII	Activin receptor II
AGM	aorta-gonad-mesonephros
ALK	activin receptor-like kinase
AML	acute myeloid leukemia
Angptl	angiopoietin-like
BAMBI	BMP Activin receptor membrane bound inhibitor
BFU-E	burst forming unit-erythroid
BM	bone marrow
BMP	bone morphogenetic protein
BMPRII	BMP receptor II
BMT	bone marrow transplantation
CB	cord blood
CDKI	cyclin-dependent kinase inhibitor
cDNA	coding DNA
CFU-E	colony-forming unit-erythroid
CFU-GM	colony-forming unit-granulocyte-macrophage
CFU-S	colony-forming unit-spleen
CLP	common lymphoid progenitor
CMP	fluorescence-activated cell sorting
CRU	competitive repopulating unit
DNA	deoxyribonucleic acid
E	embryonic day
ECM	extra-cellular matrix
EMT	epithelial to mesenchymal transition
ESC	embryonic stem cell
FACS	fluorescence-activated cell sorting
FGF	fibroblast growth factor
Floxed	flanked by loxP
G-CSF	granulocyte colony-stimulating factor

GDF	growth and differentiation factor
GFP	green fluorescent protein
GM-CSF	granulocyte macrophage colony-stimulating factor
GVHD	graft-versus-host disease
GVL	graft-versus-leukemia
HA	hyaluronic acid
HLA	human leukocyte antigen
HOX	homeobox
HSC	hematopoietic stem cell
IL	interleukin
iPS	induced pluripotency
I-Smad	inhibitory Smad
KD	knock-down
LMPP	lymphoid primed multipotent progenitor
LSK	lineage- Sca-1 ⁺ c-kit ⁺
LTC-IC	long-term culture initiating cell
LT-HSC	long-term HSC
MAD	mothers against decapentaplegic
MAPK	mitogen-activated protein kinase
MBP	mobilized peripheral blood
MFI	mean fluorescent intensity
MH	mad homology
MIG	MSCV-IRES-GFP
MIS	muellerian inhibiting substance
MPP	multipotent progenitor
mRNA	messenger RNA
MSCV	murine stem cell based vector
NK-cell	natural killer-cell
NOD/SCID	non-obese diabetic/SCID
NOG	NOD/SCID/C γ null
OPN	osteopontin
PB	peripheral blood
PCR	poly chain reaction

PI3K	phosphatidylinositol-3-kinase
pSP	para-aortic splancholeura
Rb	retinoblastoma protein
RNA	ribonucleic acid
RNAi	RNA interference
R-Smad	receptor-regulated Smad
RU	repopulating unit
SARA	smad anchor for receptor activation
SBE	smad binding element
SCF	stem cell factor (Kit ligand)
SCID	severe combined immunodeficiency
SCL	stem cell leukemia
SCNT	somatic cell nuclear transfer
SDF	stromal cell derived factor
Shh	sonic hedgehog
shRNA	short hairpin RNA
SIN	self-inactivating
siRNA	small interfering RNA
Smad	the mammalian version of MAD
Smurf	smad ubiquitination-related factor
SP	side population
SRC	SCID repopulating cell
ST-HSC	short-term HSC
T β RII	TGF- β receptor II
TGF- β	transforming growth factor- β
TIF	transcriptional intermediary factor
TNF- α	tumor necrosis factor- α
TPO	thrombopoietin
VCAM	vascular cell adhesion molecule
VEGF	vascular endothelial growth factor
VLA	very late antigen
wt	wild-type
QRT-PCR	quantitative reverse transcriptase PCR

SVENSK SAMMANFATTNING

Blodet innehåller flera olika sorters celler som har till uppgift att förse kroppen med syre (röda blodkroppar), levera blodet för att förhindra att vi förblöder vid skada (blodplättar), och skydda oss mot bakterier och virus (vita blodkroppar som utgör immunförsvaret). Dessa celler är kortlivade, och varje dag genom hela livet byts 1 trillion blodceller ut. Denna process kallas blodbildning eller hematopoes, och är beroende av ett litet antal blodstamceller som finns i benmärgen. Blodstamceller kan per definition både ge upphov till nya stamceller för att säkerställa en stamcellpool som varar livet ut, och dessutom bilda alla typer av celler som finns i blodet, och därmed bilda ett helt nytt blodsystem (**Figur 1-2**). Denna process kräver noggrann reglering för att inte livshotande sjukdomar som t.ex. leukemi skall utvecklas. För att öka förståelsen för mekanismerna bakom dessa cellers reglering har jag under min doktorandtid studerat proteiner involverade i signalering som styr blodstamcellerna.

Leukemi, eller blodcancer, behandlas idag framgångsrikt genom att ta bort patientens sjuka blodsystem med cellgifter och/eller strålning, och sedan transplantera patienten med friska blodstamceller. Dessa celler hittar sin väg tillbaka till benmärgen, varifrån de bygger upp ett nytt blodsystem med kapacitet att generera nya blodceller livet ut. Många viktiga kontrollsysteem i kroppen är väl bevarade mellan olika arter. Därför studerar man ofta funktionen av proteiner som man tror är viktiga för olika organfunktioner eller sjukdomsbilder i djurmodeller, t.ex. i möss. Det mest noggranna och rättvisande sättet att studera funktionen av ett protein är att ta bort genen som kodar för det specifika proteinet och se vad som händer. Detta är tekniskt möjligt att göra i så kallade "knockout-möss", där möss saknar en eller flera gener som man vill studera. Ett problem med den här tekniken är att många gener är livsnödvändiga under fosterutvecklingen, och alltså gör det svårt att studera funktionen av dessa proteiner i vuxna möss. Det finns dock inducerbara "knockout-möss" som inte saknar genen, utan har den "inom parentes". Forskaren kan sedan själv bestämma när, och i vilken typ av celler, genen "inom parentes" ska tas bort. Andra sätt är att över- eller underuttrycka en gen i celler utanför kroppen (*ex vivo*) med hjälp av virala vektorer (baserade på virus som kan ta sig in i arvsmassan). I den här avhandlingen har samtliga metoder använts.

Denna avhandling är baserad på tre studier där vi undersöker rollen av två viktiga kandidater för reglering av vuxen blodbildning, **BMP** och **Endoglin**, vilka båda är medlemmar av TGF- β -familjen. TGF- β -familjen

består av flera olika tillväxtfaktorer som t.ex. TGF- β och BMP, vilka reglerar en mängd viktiga funktioner i kroppen, bl.a. blodbildning. Då flera av dessa faktorer är viktiga under fosterutvecklingen, dör knockout-mössen innan födseln om de saknas. Därför är kunskapen om deras funktion ofta baserad på experiment utförda i väldigt tidig fosterutveckling, eller i en konstgjord laboriemiljö (*in vitro*), vilket ofta inte speglar deras faktiska roll i en levande organism (*in vivo*). Ett stort antal artiklar har beskrivit vikten av fungerande BMP-signaler för att blod ska bildas under tidig fosterutveckling (**Figur 9**), medan väldigt lite är känt om dess roll i ett befintligt blodsystem. Vi har använt oss av inducerbara knockout-möss och slagit ut hela BMP-signalvägen i blodstamceller genom att ta bort generna som kodar för Smad1 och Smad5, vilket avbryter BMP-signalernas väg från cellens yta till cellkärnan (**Figur 7**). För att studera blodbildning transplanterades sedan dessa modifierade blodceller till möss, som genom strålningsbehandling mist sina egna funktionella blodstamceller. Våra resultat avslöjar att blodstamceller som saknar BMP-signaler ändå kan bilda ett nytt fungerande blodsystem innehållande alla typer av blodceller (**Artikel I och II**). Detta antyder att BMP-signaler inte är viktigt för vuxen blodbildning, även om det spelar en livsavgörande roll för uppkomsten av blod i det utvecklande embryot.

Endoglin är en hjälpreceptor till TGF- β som finns uttryckt på blodstamcellernas yta, och kan användas för att identifiera dessa väldigt ovanliga celler. Endoglin fyller en viktig funktion vid bildandet av blodkärl, men dess roll för reglering av blodstamceller har tills nu varit okänd. Vi har studerat detta genom att både öka och minska mängden Endoglin som finns på ytan av blodstamcellerna med hjälp av virala vektorer. I **Artikel III** visar vi att mängden Endoglin är viktig för bildandet av röda blodkroppar. Däremot påverkades inte blodstamcellernas förmåga att nybilda ett fullt fungerande blodsystem av vare sig upp- eller nedreglering av Endoglin.

Sammantaget har våra studier bidragit till ökad förståelsen för hur blodstamceller regleras. Resultaten är av klinisk relevans då lämpliga donatorer av friska stamceller för transplantation är en bristvara, och mycket av dagens forskning strävar efter att lära sig kontrollera dessa celler för att förbättra möjligheten att behandla fler patienter och fler typer av sjukdomar.

PREFACE

Stem cells are undifferentiated cells defined by their ability to both self-renew and differentiate to produce mature progeny. The most primitive form is the *embryonic stem cell* (ESC) that is derived from the very early blastocyst stage of a developing embryo. ESCs are pluripotent, hence can give rise to all of the specialized embryonic tissues. Additionally, there are adult stem cells, or *tissue specific stem cells*. These are multipotent, and act as a repair system for the body, replenishing specialized cells within a certain type of tissue, and maintain normal turnover of regenerative organs such as blood, skin or intestinal tissues.

Hematopoietic stem cells (HSCs), or blood stem cells, are by far the best characterized multipotent stem cells, in part owing to that they are relatively easy to access where they reside in the bone marrow (BM). More importantly, the existence of primitive hematopoietic multipotent progenitor cells was discovered almost half a century ago (Till and McCulloch, 1961) allowing for immense progress in isolation of these cells, as well as development of assays to characterize them. However, although much is known, the exact mechanisms that govern HSC fate still remain elusive. This thesis describes the role of the two important regulatory candidates ***Bone Morphogenetic Protein (BMP) signaling*** and ***Endoglin*** in adult hematopoiesis.

BACKGROUND TO THIS THESIS

HEMATOPOIESIS

The word hematopoiesis means formation of blood, and stems from the ancient Greek words “haima” meaning blood, and “poiesis”, which means to make. The blood system is a highly complex tissue that is constantly renewed and adapted to face the surrounding demands. Around 1 trillion (10^{12}) new blood cells are made in the human body every day throughout life under steady state conditions (Ogawa, 1993). Under stressed situations, such as massive bleeding, the production of blood cells is even higher.

The Function of the Blood & Immune System

The blood consists of several different cell types, all with specific functions (reviewed in (Orkin, 2000)). Most frequent are the *red blood cells*, or erythrocytes, which transport oxygen from the lungs to the rest of the body. *Platelets*, or thrombocytes, are derived from giant megakaryocytes residing in the BM. One megakaryocyte can give rise to thousands of platelets, which migrate into the blood stream and in cooperation with a number of coagulation factors form blood clots to prevent bleeding at sites of injury. The remaining blood cells are *white blood cells*, or leukocytes, which compose the immune system defending the body against invading bacteria, virus, parasites and fungi, as well as cancer cells.

The immune system can be divided into innate immunity and adaptive immunity. *Innate immunity* is referred to as the first line of host defense, and is mediated by phagocytes including *macrophages* derived from monocytes, *granulocytes* (neutrophils, eosinophils, basophils/mast cells), and *dendritic cells* (Akira et al., 2006). This first response to invading pathogens is fairly non-specific, and the innate immune system is primarily able to discriminate between self-antigens and a variety of pathogens by recognizing a limited number of microbial components. Phagocytes ingest and degrade pathogens and subsequently present antigens from the foreign microorganism on their surface, thereby activating the adaptive immune system. Macrophages also release cytokines and chemokines that further stimulate other cells of the immune system. *Natural killer (NK)-cells* do not phagocytose, but rather lyse susceptible targets by releasing enzyme-containing granules, and play an important role in tumor immune-surveillance and in combating infections. Like macrophages, NK-cells also produce substances to recruit and amplify the inflammatory response (Di

Santo, 2006). *Adaptive immunity*, described as the second line of defense, consist of the lymphoid *B- and T-cells*, and is involved in the late phase elimination of pathogens (Germain, 2001). The adaptive immunity is highly specific due to clonal selection from an immense range of lymphocytes bearing antigen-specific receptors. When B- and T-cells are activated by antigen presenting cells they rearrange their antigen receptor genes, and mature into effector cells producing antibodies and inflammatory cytokines respectively. Most lymphocytes generated in response to infection die, but some remain through out life and generate an immunological memory, which enable a fast response the second time a microorganism invade the body.

The Hematopoietic Hierarchy

The majority of the mature effector cells described above are non-dividing and have a limited life span ranging from days to months, with the exception of memory B- and T-cells. It is therefore crucial to have a continuous production of new blood cells. Ultimately, life long renewal of the blood system is maintained by a rare population of *HSCs*, which reside primarily in the BM of adult mammals. The HSC can per definition both self-renew, and thereby maintain the stem cell pool, as well as differentiate into all mature lineages of the hematopoietic system. In between the primitive HSC and the large numbers of mature blood cells, exist several maturation stages of increasingly lineage-restricted progenitors with concurrent decreasing self-renewal capacity. The hematopoietic system is therefore often described as a hierarchical structure depicted in **Figure 1** (further discussed under “Identification of hematopoietic stem and progenitor cells”). What was initially thought to be the HSCs population (Spangrude et al., 1988) has today been further subdivided into long-term HSCs (LT-HSC), short-term repopulating HSCs (ST-HSC) and multipotent progenitors (MPP) (Morrison et al., 1997a), where LT-HSC are the only true stem cells able to give rise to an infinite functional blood system. ST-HSCs can give rise to all mature lineages, but have a diminished ability to self-renew and can therefore only reconstitute transiently (Yang et al., 2005). Further downstream follow oligo-potent progenitors dividing into a lymphoid branch (common lymphoid progenitor; CLP) (Kondo et al., 1997)) and a myeloid branch (common myeloid progenitor; CMP) (Akashi et al., 2000)). CLPs can differentiate into mature B-cells, T-cells and NK-cells, while CMP give rise to monocytes/macrophages, granulocytes, megacaryocytes/platelets, and erythrocytes. Dendritic cells have been reported to derive from both CLPs and CMPs (Manz et al., 2001). However,

the branching point between the myeloid and lymphoid restricted cell populations remains controversial (Adolfsson et al., 2005; Pronk et al., 2007; Reya et al., 2001). Adolfsson et al. recently presented evidence for an adult BM progenitor population termed LMPP for lymphoid primed multipotent progenitor. In contrast to the classical MPP, LMPPs display sustained lympho-myeloid differentiation potential, but lacks the ability to become erythroid and megakaryocytic cells (Adolfsson et al., 2005), and hence challenges the classical hematopoietic hierarchy (Kondo et al., 1997).

Interestingly, Enver and colleagues have shown that single multipotent hematopoietic cells co-express genes normally found at high levels in mature progenitors, such as the erythroid β -globin gene and the myeloid gene myeloperoxidase (Hu et al., 1997). Commitment of HSCs and progenitor cells to a certain lineage, so called “lineage priming”, is therefore believed to occur by stepwise extinction of all but one lineage-specific transcriptional program from an initial co-existence of several transcriptional programs. However, gene expression programs of lymphocytes does not seem to be represented in HSCs (Miyamoto et al., 2002), suggesting that HSCs have to go uphill to become lymphoid.




Figure 1: The hematopoietic hierarchy. The hematopoietic system is often described as a hierarchical structure with a few primitive HSCs at the top, followed by several maturation stages of increasingly lineage-restricted progenitors with concurrent decreasing self-renewal capacity (marked by the curved arrow), and large numbers of mature blood cells at the bottom. The primitive LSK compartment (Lineage⁻ Sca1⁺ c-Kit⁺) can be further subdivided into long-term HSCs (LT-HSC), short-term repopulating HSCs (ST-HSC) and multipotent progenitors (MPP), where LT-HSC are the only true stem cells. Further downstream follow oligo-potent progenitors dividing into a lymphoid branch (common lymphoid progenitor; CLP) and a myeloid branch (common myeloid progenitor; CMP), although this branching point is debated. CMPs are subsequently restricted towards a Granulocytic/Macrophage fate (GMP) or a Megakaryocytic/Erythroid fate (MEP). Modified from a figure by Dr. Ann Brun with permission.

The Discovery of Hematopoietic Stem Cells

In the late 1950s, it was shown that BM contains cells capable of rescuing hematopoiesis in lethally irradiated mice (Ford et al., 1956). Soon BM transplantation was also applied in the clinic as treatment for leukemia (Thomas et al., 1959), which was rewarded with the Nobel Prize in 1990. However, it was in 1961 that Till and McCulloch first demonstrated a functional definition of HSCs (Till and McCulloch, 1961). When transplanting BM into lethally irradiated mice, they discovered that a proportion of the injected BM gave rise to macroscopic colonies in the recipient spleens. These so-called colony-forming units spleen (CFU-S) were found to contain cells of multiple blood lineages (Till and McCulloch, 1961). A subset of cells derived from CFU-S also resulted in new CFU-S when transplanted into secondary recipients, thereby displaying self-renewal capacity (Siminovitch et al., 1963). By introducing chromosome aberrations through irradiation of the BM giving rise to CFU-S, subsequent experiments established that every CFU-S originated from one cell, and were hence clonal (Becker et al., 1963; Wu et al., 1968). Although later studies demonstrated that CFU-S are not actual LT-HSCs, but rather primitive multipotent progenitors (Magli et al., 1982), these ground breaking experiments defined the properties of stem cells that are still valid today: 1) self-renewal capacity, 2) multi-lineage differentiation potential, and 3) extensive proliferation ability. HSCs have been demonstrated to maintain stem cell function through multiple serial transplantations (Harrison et al., 1978).

Identification of Hematopoietic Stem & Progenitor Cells

HSCs cannot be selected for by morphology or *in vitro* culturing conditions. Isolation of these primitive cells therefore rely on the expression of specific cell-surface antigens, which can be identified by staining with a combination of specific monoclonal antibodies conjugated to fluorescent markers, and subsequent detection by fluorescence-activated cell-sorting (FACS). Technical advances have recently made it possible to identify, or at least isolate populations highly enriched for various stages of maturation. All HSC activity is found within the cell population negative for mature lineage markers, and positive for Sca-1 and c-kit (LSK), which constitute approximately 0.1% of total BM cells (Ikuta and Weissman, 1992; Okada et al., 1992; Okada et al., 1991; Spangrude et al., 1988). However, only a fraction of this infrequent LSK population comprises true LT-HSCs, which can be further identified by the use of additional surface markers. LT-HSCs are found to also express low levels of Thy1/CD90 (Spangrude et al., 1988),

be negative for CD34 (Osawa et al., 1996) and Flt3/Flk2 (Adolfsson et al., 2001), and positive for the SLAM family receptor CD150 (Kiel et al., 2005). Another marker defining LT-HSCs is *Endoglin* (Chen et al., 2002) (further discussed under “The Role of the TGF- β Family Signaling in Hematopoiesis and Disease” and **Article III**). Furthermore, HSCs can be isolated by their ability to efficiently efflux Hoechst 33342 dye, and form a small and distinct subset referred to as the side population (SP) when Hoechst fluorescence is analyzed at two emission wavelengths simultaneously (Goodell et al., 1996). Although human stem and progenitor cells are not as well characterized as the murine HSCs, human HSCs have been demonstrated to be comprised within the lineage⁻ CD34⁺CD38⁻CD90/Thy1⁺ population of both BM and cord blood (CB) (Majeti et al., 2007).

It should be kept in mind that some of these HSC-enriching surface markers change with cell cycle status, and can therefore not be used for a certain period of time after transplantation or other stress situations. One example is the expression of CD34, which is reversibly increased upon activation of HSCs (Ogawa, 2002). Furthermore, LT-HSCs down-regulate c-kit and up-regulate Mac-1 expression after 5-fluorouracil (5-FU) treatment, making it hard to distinguish them from more differentiated progenitors (Randall and Weissman, 1997). Additionally, the expression of Endoglin, Mpl and Tie-2 is down-regulated upon culturing of LT-HSCs, although this difference in cell surface phenotype did not significantly alter their repopulation ability (Zhang and Lodish, 2005). However, the SLAM family receptors are conserved both in old, reconstituted and cytokine-mobilized cells (Yilmaz et al., 2006a).

Fate Options

The indefinite contribution of HSCs to the hematopoietic system is partly attributed to their ability to remain *quiescent*, demonstrated by that HSCs are spared after treatment with cytotoxic drugs, which selectively depletes proliferating cells (Lerner and Harrison, 1990). However, studies have shown that 3-5% of LT-HSCs are found in active cell cycle (S/G2/M phase) at any given time (Cheshier et al., 1999; Morrison and Weissman, 1994), and virtually all HSCs have cycled within 30 days, as shown by BrdU incorporation (Bradford et al., 1997; Cheshier et al., 1999). This demonstrates that HSCs divide regularly rather than remaining quiescent for long periods of time. However, in a very recent study Wilson et al. demonstrate the existence of a very rare population of HSCs in mice, so-called dormant HSCs, that only divide about every 145 days, as measured

by BrdU retention in vivo and computational modeling (Wilson et al., 2008). When a stem cell divides the daughter cells commit to one of several cell fate options (**Figure 2**). HSCs can per definition both *self-renew* to keep the stem cell pool intact, and also *differentiate* into all mature blood lineages to replenish the blood system upon demand. HSCs can also undergo *apoptosis* to regulate HSCs numbers. Additionally, the cells can either remain in the BM or *migrate* through the blood stream to distinct BM sites, or to extra-medullary hematopoietic organs. The importance of migration is especially clear during embryonic development (see “Development of the Hematopoietic System”). The regulation of these fate decisions is discussed in more detail below.

While *symmetric division* generates identical progeny, *asymmetric division* yields daughter cells with different fates, giving three possible scenarios: Asymmetric divisions resulting in maintenance (one HSC and one committed daughter cell), symmetric division giving rise to two HSCs, thereby leading to expansion, and symmetric division resulting in two committed daughter cells, which in the long run would result in exhaustion of the stem cell pool (**Figure 2**). Asymmetric division can depend on both intrinsic and extrinsic mechanisms, where intrinsic cues results in differential segregation of cell fate determinants along an axis of polarity, and subsequent orientation of the mitotic spindle along this axis. The other condition is that the two daughter cells following a symmetric division get positioned in diverse locations in the microenvironment, and hence get exposed to different extrinsic factors (Congdon and Reya, 2008; Morrison and Kimble, 2006).

The decision to self-renew or differentiate can be modeled as either a random *stochastic* process governed by intrinsic determinates that cannot be influenced, or an instructive *deterministic* process, in which exogenous cues influence the cell fate decision (reviewed in (Muller-Sieburg and Sieburg, 2006; Viswanathan and Zandstra, 2003)). Though early studies mainly support the stochastic model, an increasing body of evidence has demonstrated the important role of cytokines in fate determination. The controversy has therefore shifted to debate whether cytokines play an *instructive* role (determining the fate decision of a cell) or *permissive* role (allowing for a cell to commit to a predestined fate) (Kondo et al., 2000; Ogawa, 1993). It is likely that the initial divisions of HSC are stochastic to secure maintenance of the HSC pool also in substantial demand for one particular lineage, but that deterministic processes become increasingly important as the cells commit to a certain lineage, and have to respond to immediate changes in the microenvironment (Enver et al., 1998).




Figure 2: Fate options of HSCs. HSCs can except for remaining quiescent also (1) *self-renew* to keep the stem cell pool intact, (2) *differentiate* into all mature blood lineages to replenish the blood system upon demand, (3) undergo *apoptosis* to regulate HSCs numbers, and finally either remain in the BM or (4) *migrate* through the blood stream to distinct BM sites, or to extra-medullary hematopoietic organs.

Regulation of Hematopoietic Stem Cells

Because of the high turnover rate of blood cells it is absolutely crucial with functional homeostatic control mechanisms, assuring a proper balance between the different cell fate options to not develop hematological diseases like leukemia. Although the molecular mechanisms behind this regulation are not fully understood, it is well recognized that cell fate decisions depend on a complex combination of cell-intrinsic and cell-extrinsic signals (reviewed in (Akala and Clarke, 2006; Blank et al., 2008)) (**Figure 3**). The importance of these signals are underlined by the fact that deregulation of many of the factors implicated in HSC self-renewal also have been reported to promote tumorigenesis (Reya et al., 2001).

i) Intrinsic Factors

Transcription Factors

Transcription factors are sequence-specific DNA binding proteins that control the transcription of genetic information from DNA to RNA. The very early initiation of hematopoiesis during embryonic development is dependent on the transcription factor *stem cell leukemia (SCL)/tal1*. Homozygous deletion of SCL results in complete absence of yolk sac hematopoiesis, as determined by cultures of yolk sac cells from these mice (Robb et al., 1995). By over-expressing the SCL homolog in Zebrafish, it was later determined that SCL specifies the formation of the “hemangioblast”, the common precursor for the hematopoietic and endothelial lineages (Gering et al., 1998). Likewise, *acute myeloid leukemia (AML)1/Runx1*, which is the most frequent target of chromosomal rearrangement in human leukemias, is also critical for the generation of hematopoiesis in the embryo. Embryos deficient for AML1 display normal yolk sac derived erythropoiesis, but lack definitive hematopoiesis (Okuda et al., 1996). Although both SCL and AML1 have more recently been shown to be dispensable for adult HSC function when conditionally deleted in adult mice, they both remain important for proper differentiation of blood cells in adult hematopoiesis (Ichikawa et al., 2004; Kunisato et al., 2004; Mikkola et al., 2003). In contrast, the transcription factor *Tel/Etv6*, which is also frequently targeted in translocations in human leukemias (Golub et al., 1996), seems to be redundant in embryonic hematopoiesis but crucial for HSC function in adults. Whereas, *Tel* deficient embryos exhibit largely unperturbed blood formation (Wang et al., 1997), conditional deletion of the gene in adult mice results in almost complete HSC depletion, as determined by transplantation experiments (Hock et al., 2004b).

An additional set of transcription factors that are crucial for embryonic body patterning and organogenesis, are the *homeobox (Hox) genes*, many of which are highly expressed in HSCs and then down-regulated upon differentiation. Most extensively studied is *HoxB4*, which has been shown to greatly expand HSCs both *in vitro* and *in vivo* when over-expressed (Antonchuk et al., 2002; Miyake et al., 2006; Sauvageau et al., 1995). It was therefore surprising when it was shown that *HoxB4* is not required for the generation of HSCs or the maintenance of steady state hematopoiesis *in vivo*, using a conditional *HoxB4*-knockout mouse (Brun et al., 2004). This discrepancy can possibly be explained by compensatory mechanisms from related *Hox*-genes. To address this, a triple knockout of

HoxB3, HoxB4 and HoxA9 was created in our laboratory. Although triple knockout HSCs display a significantly reduced repopulative capacity, it was not more severe than the repopulation defect seen when HoxA9 was deleted alone (Lawrence et al., 2005), suggesting that that even though these transcription factors play a role in regulating HSCs, they are not absolutely essential for formation of all major blood lineages (Magnusson et al., 2007). Additionally, the Hox cofactor *Pbx1* has been implied in HSC regulation, as conditional inactivation of the gene results in progressive loss of LT-HSCs (Ficara et al., 2008). Interestingly, HoxB4-induced self-renewal of HSCs is accompanied by increased expression of another transcription factor, the proto-oncogene *c-Myc* (Sato et al., 2004). *c-Myc* is known to induce a number of target molecules involved in regulating cell cycle progression (Eilers et al., 1991), and has recently been reported to control the balance between HSC self-renewal and differentiation. Conditional deletion of *c-Myc* results in severe cytopenia of all blood lineages and accumulation of self-renewing HSCs in the BM due to failure to initiate differentiation (Wilson et al., 2004). This retention of HSCs in the niche might be explained by the concurrent increase in expression of stromal adhesion molecules (see “Adhesion Molecules”) (Wilson et al., 2004).

Yet another protein important for HSC maintenance is *Gfi-1*, a transcription factor previously implicated in regulation of lymphopoiesis. HSCs deficient in *Gfi1* display increased proliferation rates and are functionally compromised in their competitive repopulation ability in mice. Hence, *Gfi1* was shown to prevent exhaustion of HSCs by suppressing proliferation (Hock et al., 2004a; Zeng et al., 2004). Furthermore, a recent study demonstrates a pivotal role for the transcription factor *FoxO3a* in maintaining the HSC pool. Deletion of *FoxO3a* in mice was accompanied with impaired long-term reconstitution, elevated levels of reactive oxygen species and defective maintenance of quiescence, suggesting that *FoxO3* also plays a role in regulating stress resistance of HSCs (Miyamoto et al., 2007).

Epigenetic Factors

Bmi-1 is a transcriptional repressor from the Polycomb group of genes, which control gene silencing by epigenetic modifications including histone methylation and deacetylation. *Bmi-1* deficient mice display normal numbers of fetal liver HSCs while the number of HSCs in BM after birth is reduced, and when transplanted both fetal liver and BM HSCs possess only transient repopulative capacity (Park et al., 2003). Gene expression analysis revealed that *Bmi-1* target the cell cycle inhibitors p16 and p19 to allow

proliferation and inhibit apoptosis respectively (see below) (Oguro et al., 2006; Park et al., 2003). In agreement with the loss-of-function studies, over-expression of Bmi-1 enhances symmetric cell division and promotes HSC expansion (Iwama et al., 2004).

Cell Cycle Regulators

The cell cycle consists of the resting G0/G1 stage, and the actively dividing S/G2/M stage. Cyclin-dependent kinase inhibitors (CDKIs) are central components of the cell cycle control system, and serve as checkpoints restricting transition through the cycle, mainly during the G1-phase. CDKIs are composed of two families, the early acting Ink4 family with members like p15, p16, p18 and p19, and the late acting Cip/Kip family including p21, p27, and p57 (reviewed in (Cheng, 2004)). *p21* governs the cell cycle entry of stem cells. In the absence of p21 HSCs are more prone to proliferate under normal homeostatic conditions, but demonstrate impaired serial transplantation capacity and exhaustion under conditions of stress (Cheng et al., 2000b). The related *p27* does not affect HSC function or numbers on its own, but alters the proliferation of more mature hematopoietic progenitors, as assessed by colony-forming assays (Cheng et al., 2000a). However, concurrent deletion of p27 and the Myc-antagonist MAD1 results in an expanded pool of quiescent HSCs, which exhibit an enhanced proliferative response in conditions of stress (Walkley et al., 2005). In sharp contrast, HSCs deficient in the early acting p18 display improved long-term engraftment, largely by increased self-renewal divisions of the transplanted HSCs (Yu et al., 2006; Yuan et al., 2004). Early acting CDKIs interact with the retinoblastoma protein (*Rb*), which plays a central role in the regulation of the G1-S transition. It was therefore quite surprising when it was discovered that Rb is not intrinsically required for self-renewal and multi-lineage differentiation of adult HSCs (Walkley and Orkin, 2006).

Adaptor Proteins

Adaptor proteins are accessory to main proteins in a signal transduction pathway, and generally drive the formation of protein complexes. One example is *Pten*, a tumor suppressor that negatively regulates signaling through the phosphatidylinositol-3-kinase (PI3K)-Akt pathway, which is important in cell proliferation, differentiation and migration (Stiles et al., 2004). Conditional deletion of *Pten* leads to a transient expansion and subsequent depletion of the HSC pool, mainly due to increased HSC activation. Moreover, *Pten* deficient HSCs are unable to long-term

reconstitute recipients (Yilmaz et al., 2006b; Zhang et al., 2006b). Intriguingly, deletion of *Pten* also results in generation of transplantable leukemia, indicating different self-renewal mechanisms for maintenance of normal HSCs and leukemic stem cells (Yilmaz et al., 2006b).

Anti-apoptotic Proteins

A significant body of evidence suggests that suppression of apoptosis, a form of programmed cell death, is required for HSC maintenance. This is supported by studies using mice with modified expression of the apoptosis suppressing genes *Bcl2* and *Mcl-1*. Forced expression of *Bcl2* protects HSCs from several apoptotic stimuli such as growth factor deprivation and chemotherapeutic agents, and lead to increased numbers of HSCs in the BM (Domen et al., 2000; Domen and Weissman, 2003). Furthermore, these HSCs display a repopulative advantage compared to wt HSCs when transplanted in a competitive setting (Domen et al., 2000). In contrast, deletion experiments demonstrate that *Bcl2* is not essential for HSCs self-renewal, although critical for the formation of lymphoid development (Matsuzaki et al., 1997). The related *Mcl-1* gene is, however, required for HSC survival, as assessed by induced deletion of the gene and subsequent transplantation experiments (Opferman et al., 2005).

ii) Extrinsic Factors

Extrinsic cues consist of membrane-bound and secreted factors provided by cells and extra-cellular matrix (ECM) components of the surrounding microenvironment (further discussed under “The Hematopoietic Stem Cell Niche”), which promote HSC maintenance and regulate HSC migration, quiescence and differentiation.

Cytokines & Growth Factors

Cytokines are signaling molecules extensively involved in cellular communication, which are capable of stimulating or inhibiting cellular growth, proliferation and differentiation. Since finding means to efficiently expand HSCs *ex vivo* would be very beneficial for clinical purposes, there is a great search for the optimal combination of cytokines for HSC expansion. Although single or combinations of cytokines can promote a few rounds of self-renewing division, there is to this date no effective way to expand HSCs *ex vivo* ensuring that the expanded cells maintain their stem cell properties. The most commonly used cytokines for maintaining HSC viability in culture are different combinations of Stem Cell Factor (SCF),

Thrombopoietin (TPO) and Flt3 ligand (Ema et al., 2000; Goff et al., 1998; Miller and Eaves, 1997; Yagi et al., 1999). *SCF*, which is also known as Kit ligand or Steel factor, has repeatedly been shown to promote survival and proliferation of HSCs *in vitro* (Domen and Weissman, 2000; Li and Johnson, 1994). Furthermore, it was recently shown that the SCF receptor *c-Kit* regulates maintenance of HSC quiescence *in vivo*, as *c-Kit* mutants (*Kit*^{W41/W41}) have an almost two-fold reduction of long-term HSCs. Additionally, self-renewing *Kit*^{W41/W41} HSCs were progressively depleted when transplanted, suggesting a role for *c-Kit* in promoting HSC survival (Thoren et al., 2008). Similarly, deletion studies have demonstrated a vital and non-redundant role for *TPO* and its receptor *c-Mpl* in self-renewal and expansion of HSCs (Kaushansky, 2005; Kimura et al., 1998). BM cells from *c-Mpl* deficient mice generate almost ten-fold fewer spleen colonies than wt BM, and fail to long-term reconstitute irradiated recipients when transplanted in a competitive setting (Kimura et al., 1998). The importance of TPO in HSC regulation was further high-lighted when it was recently connected to *LNK*, a cytokine signaling inhibitor of several cytokine signaling pathways including TPO and SCF. *LNK*-deficient mice display increased numbers of HSCs, which additionally possess elevated self-renewal capacity (Ema et al., 2005). A phenotype that was later demonstrated to be TPO dependent (Buza-Vidas et al., 2006). The third growth factor commonly used when culturing HSCs *in vitro* is *Flt3 ligand*. It has, however, been shown that the receptor Flt3 is not expressed on long-term HSCs, and that up-regulation of Flt3 expression on murine primitive LSK cells is accompanied with loss of self-renewal capacity, suggesting that Flt3 ligand may not contribute to survival of the actual LT-HSCs *in vitro* (Adolfsson et al., 2001). These survival cytokines are often combined with Interleukins (IL) like IL-3, and IL-6, which promotes growth (Bryder and Jacobsen, 2000) (Audet et al., 2001). However, because the magnitude of expansion of HSCs *ex vivo* has been rather modest so far, additional strategies are needed.

Some promising factors and signaling pathways that have proven important for regulating HSC self-renewal include Fibroblast Growth Factor-1 (FGF1), Angiopoietin-like (Angptl) proteins, and Notch and Wnt signaling, which are reviewed below. De Haan et al. have demonstrated that prolonged cultures of BM cells in serum-free medium supplemented only with *FGF1* result in robust expansion of HSCs capable of multi-lineage long-term repopulation (de Haan et al., 2003). Intriguingly, Lodish and colleagues have established a further 24- to 30-fold net expansion of long-term HSCs, when HSCs were cultured with *Angptl* protein 2 or 3, in

combination with SCF, TPO, IFG2, and IGF1 for 10 days, as determined by reconstitution of irradiated mice (Zhang et al., 2006a). *Notch signaling* is highly active in HSCs and is down-regulated upon differentiation. Inhibition of Notch signaling in adult murine HSCs results in accelerated differentiation *in vitro* and depletion of HSCs *in vivo* (Duncan et al., 2005). Accordingly, enforced activation of Notch1 lead to decreased differentiation and enhanced self-renewal of HSCs *in vivo* (Stier et al., 2002). Notch signaling has also been reported to play an indirect role in HSC expansion via the niche. Constitutive activation of osteoblasts in transgenic mice results in increased numbers of osteoblasts, which display enhanced expression of the Notch-ligand Jagged1. This lead to increased self-renewal capacity of wt primitive hematopoietic cells, as measured by long-term culture initiating cell (LTC-IC) assay (Calvi et al., 2003). However, Notch1-deficient HSCs were later shown to be able to reconstitute mice with Jagged1-deficient BM stroma (Mancini et al., 2005), suggesting that Notch signaling through these molecules is dispensable for HSC function *in vivo*.

Wnt signaling is another pathway shown to be involved in HSC self-renewal (Staal and Clevers, 2005). Exposure of BM HSCs to purified Wnt3a protein was found to expand HSCs *in vitro*, while maintaining their ability to reconstitute recipients (Willert et al., 2003). In agreement, Wnt3a deficiency leads to a decrease in HSCs derived from fetal liver, and severely reduces their reconstitution capacity, as measured by secondary transplantation assays (Luis et al., 2008). Furthermore, constitutive activation of β -catenin, a down-stream component of Wnt signaling, results in expansion of HSCs *in vitro*, as well as increased reconstitution potential *in vivo* (Reya et al., 2003). Accordingly, enhanced degradation of β -catenin by the expression of Axin inhibits HSC growth *in vitro*, and reduces reconstitution *in vivo* (Reya et al., 2003). In sharp contrast, Cobas et al. show that conditional deletion of β -catenin in murine adult HSCs does not impair their ability to self-renew or reconstitute all hematopoietic lineages, even in a competitive setting (Cobas et al., 2004). Furthermore, another study reports that constitutive activation of Wnt signaling through conditional expression of a stable form of β -catenin, causes multi-lineage differentiation block and compromised HSC maintenance (Kirstetter et al., 2006). Thus, although Wnt may prove useful for *ex vivo* expansion of HSCs, the full role for Wnt signaling *in vivo* remains to be determined. Interestingly, Duncan et al showed that intact Notch signaling is required for Wnt-mediated maintenance of undifferentiated HSCs, but not for survival or entry into the cell cycle *in vitro* (Duncan et al., 2005). These data provide a model for how HSCs may integrate multiple signals to

maintain the stem cell state. This phenomenon has also been demonstrated for other HSC regulatory pathways. For example, stimulation with *Sonic hedgehog* (*Shh*) was shown to induce expansion of human CB HSCs *in vitro* in a Bone Morphogenetic Protein (BMP) dependent manner (Bhardwaj et al., 2001). In turn, **BMP signaling** plays a major role in the specification of hematopoiesis during embryonic development (Sadlon et al., 2004), and high concentration of BMP4 has also been shown to maintain human HSCs derived from CB in culture (Bhatia et al., 1999). However, we have now demonstrated that BMP signaling does not seem to be important in adult hematopoiesis (**Article I** and **Article II**), which will be discussed in greater detail later in this thesis.

Much less is known about *negative regulators*. Apart from Transforming Growth Factor- β (TGF- β), which will be further discussed under “The role of the TGF- β Signaling Family in Hematopoiesis”, Tumor Necrosis Factor- α (TNF- α), and Interferon- γ (IFN- γ) have been reported to negatively regulate hematopoietic stem and progenitor cells *in vitro* (Bryder et al., 2001; Sato et al., 1995).

Adhesion Molecules

Although the vast majority of HSCs reside in the BM, at any given moment a few HSCs can be found in the blood stream (Wright et al., 2001). The fate options to either remain quiescent in the BM, proliferate, or migrate out into the periphery are largely affected by expression of various adhesion molecules on cells surrounding the HSCs. This is a possible explanation why stromal cell environments can maintain HSCs in a primitive state better than combinations of soluble cytokines and growth factors *in vitro*. In response to BM injury HSCs migrate from the BM to the blood stream. This can also be induced by treatment with mobilizing agents like cyclophosphamide or granulocyte colony-stimulating factor (G-CSF) (reviewed in (Cottler-Fox et al., 2003)). Both scenarios involve the release of neutrophil proteases that degrade niche-retention signals and adhesive connection. Examples of adhesion molecules that are important for retaining HSCs in the niche are N-cadherins (Zhang et al., 2003), Angiopoietin-1 (Ang-1) exclusively found on osteoblasts and its receptor tyrosine kinase Tie2 expressed on HSCs (Arai et al., 2004), and Stromal cell Derived Factor SDF-1/CXCL12 and its receptor CXCR4 (Sugiyama et al., 2006), which will all be further discussed below. The cytoskeleton also plays a role in regulating migration and adhesion. *Rho GTPases* are critical regulators of actin assembly and motility in mammalian cells, and have also been shown to regulate adhesion and migration in a wide variety of hematopoietic cells.

Concurrent deletion of the Rho GTPase Rac1 and Rac2 leads to a massive egress of hematopoietic stem and progenitor cells to the blood from the BM niche (Gu et al., 2003), suggesting that Rac1 and Rac2 play essential roles in lodging and retention of HSCs in the niche.




Figure 3: Regulation of HSCs. HSC fate decisions depend on a complex combination of cell-intrinsic and cell-extrinsic signals.

The Hematopoietic Stem Cell Niche

The concept of a stem cell niche was first proposed by Schofield in 1978, who suggested that HSCs reside in a distinct three dimensional structure within a specific location in the BM (Schofield, 1978) (**Figure 4**). This specialized microenvironment has later been further localized to the *endosteal surface* of trabecular bone, which is lined with supporting stromal cells (Haylock et al., 2007; Nilsson et al., 1997; Nilsson et al., 2001; Zhang et al., 2003). Recent studies have demonstrated the importance of interactions between HSCs and osteoblasts at the endosteal surface (Arai et al., 2004; Calvi et al., 2003; Zhang et al., 2003), although other environmental cell types and ECM proteins also contribute to the niche. Osteoblasts can activate independent signaling pathways to either expand the HSC pool by producing hematopoietic growth factors like G-CSF and IL-6 (Taichman and Emerson, 1994; Taichman et al., 1997) and activate Notch-1 (Calvi et al., 2003) (see “Cytokines & Growth Factors), or promote HSC quiescence by expressing Ang-1 (Arai et al., 2004), activate PI3K/Akt-mediated regulation of p21 (Hirao et al., 2004), and express the glycoprotein osteopontin (OPN) (Nilsson et al., 2005) (further discussed below).

Recently, an increasing body of evidence shows that HSCs also reside adjacent to *sinusoidal blood vessels* in the BM (Kiel et al., 2005; Watchman et al., 2007), where perivascular cells secrete HSC maintaining factors like SDF1/CXCL12 and Ang-1 (Sacchetti et al., 2007; Sugiyama et al., 2006). In addition, endothelial cells can promote the maintenance of HSCs in culture (Ohneda et al., 1998). Furthermore, the BM is richly innervated with *sympathetic nerve fibers*, which terminate on perivascular stromal cells (Yamazaki and Allen, 1990). Although there is some controversy regarding the role for direct neural input in controlling hematopoiesis, several studies have shown that chemical and/or mechanical denervation of these nerves results in decreased femoral cellularity and increased mobilization of cells into the peripheral circulation, suggesting that BM innervation may play a role in regulating cellular retention in the HSC niche during steady state (Afan et al., 1997; Benestad et al., 1998; Maestroni, 1998; Miyan et al., 1998). Interestingly, a study using mice with defective adrenergic neurotransmission recently indicated that norepinephrine signaling controls G-CSF-induced osteoblast suppression, bone CXCL12 down-regulation, and mobilization of hematopoietic stem and progenitor cells, thus indicating that the sympathetic nervous system regulates the attraction of HSCs to their niche (Katayama et al., 2006).

The exact role of the endosteal versus the vascular niche remains elusive. One theory is that endosteal niche is more quiescent than the vascular niche, and that activated HSCs might be recruited to the vascular niche in response to injury (Wilson et al., 2007).

Engraftment & Homing To the Niche

The niche not only plays a regulatory role for HSC, but also influences the attraction, lodging, retention and release of the residing stem cells (Haylock and Nilsson, 2005; Lapidot et al., 2005). Some examples of critical players in the lodgment of HSCs to their niche are Hyaluronic acid (HA), OPN, and the membrane-bound form of cytokine SCF. *HA*, is a component of the ECM within the BM microenvironment, but is also expressed on both human and murine HSCs. Enzymatic removal of HA from HSCs prior to transplantation results in a significant alteration in spatial distribution of HSCs, demonstrating a critical role for HA in the lodgment of transplanted HSCs within the BM (Nilsson et al., 2003). The glycoprotein *OPN* is expressed by osteoblasts and plays a dual role in regulating HSCs in the endosteal niche. First it contributes to HSC trans-marrow migration towards the niche via interaction with $\beta 1$ -integrins on the HSCs cell surface. Within the niche OPN is subsequently involved in anchoring of HSCs to the osteoblasts (Haylock and Nilsson, 2006). Mice deficient in OPN display massively increased cycling, as determined by BrdU incorporation, and a concurrent two-fold increase in the number of HSCs (Nilsson et al., 2005). Additionally, the same effect was seen when wt HSCs were transplanted into OPN-deficient recipients, suggesting that the OPN production of osteoblasts regulates HSCs in a negative manner (Stier et al., 2005). Both HA and OPN bind to the cell surface glycoprotein CD44, which is expressed on HSCs (Wilson and Trumpp, 2006). The *membrane bound form of SCF* is expressed by osteoblasts, and has an increased capacity to activate c-Kit on the cell surface of HSCs as compared to the soluble form, thereby contributing to controlling HSCs in the niche (Driessen et al., 2003; Miyazawa et al., 1995).

A number of recent publications have discovered several important molecules involved in HSC migration to and localization in the BM. One such critical component is *N-cadherin*, which has been shown to anchor HSCs to the osteoblasts in the niche (Zhang et al., 2003). Supporting this, ectopic expression of N-cadherin by OP9 stromal cells significantly increased the ability to maintain murine HSCs *in vitro* (Arai et al., 2004). The latter study also demonstrated that interaction of *Tie2* found on HSCs with its ligand *Ang-1* produced by osteoblasts maintains long-term

repopulating activity of HSCs *in vivo*. Furthermore, Ang-1 enhances the ability of HSCs to become quiescent and induces adhesion to bone, resulting in protection of the HSC compartment from myelosuppressive stress. Together these data suggest that the Tie2/Ang-1 signaling pathway plays a critical role in the maintenance of HSCs in a quiescent state in the BM niche (Arai et al., 2004). Furthermore, *SDF-1/CXCL12* and its receptor *CXCR4* have been shown to regulate HSC migration to and localization in the BM (Petit et al., 2002). Another study demonstrated that most HSCs in the niche are found in close contact with reticular cells abundant in CXCL12 production (so-called CAR cells), which reside both surrounding sinusoidal endothelial cells and near the endosteum (Sugiyama et al., 2006). Induced deletion of CXCR4 lead to severe reduction in HSC numbers and increased sensitivity to myelotoxic drugs (Sugiyama et al., 2006). Additionally, CXCL12 plays a crucial role in colonization of the BM by HSCs during ontogeny (Ara et al., 2003). Other cell-surface adhesion molecules, like integrins, are also important in regulating HSC migration. Pretreatment with antibodies against either the $\beta 1$ -integrin Very Late Antigen (VLA) 4, or its ligand Vascular Cell Adhesion Molecule (VCAM) before transplantation both result in significantly reduced homing to the BM (Papayannopoulou et al., 1995). In addition administration of the same antibodies to normal mice causes mobilization of hematopoietic progenitors into the blood stream (Papayannopoulou et al., 1995), conclusively indicating a crucial role for the VLA4-VCAM interaction in retaining HSCs in their niche.

When HSCs are transplanted into the blood, they find their way back into the BM niche. Wright et al. elegantly demonstrated that transplanted cells are cleared from the blood within just minutes (Wright et al., 2001). About 0.1-1% of all HSC niches are open at any given time and available for HSC engraftment (Bhattacharya et al., 2006). However, in both experimental and clinical settings the absolute majority of recipients of bone marrow transplants (BMT) undergo a preconditioning myeloablative treatment with irradiation and/or cytotoxic drugs to obtain improved engraftment of the transplanted cells and suppress host immunity. Several groups have shown that long-term engraftment is dependent on that the transplanted cells remain quiescent (Bowie et al., 2006; Glimm et al., 2000; Passegue et al., 2005). Morrison et al. showed that mobilization of HSCs using cyclophosphamide and G-CSF drove both ST and LT multipotent progenitors into cycle. However, although an increased percentage of HSCs isolated from BM and spleen were cycling, HSCs released into the blood tended to be in G0/G1 (Morrison et al., 1997b). This is in agreement with

previous publications (Donahue et al., 1996; Roberts and Metcalf, 1995; Uchida et al., 1997). Nygren et al further stress the importance of quiescence for successful engraftment by showing that although fetal liver HSCs are expanding rapidly, they too display a prolonged G1 transit and passage through a state of relative G0 quiescence (Nygren et al., 2006). How efficiently single HSCs can engraft and long-term reconstitute a host is highly debated, and range between 21% and 96% depending on what cell population are used, and how much competition the single HSC is faced with (Benveniste et al., 2003; Camargo et al., 2006; Matsuzaki et al., 2004; Osawa et al., 1996).




Figure 4: The endosteal niche. HSCs reside in the BM in close contact with specialized osteoblasts, extra-cellular matrix (ECM) and other stromal cells. Depicted are a number of factors and adhesion molecules that influences the attraction, migration, and lodging to the niche, as well as retention or release of residing HSC.

DEVELOPMENT OF THE HEMATOPOIETIC SYSTEM

The hematopoietic system develops early during embryogenesis in a complex manner involving multiple anatomical sites (**Figure 5**). This shift in location during hematopoietic development is necessary since the embryo changes during organogenesis. Moreover, it might allow for different regulating signals from the various niches to support development of primitive HSCs in one site, while generating lineage-committed cells in other locations.

Hematopoietic tissue arises from the *mesoderm* germ layer, via a common mesodermal precursor for endothelial and hematopoietic lineages, the so-called “hemangioblast” (Dieterlen-Lievre, 1998). The first visible hematopoietic cells are the primitive erythrocytes, which are formed in close proximity to developing vasculature as blood islands in the extra-embryonic *yolk sac* between embryonic day (E)7 and E7.5 (Palis and Yoder, 2001; Sabin, 2002). Definitive erythroid progenitors arise in the yolk sac one day later, as determined by colony formation *in vitro* of primitive erythroid burst forming units (BFU-E), and the more mature erythroid colony forming units (CFU-E) (Palis and Yoder, 2001). Furthermore, progenitors of several myeloid lineages originate and expand in the yolk sac (Palis and Yoder, 2001), while progenitors with both lymphoid and myeloid potential are generated *de novo* from E7.5 in the para-aortic splanchnopleura (pSP) region (that later becomes aorta-gonad-mesonephros (AGM)) within the embryo proper, as determined by explant cultures (Cumano et al., 1996). Multiple studies have demonstrated that definitive HSCs originate from sites in the embryo proper (reviewed in (Dzierzak and Speck, 2008) and (Mikkola and Orkin, 2006)). HSCs able to engraft and confer long-term multi-lineage hematopoietic reconstitution of irradiated adult recipients mice first appear at E10 in the *AGM region* in the embryonic body (Medvinsky and Dzierzak, 1996), and in the viteline and umbilical arteries (de Bruijn et al., 2000). Shortly thereafter HSCs are also found in the placenta, yolk sac and fetal liver. The fetal liver does not generate hematopoietic cells, but gets colonized by cells formed in other locations, beginning at E9 (Johnson/Moore 1975). However, both yolk sac and *placenta* contribute to the HSC pool in the fetal liver, either through *de novo* generation of HSCs, or by expansion of pre-existing cells (Alvarez-Silva et al., 2003; Gekas et al., 2005; Kumaravelu et al., 2002; Ottersbach and Dzierzak, 2005). Proving where a specific population of hematopoietic cells is actually generated is complicated by the circulation, which is initiated on E8.5 (Delassus and Cumano, 1996). Two studies have elegantly provided

evidence for *de novo* production of definitive myeloid progenitors in the yolk sac by preventing the formation of circulation. This was created by either deleting the endothelial marker VE-cadherin, thereby preventing the yolk sac to get connected to the vasculature of the embryo (Rampon and Huber, 2003), or by deleting the *Ncx1* gene (Lux et al., 2008). *Ncx1*-deficient embryos fail to initiate a heartbeat on E8.25, but continue to develop until E10, revealing that fairly all primitive and definitive progenitors that seed the fetal liver at 9.5 are generated in the yolk sac (Lux et al., 2008). Since HSCs are evaluated by their ability to long-term reconstitute irradiated recipients, one explanation for the lack of HSC activity before E10 could be that true HSCs exist, but are unable to engraft in the adult hematopoietic microenvironment. In fact, several reports demonstrate that true HSCs exist as early as E8, as shown by transplantation of different subsets of cells into busulfan-treated embryos (Yoder and Hiatt, 1997) and *Rag2-γc* mice, which are depleted of B- T- and NK-cells (Cumano et al., 2001). Contradicting previous reports, a tracking study recently demonstrated that yolk sac cells that were marked at E7.5 contribute to hematopoiesis of all lineages, including lymphoid cells, in adult mice (Samokhvalov et al., 2007).

The *fetal liver* is the main hematopoietic organ in the embryo, and the main site for HSC expansion and differentiation. The first wave of seeding to the fetal liver initiates at E9.5-10.5 and consists of myeloerythroid progenitors, probably derived from the yolk sac. The first HSCs appear at E11.5, and are likely derived from the AGM and placenta (Mikkola and Orkin, 2006). The number of HSCs reaches a maximum of about 1000 HSCs at E15.5-16.5 (Ema and Nakauchi, 2000), where after fetal liver cells start to seed to the BM, which is the major hematopoietic organ after birth. Interestingly, HSCs in the fetal liver expands rapidly, while HSCs in the BM are mainly quiescent, indicating that there are inherited differences between fetal and adult HSCs. However, the fetal liver niche may also provide different signals than the BM to promote symmetric self-renewing divisions (Martin and Bhatia, 2005). Eaves and colleges recently showed that HSCs remain cycling until 3 weeks after birth, and then within 1 week become quiescent (Bowie et al., 2006). This transition from a proliferating fetal HSC to a dormant adult HSC is accompanied with a change in surface markers (reviewed in (Mikkola and Orkin, 2006)). As opposed to quiescent HSCs, cycling fetal HSCs express CD34 (Ogawa et al., 2001), and also certain lineage markers like the monocyte/macrophage marker *Mac1* (Morrison et al., 1995), and the B-cell marker *AA4-1* (Jordan et al., 1995).

Like adult HSCs, fetal HSCs also express Sca1 (Morrison et al., 1995), Tie2 (Hsu et al., 2000), and CD150 (Kim et al., 2006).




Figure 5: Development of the hematopoietic system in the embryo.

The figure is modified from Dzierzak & Speck 2008.

CLINICAL USE OF HEMATOPOIETIC STEM CELLS

Bone Marrow Transplantations

HSCs have been used clinically since 1959 when Dr. Thomas performed the first successful bone marrow transplantation (BMT) (Thomas et al., 1959), which since then has become a routine treatment mainly for *hematopoietic malignancies* like leukemias and lymphomas. BMTs are either autologous, transplanting back the patients/hosts own BM, or allogenic, where the BM graft comes from an appropriate human leukocyte antigen (HLA)-matched donor. HLAs are expressed by white blood cells and are used by the immune system to distinguish between “self” and “foreign”. Although the donor and host are HLA-matched, lymphoid cells from an allogenic graft can mount an immune response against the host-cells. This syndrome is known as graft-versus-host disease (GVHD), and constitutes a great risk that can even be lethal (Copelan, 2006). Since autologous BMT present perfect compatibility between the graft and the recipient, this does not result in GVHD. However, for the same reason an autologous graft also do not present a graft-versus-leukemia (GVL) effect that helps to fight the cancer, which is the main disadvantage of using this setting. Additionally, autologous grafts also risk being contaminated with remaining leukemic cells (Kondo et al., 2003).

Another use of allogenic BMT is to cure diseases that involve genetic or acquired *BM failure* such as aplastic anemia, thalassemia, and sickle cell anemia (Copelan, 2006), but also inborn metabolic disorders including osteopetrosis (Askmyr et al., 2008). Autologous BMT is increasingly used in treatment of *autoimmune diseases* like type-1 diabetes (Beilhack et al., 2005) and rheumatoid arthritis, where the BMT replaces an autoimmune blood system with one that lacks the autoimmune risk gene.

Gene Therapy

Autologous BMT can also be used for *gene therapy*. Gene therapy means to correct a defective gene or insert a missing gene into cells of a patient to treat a disease. Because of the unique ability of HSCs to long-term reconstitute hematopoiesis following myeloablation, genetically modified HSCs are expected to last a lifetime in the recipient following transplantation, and can therefore potentially cure hematological disorders. Oncoretroviral vectors have been the main vehicles used for HSCs due to their ability to integrate into the DNA (Kay et al., 2001). However, since oncoretroviral vectors require dividing target cells for efficient integration

of the provirus, and only a small fraction of HSCs is dividing at any given time, the transduction efficiency of oncoretroviral vectors of human HSCs in clinical trials has been low (Karlsson et al., 2002). To ensure that the small set of transduced HSCs are not out-competed, it is possible to add a selective marker (Neff et al., 2006), or to reduce the mass of untransduced HSCs with chemotherapy and/or irradiation. However, if the genetically corrected cells obtain a selective advantage, low transduction efficiency is enough to successfully treat a disease. One such example is the treatment of patients with severe combined immunodeficiency (SCID) (Cavazzana-Calvo et al., 2000), which constitutes a great breakthrough for the gene therapy field. However, the success is hampered by the adverse effect seen in some patients, where the gene transfer resulted in clonal T-cell proliferation due to insertional mutagenesis into the proto-oncogene LMO2 (Hacein-Bey-Abina et al., 2003).

The risk associated with gene integration strongly demonstrates the need for safer vectors. Lentiviral vectors have recently emerged as promising vehicles for human HSCs since they also transduce non-dividing cells. The need to manipulate the HSCs *ex vivo* to get them into cycle, which also affects their differentiation and repopulation ability (Glimm et al., 2000; Passegue et al., 2005), is thereby abolished. Additionally, lentiviral vectors are safer since they do not appear to preferentially integrate into promotor-proximal regions like oncoretroviral vectors do (Neschadim et al., 2007). Another way to improve the safety of genome integrating vectors is the use of self-inactivating (SIN) vectors with an internal weak or tissue-specific promoter (Cavazzana-Calvo and Fischer, 2007; Neschadim et al., 2007).

Cell Sources

Donor cells used for hematopoietic transplantations were originally derived from the BM. Standard clinical practice today is, however, to use mobilized peripheral blood (MPB), where hematopoietic stem and progenitor cells are recruited from the BM into the blood using mobilization factors, such as cyclophosphamide and/or G-CSF (Kondo et al., 2003). Unrelated umbilical CB was discovered as a potential source of transplantable HSCs almost 20 years ago (Broxmeyer et al., 1989) and is now increasingly being used. As a banked source CB HSCs are rapidly available for transplantation. Additionally, for a given HLA match the risk of GVHD is lower with CB than with HSCs derived from BM or MPB, possibly due to that the immune system of a newborn baby has not been primed against foreign antigens yet (Barker and Wagner, 2003).

Additionally, CB contains a higher proportion of primitive hematopoietic cells with superior proliferative response *in vitro* and engraftment capacity *in vivo* compared to adult BM and MPB (Barker and Wagner, 2003). The main disadvantage is the limited cell dose per graft. Although the number of HSCs in CB is often enough to efficiently engraft children, it is generally not sufficient to repopulate adult patients, as demonstrated by delayed engraftment and aberrant immune reconstitution (Barker and Wagner, 2003). As for adult HSCs, attempts to expand CB derived HSCs *ex vivo* have failed to improve engraftment because of concurrent differentiation of the expanded cells (Hofmeister et al., 2007).

To provide a wider access to cell therapy and to avoid the risk of GVHD, attempts have been made to *produce pluripotent stem cells* from adult tissue specific cells (reviewed in (Daley and Scadden, 2008)). This can be achieved in two ways; (1) by somatic cell nuclear transfer (SCNT), in which a cell nucleus from an adult somatic cell is injected into an enucleated oocyte (Markoulaki et al., 2008), or (2) by direct reprogramming of an adult somatic cell back to a pluripotent state by over-expressing specific transcription factors, so-called induced pluripotency (iPS) (Takahashi et al., 2007). The latter groundbreaking work by Yamanaka and colleagues demonstrated that retroviral transduction of only four genes encoding for the transcription factors c-Myc, Klf4, Oct4 and Sox2 is enough to induce pluripotency in both adult murine and human fibroblasts (Takahashi et al., 2007; Takahashi and Yamanaka, 2006). By reprogramming adult somatic patient cells to iPS, and subsequently differentiate them into the tissue type that is needed, the goal is to generate patient-specific tissue for regenerative medicine in the future.

ASSAYS & METHODS

Functional Biological Assays Evaluating HSCs

As previously described, it is possible to select for cell populations highly enriched for HSCs using FACS. However, functional HSCs cannot be measured solely based on immunophenotypical analysis. The only assay truly defining HSCs is the *long-term repopulating assay* (**Figure 6**). In brief, a source of HSCs with unknown features is transplanted with or without competitor cells into recipients, which have usually undergone myeloablative treatment such as irradiation. When preformed in a competitive manner, this evaluates the quality of the test cells in relation to normal wt cells, and can be measured as repopulating units (RU) (Harrison et al., 1993). The outcome of the transplantation is subsequently assessed by taking out and analyzing PB or BM at different time-points. Multi-lineage donor reconstitution observed later than 12 weeks post transplant is considered to be derived from LT-HSCs, while earlier readouts measure the activity of more mature progenitors. To distinguish the donor cells from endogenous recipient or competitor cells, congenic mouse strains are often used that differ only in the pan-hematopoietic gene CD45 (CD45.1, 5.2, or 5.1/5.2). Furthermore, the frequency of HSCs can be measured using the *limited dilution assay* (reviewed in (Purton and Scadden, 2007)). A series of dilutions of repopulating cells are transplanted together with a fixed number of competitor cells into groups of lethally irradiated recipients. Mice with both donor derived myeloid and lymphoid cells 10 to 16 weeks post transplant are scored as positive. Readout at 37% negative mice gives the number of cells containing 1 competitive repopulating unit (CRU), as calculated using Poisson statistics (Szilvassy et al., 1990). To further evaluate the self-renewal capacity of HSCs, BM from primary recipients can be re-transplanted into secondary recipients. Only the most primitive HSCs are able to sustain hematopoiesis through serial transplantations, presumably through self-renewing divisions.

Primitive human hematopoietic cells can be assayed on the basis of their ability to repopulate immune-deficient non-obese diabetic (NOD)/SCID mice, and have been termed SCID repopulating cells (SRCs). Since NOD/SCID mice lack a functioning immune system, they are unable to reject the human graft (Dick et al., 2001). A limiting factor is that human cells engraft with rather low efficiency, possibly due to biological differences between mouse and human in the BM niche. Furthermore, transplanted NOD/SCID mice die early, making it hard to evaluate long-

term repopulation. However, a new strain of mice used for xenotransplantations has been developed, called the NOD/SCID/C γ null (NOG)-mouse, which seems to greatly improve the ability to study the function of human HSCs *in vivo* (Ito et al., 2008).

The original quantitative stem cell assay is the *CFU-S assay* developed by Till & McCulloch in 1961 (Till and McCulloch, 1961). This short-term *in vivo* assay measures the ability of early engrafting progenitors to form colonies in the spleen after transplantation. Colonies formed after 12 days represent more primitive cells than the ones scored on day 8, although none of the readouts measure true stem cells. Although *in vivo* assays are preferable when studying stem cell function, these assays are generally time consuming and expensive, and are not always available. Additionally, transplantation assays rely on that the transplanted cells display unperturbed homing and engraftment ability, which is not always the case. Two assays that are used to predict HSC frequency *in vitro* are the *Cobble-stone-forming cell* (CAFC) assay, and the *long-term culture-initiating cell* (LTC-IC) assays, which both employ co-culturing of primitive cells with stroma for more than five weeks. The LTC-IC assay is based on the ability of HSCs, as opposed to more mature cells, to maintain progenitors with clonogenic potential in long-term cultures. In the CAFC assay, cell populations including HSCs are plated onto a monolayer of stromal cell. When grown, stem and progenitor cells form “cobble stone areas” under the stromal layer, and the longer they maintain growth, the more primitive are the cells (van Os et al., 2004).

Assays Evaluating Committed Progenitors

Limitations of the CFU-S assay, such as the difficulty to follow CFU-S formation in the spleen and that it cannot be used to study human cells, led to the development of colony assays *in vitro* allowing for growth of hematopoietic progenitors derived from BM and spleen (Bradley and Metcalf, 1966). The *colony-forming unit (CFU)-assay* measures the ability of progenitor cells to form colonies in semi-solid methylcellulose supplemented with various cytokines. The more primitive the initiating cell is, the more diverse is the formed colony. The most immature colony, the CFU-GEMM, is scored on day 12 in the murine setting and contains granulocytes, erythroid cells, macrophages and megakaryocytes. However, the majority of CFUs consist of lineage-restricted colonies such as the myeloid CFU-GMs or the erythroid CFU-Es. Using the CFU-assay, it is also possible to measure the proliferation potential of the commencing cell by assessing the size of the colony (Purton/Scadden 2007). Furthermore,

proliferation capacity of progenitors can be measured using *in vitro* proliferation assays, where the cells are plated either as single cells or in bulk in medium supplemented with maintaining cytokines (see Cytokines & Growth Factors). The cell number per well and number of proliferating clones is commonly scored on day 12.




Figure 6: Competitive transplantation assay. A source of HSCs with unknown features (donor cells) is transplanted together with competitor cells from congenic mice into irradiated recipients. The outcome of the transplantation is subsequently assessed by analyzing peripheral blood (PB) at different time-points. Multi-lineage donor reconstitution observed later than 12 weeks post transplant is considered to be derived from LT-HSCs, while earlier readouts measure the activity of more mature progenitors. To further evaluate the self-renewal capacity of HSCs, bone marrow (BM) cells from the primary recipient are re-transplanted into secondary recipients. The donor cells are distinguished from endogenous recipient or competitor cells, by staining for the different versions of the pan-hematopoietic gene CD45 (Donor = CD45.2, Recipient = CD45.1, and competitor = CD45.1/5.2) and analyze by FACS.

MOLECULAR BIOLOGY OF TGF- β SIGNALING

Ligands, Receptors & Smads

As described above HSCs are governed by an intricate network of signaling pathways. One pathway that has proven important in hematopoiesis is the one including the TGF- β superfamily of growth factors, which can be subdivided into the TGF- β /Activin/Nodal family, and the BMP/Growth and Differentiation Factor (GDF)/Muellerian Inhibiting Substance (MIS) family, based on sequence similarity and the specific signaling pathway that they activate (**Figure 7**). Signaling by these growth factors is initiated when binding of the ligand induces the assembly of a heteromeric complex of type I and type II serine/threonine kinase receptors. Type II receptors for TGF- β and activin (T β RII, ActRII), bind their ligands with high affinity, while type II receptors for BMP (BMPRII) bind BMPs only weakly in the absence of type I receptors (Kawabata et al., 1998). Type II receptors, which are constitutively active kinases, recruit and activate type I receptors, (also known as activin receptor-like kinases (ALKs)), by phosphorylating its cytoplasmic Gly-Ser (GS) domain (Wrana et al., 1994). The activated type I receptor in turn activates specific intracellular receptor-regulated Smads (R-Smads: Smad1-3, 5, and 8) by phosphorylation (Shi and Massague, 2003; ten Dijke and Hill, 2004). Dimers of activated R-Smads subsequently form complexes with the common-partner Smad4 and translocate into the nucleus, where they participate in transcriptional regulation of more than 500 target genes in a cell-specific, ligand dose-dependent manner (Massague et al., 2005; Shi and Massague, 2003; ten Dijke and Hill, 2004). To provide a balanced response to ligand-induced activation, R-Smads are constantly dephosphorylated, resulting in dissociation of the Smad complex and export of inactive Smads to the cytoplasm, which are then available for reactivation. Generally, Smad2 and 3 act downstream of the TGF- β and activin receptors, while Smad1, 5, and 8 primarily mediate BMP signals. However, in endothelial cells TGF- β signals via both ALK5 and ALK1, inducing phosphorylation of Smad2/3 and Smad1/5 respectively, which plays an important role in balancing processes of angiogenesis (Goumans et al., 2003; Goumans et al., 2002).


TGF- β family signaling is carefully regulated at several levels. The majority of the *ligands* are dimeric proteins produced as large precursor proteins that require proteolytic cleavage to become active (Derynck et al., 1985). Moreover, ligand traps such as Decorin antagonizing TGF- β , Follistatin inhibiting Activin and BMP binding, as well as Noggin and


Chordin that prevent BMP activation, sequester ligands and control their accessibility to the receptor (Kawabata et al., 1998; Shi and Massague, 2003). The serine/threonine kinase *receptors* comprises seven type I receptors and five type II receptors, which can form complexes in different combinations. A ligand can thus induce different responses depending on the composition of the receptor complex (Derynck and Zhang, 2003). Additionally, the specificity of the signaling is modulated by accessory receptors such as Betaglycan, which promotes the binding of TGF- β to T β RII. The Betaglycan-related co-receptor *Endoglin* is capable of binding several superfamily ligands, but only when it is associated with a typeI/typeII receptor complex (reviewed in (Fonsatti et al., 2001)). Its function is best characterized in endothelial cells, where it serves to modulate TGF- β signaling through ALK1 and ALK5, balancing activating and inhibitory signals regulating cell migration and proliferation respectively (Blanco et al., 2005; Lebrin et al., 2004; Pece-Barbara et al., 2005). Conversely, BMP and Activin receptor membrane bound inhibitor (BAMBI) inhibit receptor activation by competing with the type I receptor for incorporation into ligand-induced receptor complexes (Shi and Massague, 2003). Receptor activation is also regulated by *intracellular proteins*. The protein Smad anchor for receptor activation (SARA) facilitates Smad presentation to the activated receptor complexes, and also tethers Smads in the cytoplasm in the basal state (Shi and Massague, 2003). Moreover, inhibitory Smads (I-Smad: Smad6 and 7) negatively regulate TGF- β signaling by competing with the R-Smads for receptor or Smad4 interaction, and by marking the receptors for degradation by recruiting E3-ubiquitin ligases (Smad ubiquitination-related factor; Smurf) (Shi and Massague, 2003).

Target Gene Selection & Transcriptional Control

Activated Smad complexes bind to DNA of target genes at the Smad binding element (SBE, 5'-CAGAC-3') (Dennler et al., 1998; Johnson et al., 1999). Both activation and repression of target genes use the same set of activated Smad proteins. The gene response depends on the cell-type, and the cell-status at the time of stimulation (Massague, 2000). This diversity in biological response to the same signaling pathway is partly explained by the recruitment of different accessory proteins. Since individual Smad proteins have a rather low DNA binding affinity, transcriptional co-activators and co-repressors are needed to obtain a specific transcriptional response. Some of these co-factors are restricted to certain cell-types, thereby providing a cell-specific response. Examples of co-activators are CBP and p300, while

Ski and SnoN regulate Smad-dependent transcription in a negative manner (Massague et al., 2005; Shi and Massague, 2003).





Ligand	Type II	Type I	R-Smad
TGF- β	T β RII	ALK5 (T β RI)	Smad2, 3
		ALK1	Smad1, 5, 8
Activin	ActRIIA, ActRIIB	ALK4 (ActRIB)	Smad2
		ALK7	Smad2
BMP	BMPRII	ALK3 (BMPRIA)	Smad1, 5, 8
		ALK6 (BMPRIB)	Smad1, 5, 8
	ActRIIA, ActRIIB	ALK2 (ActRIA)	Smad1, 5

Figure 7. Signaling of the TGF- β family. Signaling is initiated when a ligand bind to a constitutively active type II serine/threonine kinase receptor, which subsequently recruits and activates a type I receptor/ALK by phosphorylating its cytoplasmic Gly-Ser (GS) domain. This induces the assembly of a heteromeric complex of two type I, and two type II receptors. The activated type I receptor in turn activates specific intracellular receptor-regulated Smads (R-Smads: Smad1-3, 5, and 8) by phosphorylation. Dimers of activated R-Smads subsequently form complexes with the common-partner Smad4 and translocate into the nucleus, where they take part in transcriptional regulation of more than 500 target genes in a cell-specific, ligand dose-dependent manner. To provide a balanced response to ligand-induced activation, R-Smads are constantly dephosphorylated, resulting in dissociation of the Smad complex and export of inactive Smads to the cytoplasm, which are then either degraded or available for reactivation. The table summarizes the different combinations of typeI/typeII receptors and R-Smads that are activated by the different ligands. The figure is modified from Derynck & Zhang 2003.

Features of the Smad Proteins

The Smad proteins are, as mentioned above, the intracellular mediators of TGF- β family signaling. The Smads are well conserved between species, and the name is a combination of the two homologs of the drosophila protein, mothers against decapentaplegic (MAD), and the *C. elegans* protein SMA. A curious detail is that it was found in drosophila that a mutation in the “mad-gene” in the mother, repressed the gene decapentaplegic in the embryo. The phrase “Mothers against” was added since mothers often form organizations opposing various issues e.g. Mothers Against Drunk Driving.

Smad proteins consist of two conserved globular domains, the Mad homology (MH)1 and MH2 domain, and a variable linker region (**Figure 8**). The *MH1 domain* is highly conserved among R-Smads and Smad4, and contains a β -hairpin structure responsible for DNA-binding and sites involved in nuclear import, while I-Smads lack the MH1 domain. The *linker* region of R-Smads encloses multiple phosphorylation sites for mitogen-activated protein kinase (MAPK) and CDKs allowing for crosstalk between different pathways. The R-Smad and I-Smad linker also contain a PY motif recognized by Smurf ubiquitin ligase for degradation. The *MH2 domain* of R-Smads has a conserved C-terminal motif, Ser-X-Ser, that is phosphorylated by activated type I receptors. In both R-Smads and Smad4 it also includes a basic pocket for oligomerisation with R-Smads. Additionally, the R-Smad MH2 domain interacts with different co-activators and co-repressors, as well as SARA for cytoplasmic retention (reviewed in (Massague et al., 2005)).

Smad-dependent & Smad-independent Signaling Crosstalk

Apart from Smad-mediated transcription, TGF- β can also activate other signaling pathways, including the Erk, JNK and p38 MAPK pathways, as well as Wnt and Notch signaling (review in (Derynck and Zhang, 2003; Guo and Wang, 2008)). A growing number of studies indicate that this crosstalk is more extended than initially thought, and although the biological consequences of non-canonical TGF- β signaling remains quite elusive, it has been shown that activation of other pathways in addition to the Smads and can result in both cooperating and counteracting outcomes (Derynck and Zhang, 2003; Kimura et al., 2000).




Figure 8. Structure of the Smad proteins, including a β -hairpin for DNA-binding, multiple kinase sites for crosstalk, a PY motif for degradation, a Ser-X-Ser (S-X-S) motif that is phosphorylated by activated type I receptors, and a basic pocket (BP) for oligomerisation with R-Smads.

THE ROLE OF THE TGF- β FAMILY SIGNALING IN HEMATOPOIESIS AND DISEASE

The TGF- β superfamily of growth factors regulates a wide variety of biological functions such as proliferation, differentiation, migration and apoptosis in a highly context dependent manner. The outcome of the signaling depends on environmental features, the differentiation stage of the cell, expression of assisting and opposing factors, the concentration and isoform of the cytokine, as well as if the action of the growth factor is paracrine or autocrine (Ruscetti et al., 2005). Therefore studies performed *in vitro* and *in vivo* often result in dissimilar conclusions. Members of the TGF- β signaling family have been shown to be important regulators of hematopoiesis (Larsson and Karlsson, 2005; Ruscetti et al., 2005), which will be discussed in detail below (**Figure 9**).

TGF- β

TGF- β is the founding member of the signaling family, and exists in 3 isoforms in mammals: TGF β 1 (Derynck et al., 1985), TGF β 2 (de Martin et al., 1987; Madisen et al., 1988) and TGF β 3 (Derynck et al., 1988; ten Dijke et al., 1988). These isoforms share 70-80% identity, and signal through the same receptors (T β RII, T β RI/ALK5 and ALK1). While they have similar actions *in vitro*, the isoforms display different expression patterns and *specific functions in vivo* (Fortunel et al., 2000; Larsson and Karlsson, 2005). A significant number of studies have demonstrated that TGF- β 1, which is the best studied isoform, inhibit proliferation of both human and murine hematopoietic stem and primitive progenitor cells *in vitro* (Batard et al., 2000; Jacobsen et al., 1991a; Keller et al., 1990; Lu et al., 1993; Sitnicka et al., 1996), whereas further differentiated progenitors are more resistant to TGF- β inhibition (Jacobsen et al., 1991a; Keller et al., 1990). However, the effect on mature cells seems to be more complex and depend on the presence of other growth factors (Ruscetti and Bartelmez, 2001). Furthermore, hematopoietic stem and progenitor cells derived from fetal liver, which are more actively cycling than BM cells, are less sensitive to TGF- β growth inhibition (Weeks et al., 1999). Accordingly, transient blockage of autocrine TGF- β signaling by expression of a dominant negative T β RII enhances the proliferation kinetics and survival of human HSCs *in vitro* (Fan et al., 2002). In agreement with the studies performed *in vitro*, injection of TGF- β 1 into the femoral artery of mice effectively inhibits multipotent hematopoietic progenitors in the BM, establishing an inhibitory role for TGF- β 1 also *in vivo* (Goey et al., 1989). This suggests

that TGF- β 1 is important for controlling quiescence of HSCs, and both autocrine production of TGF- β by HSCs and TGF- β produced by stromal cells in the niche can contribute to this HSC maintenance (Kim and Letterio, 2003; Ruscetti et al., 2005). As opposed to TGF- β 1, TGF- β 2 has been demonstrated to also function as a positive regulator of HSCs, while TGF- β 3 only works inhibitory on primitive hematopoietic cells (Jacobsen et al., 1991a; Langer et al., 2004). When administered to liquid cultures of primitive murine LSK cells, TGF- β 2 lead to a biphasic response with stimulatory effect at low concentrations, whereas high concentrations inhibit proliferation (Langer et al., 2004). The molecular mechanisms behind these conflicting properties of TGF- β 1 and TGF- β 2 remain to be established.

The exact *mechanisms* behind TGF- β -mediated effects exercised on hematopoietic stem and progenitor cells are not fully understood, but are believed to in part be due to modifications of cytokine receptor expression. Keller and colleagues have shown that TGF- β down-regulates the expression of the receptors for granulocyte macrophage (GM)-CSF, G-CSF, IL-3, IL-1, and SCF, which are all cytokines involved in regulating hematopoiesis (Dubois et al., 1990; Dubois et al., 1994; Jacobsen et al., 1991b). Growth inhibition is exerted by the ability of TGF- β to induce two classes of anti-proliferative gene responses that effectively inhibit cell cycle progression. The first is down-regulation of the growth stimulating protein c-Myc, and the second is the induction of CDKIs like p15, p21 and p27 (Massague et al., 2000). As c-Myc antagonizes TGF- β signaling by acting as a repressor of CDKIs almost all cells inhibited by TGF- β down-regulates this protein, while different cell types have different combinations of CDK-inhibitory responses. Neither p21 nor p27 appears to be required for TGF- β -mediated proliferation inhibition of primitive hematopoietic cells (Cheng et al., 2001). Recently, a study using primary human CB cells and microarray analysis demonstrated that p57 is the only CDKI induced by TGF- β . Furthermore, by inhibiting p57 with siRNA they showed that p57 is crucial for TGF- β -mediated cell cycle arrest in hematopoietic cells (Scandura et al., 2004). In most cases this arrest is believed to be reversible, supported by several studies (Batard et al., 2000; Sitnicka et al., 1996), but in some cases it leads to terminal differentiation or apoptosis. TGF- β induced apoptosis is an essential component of proper development of some tissues and organs, like mammary gland involution, and is also involved in tumor suppression (Massague et al., 2000). Additionally, TGF- β has been reported to induce apoptosis in primitive murine hematopoietic cells (Jacobsen et al., 1995).

Targeted disruption of the TGF- β 1 gene results in embryonic lethality at E10.5 due to defective yolk sac vasculogenesis and hematopoiesis in about 50 % of the mice (Dickson et al., 1995; Kulkarni et al., 1993). The other mice survive until 3 weeks after birth, probably due to maternal transfer of TGF- β 1 (Letterio et al., 1994), and then succumb to a severe multi-focal inflammatory disease (Shull et al., 1992). This lethal inflammatory disorder is transplantable, and is hence due to intrinsic TGF- β signaling deficiency (Leveen et al., 2002). Mice lacking T β RII also die at E10.5 and display very similar defects in yolk sac hematopoiesis and formation of blood vessels (Oshima et al., 1996). Together these studies indicate a critical role for TGF- β signaling in embryonic hematopoietic development. Mice lacking T β RI also display severe yolk sac anemia (Larsson et al., 2001). However, clonogenic assays on yolk sac-derived hematopoietic precursors *in vitro* revealed that T β RI-deficient mice exhibit normal hematopoietic potential, and even display an increased number of erythroid colonies (Larsson et al., 2001). Thus, even though TGF- β seems to inhibit early hematopoietic progenitors (Larsson et al., 2001; Park et al., 2004), TGF- β signaling does not appear to be a crucial for the specification of hematopoiesis in the developing embryo.

Since deletion of components of TGF- β signaling result in embryonic lethality, our laboratory has assessed its role in *adult hematopoiesis* using conditional knockout mice. Conditional deletion of the receptor T β RI or T β RII both result in complete block of TGF- β signaling, and display indistinguishable phenotypes including the inflammatory disease reported in conventional receptor-knockouts (Larsson et al., 2003; Leveen et al., 2002). Intriguingly, before onset of disease all hematopoietic parameters are normal (Larsson et al., 2003). By competitively transplanting BM from mice lacking the T β RI to immune-deficient nude mice, thereby bypassing the inflammatory disease, it was revealed that HSCs deficient in TGF- β signaling still possess normal proliferation kinetics and multi-lineage repopulation capacity, both in primary and secondary recipients (Larsson et al., 2003). This also held true when TGF- β signaling deficient HSCs were further challenged with repetitive myeloablative treatment that selectively kills cycling cells, or serial transplantations (Larsson et al., 2005). Conclusively, this suggests that TGF- β is not essential for regulation of HSC quiescence or self-renewal *in vivo*. The sharp contrast discovered between the role of TGF- β *in vitro* and *in vivo* probably depends on dissimilar microenvironments, but also on possible crosstalk and compensatory mechanisms in the *in vivo* setting. This further stresses the immense context dependency that regulates the outcome of TGF- β

signaling. To address the issue of compensatory mechanisms within the TGF- β signaling family, our group has employed two separate approaches to eliminate the entire TGF- β family induced Smad-specific signaling, namely by conditionally knocking out the common Smad4 (Karlsson et al., 2007), or by over-expressing the inhibitory Smad7 (Blank et al., 2006). Surprisingly, targeted deletion of Smad4 in HSCs results in impaired self-renewal and repopulative capacity, while over-expression of Smad7 leads to increased self-renewal in a Smad4 dependent manner (Blank et al., 2006; Karlsson et al., 2007). One possible explanation for the discrepancy between the two phenotypes could be that Smad4 and/or Smad7 may interact with regulatory circuits outside of the canonical Smad pathway. As mentioned above, a growing body of evidence suggests that crosstalk exists between the Smad and MAPK pathways, as well as with Wnt and Notch signaling (Derynck and Zhang, 2003; Guo and Wang, 2008). Additionally, a recent study showed that the nuclear protein Transcriptional Intermediary Factor1 γ (TIF1 γ) could bind to phosphorylated Smad2/3 in competition with Smad4 in CB cells, and direct the primitive hematopoietic cells toward erythroid differentiation, while Smad2/3 in complex with Smad4 mediate an anti-proliferative response (He et al., 2006).

Due to the importance of TGF- β signaling for a wide range of biological functions, deregulation of many of these factors are involved in a variety of *diseases*, including developmental disorders and various types of cancers (reviewed in (Massague et al., 2000)). Interestingly, TGF- β plays a dual role in carcinogenesis. On one hand, TGF- β works as a tumor suppressor by inhibiting cell growth as described above. This function is lost in many tumor-derived cell lines, and mutations that disable components of the TGF- β pathway are commonly encountered in human cancers including pancreatic, colon and breast cancer. On the other hand, TGF- β can promote cancer by suppressing immune-surveillance and stimulating production of angiogenic factors. Since many tumor cells selectively lose the response to TGF- β -mediated growth inhibition, but still answer to migratory signals, TGF- β can also promote invasive behavior of tumor cells (Massague et al., 2000). Although TGF- β plays an important role in regulating the balance between proliferation and differentiation in hematopoietic cells, inactivating mutations in the TGF- β signaling pathway is uncommon in leukemias and other hematological malignancies (reviewed in (Kim and Letterio, 2003)).

Activins

Activins are pleiotropic dimeric proteins that signal through different combinations of the receptors ActRIIA, ActRIIB, ActRIA/ALK2 and ActRIB/ALK4. Best studied is Activin A, which has been shown to be important for the differentiation of mesodermal precursors to the hemangioblast fate during embryonic development (Johansson and Wiles, 1995; Park et al., 2004; Pearson et al., 2008). In adults Activin A is constitutively expressed by stromal cells in the hematopoietic microenvironments (Shav-Tal and Zipori, 2002), while its expression is low to undetectable in HSCs and subsequently induced during hematopoietic differentiation (Maguer-Satta et al., 2001; Utsugisawa et al., 2006). Nevertheless, Activin A demonstrates an obvious inhibitory effect on proliferation of murine HSCs when cultured *in vitro* (Utsugisawa et al., 2006). Activin A also negatively regulates B-cell lymphopoiesis by inducing cell cycle arrest, mediating apoptosis and antagonizing cytokines required for normal B-cell development (Shav-Tal and Zipori, 2002; Shoham et al., 2003). Furthermore, Activin A is involved in regulation of erythropoiesis, and has been shown to enhance erythroid differentiation of primitive human hematopoietic cells *in vitro* (Maguer-Satta et al., 2003; Shav-Tal and Zipori, 2002).

BMP

BMPs were originally identified as molecules that induce bone and cartilage formation when implanted at ectopic sites in rats (Urist, 1965), but have later been shown to be multi-functional proteins that are crucial regulators of early embryogenesis and subsequent organogenesis (Hogan, 1996; Wozney, 2002). More than 15 different BMPs have been identified in mammals, out of which BMP2 and BMP4 are the best studied. BMPs generally signal through different combinations of three types of type II receptors (BMPRII, ActRIIA and ActRIIB), and two kinds of type I receptors (BMPRIA/ALK3 and BMPRIB/ALK6). However, some BMPs including BMP7 can also bind to the activin type I receptor ALK2 (Kawabata et al., 1998).

Over the last two decades a significant number of studies have revealed an important role for BMP signaling in mesoderm patterning, and subsequent *specification of hematopoiesis* in developing embryos (reviewed in (Sadlon et al., 2004; Snyder et al., 2004)). The necessity of BMP signaling in hematopoietic initiation is largely conserved through evolution from Zebrafish and *Xenopus* to mouse and human (Bhatia et al., 1999;

Chadwick et al., 2003; Gupta et al., 2006; Huber et al., 1998; Maeno et al., 1996; Mishina et al., 1995; Winnier et al., 1995). Targeted disruption of murine BMP4 (Winnier et al., 1995), BMP2 (Zhang and Bradley, 1996), BMPRI/ALK3 (Mishina et al., 1995) or BMPRII (Beppu et al., 2000) all result in early embryonic lethality and reduced formation of mesoderm. Hence, much of the initial knowledge about its role in blood formation is generated from studies in lower vertebrates and from the use of *in vitro* systems. BMP4 has been established as a potent inducer of ventral mesoderm in *Xenopus* (Dale et al., 1992), and when BMP4 was ectopically expressed using a *Xenopus* explant assay, it was able to induce large numbers of erythroid cells from non-mesodermal tissue in cooperation with FGF or Activin (Huber et al., 1998). Additionally, further hematopoietic commitment induced by the transcription factors GATA-1 and GATA-2 requires intact BMP signaling (Huber et al., 1998; Maeno et al., 1996). Moreover, BMP4 has also been reported to induce hematopoietic differentiation in both murine and human ES cells *in vitro* (Chadwick et al., 2003; Johansson and Wiles, 1995). This transition was recently defined as a stepwise specification driven by sequential exposure to BMP4, Activin A, FGF and VEGF (Park et al., 2004; Pearson et al., 2008). By studying murine ES cells under serum-free conditions *in vitro*, BMP4 was shown to promote very efficient formation of mesoderm, while Activin A and FGF induced differentiation into the hemangioblast fate. VEGF was required for the production of fully committed hematopoietic progenitors (Pearson et al., 2008).

In concordance with BMP ligand and receptor mutants, homozygous deletion of the BMP signaling mediator **Smad5** is also embryonic lethal. Smad5 deficient mice die between E9.5 and E11.5, mainly due to defects in angiogenesis (Chang et al., 1999; Yang et al., 1999). Mice lacking the related Smad1 also die around E10.5 because of failure to connect to the placenta (Tremblay et al., 2001). Smad5 has been shown to negatively regulate the proliferation and self-renewal of early multipotent hematopoietic progenitors derived from yolk sac and embryonic bodies *in vitro* (Liu et al., 2003). Although there are some controversies regarding its role in differentiation (Liu et al., 2003; Yang et al., 1999), it can be concluded that Smad5 plays a role in murine embryonic hematopoiesis, while the role of the related Smad1 and Smad8 is largely unknown. In Zebrafish, however, loss of either *Smad1* or *Smad5* causes failure in generating definitive hematopoietic progenitors (McReynolds et al., 2007).

The fact that disruption of Smad5 leads to increased self-renewal of hematopoietic progenitors proposes that Smad5 plays an opposite role of

BMP4. This is astonishing considering that Smad5 primarily is thought to mediate BMP signaling. Interestingly, the phenotype of Smad5 deficient yolk sac (Chang et al., 1999; Yang et al., 1999) resembles the phenotypes described for mice deficient in TGF- β signaling components (Dickson et al., 1995; Larsson et al., 2001; Oshima et al., 1996), suggesting that *Smad5 might mediate TGF- β signals* in the developing embryo. In addition it has been shown that Smad5, but not Smad 1 or 8, can bind to the Smad binding element (SBE) at similar levels as the TGF- β -specific Smad3 and Smad4, further suggesting that Smad5 may play a role in TGF- β signaling (Li et al., 2001). Accordingly, Smad5 has been reported to transduce inhibitory signals from TGF- β 1 on proliferation of hematopoietic progenitors from human BM (Bruno et al., 1998) and primitive multipotent progenitors derived from murine embryonic bodies (Liu et al., 2003). However, in both studies loss of Smad5 was unable to reverse inhibition caused by higher doses of TGF- β 1, suggesting a predominating role for other Smads or pathways in the transmission of its inhibitory effects at high concentrations. As described in **Article I**, our study reveals unaltered TGF- β sensitivity of both proliferation and colony formation of adult hematopoietic progenitors lacking Smad5, demonstrating that Smad5 is not necessary for TGF- β 1 inhibition of adult murine hematopoietic progenitors *in vitro* (Singbrant et al., 2006).

While the importance of BMP signaling in embryonic hematopoiesis is well defined, very little is known about its role in *adult hematopoiesis*. A recent study demonstrated an indirect effect of BMP on the number of adult murine HSCs. By conditionally knocking out BMPRIA/ALK3 in adult mice Zhang et al. showed that impaired BMP signaling increases the niche size, and thereby enhances the number of HSCs (Zhang et al., 2003). The same study established normal reconstitution ability of ALK3 deficient cells in wt recipients, although this did not adequately address the loss of BMP signals in HSCs intrinsically, as ALK3 is not expressed by these cells (Utsugisawa et al., 2006; Zhang et al., 2003). High concentration of BMP4 has also been reported to maintain proliferation of human CB HSCs *in vitro*, while BMP2 and BMP7 and low concentrations of BMP4 inhibit proliferation (Bhatia et al., 1999). Furthermore, Shh has been shown to induce expansion of human CB HSCs *in vitro* in a BMP-dependent manner (Bhardwaj et al., 2001). In sharp contrast, when we cultured adult murine LSK CD34⁺ cells with and without BMP4, neither high nor low concentrations of BMP4 had any effect on the proliferation of HSCs (Utsugisawa et al., 2006). These diverging results could possibly be explained by biological differences between mouse and human, or by ontogenic differences in the BMP response

(further discussed under “General discussion”). Although the effects of BMP4 on the differentiation of human BM CD34⁺ hematopoietic progenitors are inconclusive, reports have suggested a stimulatory effect of BMP4 on both erythroid and myeloid colony formation *in vitro* (Detmer and Walker, 2002; Fuchs et al., 2002; Maguer-Satta et al., 2003). In the murine setting hematopoietic progenitors derived from BM has remained unresponsive to BMP4 stimulation, while BMP seems to play a role in stress induced erythropoiesis in the spleen (Lenox et al., 2005). As the entire BMP signaling pathway converge on the intracellular signaling transducers Smad1 and Smad5, we have investigated the full role of BMP signaling in adult murine hematopoiesis by using conditional knockout mice for Smad1, Smad5 and Smad1/5 to circumvent the embryonic lethal phenotypes of the conventional knockouts. As described in **Article I** and **Article II**, BM HSCs deficient in both Smad1 and Smad5, thereby completely blocking the BMP signaling, compete normally with wt BM and display unaffected self-renewal and differentiation capacity *in vivo*. Thus, we can conclude that BMP signaling is not required to maintain adult hematopoiesis despite its crucial role in the initial patterning of hematopoiesis in early embryonic development (Singbrant et al., 2006) (Manuscript Singbrant et al, 2008).

Endoglin

Endoglin, also known as CD105, is as mentioned earlier a TGF- β co-receptor that is crucial for regulation of *angiogenesis* (Lebrin et al., 2004). Studies in the murine system have revealed that complete deletion of endoglin in mice leads to embryonic lethality at approximately E10 due to abnormal yolk sac vasculature and cardiac defects (Arthur et al., 2000; Bourdeau et al., 1999; Li et al., 1999). Additionally, mutations in endoglin in both humans and mice are associated with hereditary hemmorrhagic telangiectasia, an inherited disease characterized by malformations of the blood vessels and bleedings (Bourdeau et al., 1999; McAllister et al., 1994). Since angiogenesis is a crucial feature for tumor development, anti-angiogenic therapy is a promising cancer treatment. Interestingly, assessment of neovascularization by endoglin staining, as well as levels of soluble endoglin, has been found to represent a potential predictor of prognosis in several solid and myeloid malignancies respectively (Calabro et al., 2003; Duff et al., 2003; Fonsatti and Maio, 2004).

Endoglin has also been suggested to play a role in *hematopoiesis*. The abnormal yolk sac angiogenesis in endoglin knockout mice was in on study accompanied by anemia in the embryo proper (Arthur et al., 2000).

However, pools of red blood cells could occasionally be found in distended yolk sac vessels, suggesting that hematopoiesis per se may not have been completely impaired. Endoglin is differentially expressed on hematopoietic cells, and was recently identified as a marker defining functional long-term repopulating stem cells (Chen et al., 2003; Chen et al., 2002). The potential relevance of endoglin in hematopoiesis can be insinuated from its expression on various human hematopoietic populations, including early B-cell progenitors and erythroblasts in fetal BM (Rokhlin et al., 1995), pro-erythroblasts in adult BM (Buhring et al., 1991; Rokhlin et al., 1995), CD34⁺ CB cells (Pierelli et al., 2000), macrophages (Lastres et al., 1992), and CD4⁺ T-cells (Schmidt-Weber et al., 2005). Additionally, studies assessing hematopoietic differentiation of murine ES cells *in vitro* have shown that deletion of endoglin results in profound reduction in the formation of hemangioblasts (Perlingeiro, 2007), as well as impaired erythroid and myeloid differentiation (Cho et al., 2001). However, the function of endoglin in primary adult hematopoietic cells has not previously been characterized. As described in **Article III**, we have utilized viral vectors to both knock down and over-express endoglin in murine HSC. Our results suggest that the engraftment and reconstituting capacities of HSC are not critically dependent on endoglin. However, altered endoglin expression impacts erythroid proliferation and differentiation at distinct stages (Moody et al., 2007).




Figure 9: The role of TGF-β family signaling in early hematopoiesis. While BMP4, Activin A and Endoglin have been reported to induce the formation of hematopoietic tissue during embryonic development, TGF-β and Smad5 are indicated to regulate early hematopoiesis in an inhibitory manner. The figure is modified from Larsson & Karlsson 2005.

SPECIFIC AIMS OF THIS THESIS

The over all aim of the work included in this thesis has been to delineate the previously unknown role of two important candidates in the regulation of HSC in adult hematopoiesis, namely *BMP signaling* and *Endoglin*. More explicitly we sought the answers to the following question:

1. Does Smad5 work as a negative regulator of adult hematopoiesis as has been described in the early developing embryo?
2. Does Smad5 mediate TGF- β signals in addition to BMP signals in adult murine hematopoietic cells?
3. Is there redundancy among the Smad proteins that mediate BMP signaling in adult hematopoiesis?
4. Are there ontogenic differences in the BMP response between HSCs derived from fetal liver and bone marrow?
5. Does the cell surface marker Endoglin that identifies functional long-term repopulating HSCs play a regulatory role for these cells?

SUMMARY OF RESULTS

ARTICLE I

Smad5 is dispensable for adult murine hematopoiesis. Singbrant S, Moody J.L, Blank U, Karlsson G, Zwijsen A, Umans L, Karlsson S. *Blood* 108(12): 3707-12 (2006)

Smad5 is known to transduce intracellular signals from BMPs, which belong to the TGF- β superfamily. Recent findings suggest that BMP4 stimulates proliferation of human CB HSCs *in vitro*, while Smad5 has been reported to regulate early progenitors in murine embryonic hematopoiesis in a negative manner. In this study, we evaluate the role of Smad5 in the regulation of HSC fate decisions in adult mice. To circumvent the embryonic lethal phenotype of the conventional Smad5 knockout, we have used an inducible *MxCre*-mediated conditional knockout model. Surprisingly, analysis of induced mice reveals unperturbed cell numbers and lineage distribution in peripheral blood (PB), BM and spleen. Furthermore, phenotypic characterization of the stem cell compartment reveals normal numbers of primitive LSK cells in Smad5 deficient BM. When transplanted in a competitive fashion into lethally irradiated primary and secondary recipients, Smad5 deficient BM cells compete normally with wt cells, are able to long-term reconstitute the hosts and display normal lineage distribution. Taken together, Smad5 deficient HSCs from adult mice show unaltered differentiation, proliferation, and repopulating capacity. Therefore, in contrast to its role in embryonic hematopoiesis, Smad5 is dispensable for hematopoiesis in the adult mouse.

ARTICLE II

BMP signaling is essential to preserve colon architecture, but is dispensable for hematopoietic stem cell function in adult mice.

Singbrant S, Karlsson G, Ehinger M, Jaako P, Zwijsen A, Stadtfeld M, Graf T, Karlsson S. *Manuscript* (2008)

Numerous publications have described the importance of BMP signaling in the specification of hematopoietic tissue in developing embryos. We demonstrate in **Article I** that Smad5, an intra-cellular mediator of BMP signaling, is dispensable for normal hematopoiesis in the adult mouse. In this study we further examine the possibility that the lack of phenotype in Smad5 deficient HSCs could be due to redundancy between the related Smads mediating BMP signaling, or to ontogenic differences in BMP response. We therefore investigated the full role of BMP signaling in both adult and fetal liver hematopoiesis by generating conditional knockout mice for Smad1, Smad5 and Smad1/5. Our findings demonstrate that concurrent deletion of Smad1 and Smad5 results in lethality due to extra-hematopoietic pathological changes in the colon. However, when Smad1/5 deficient BM cells are transplanted into lethally irradiated recipients, they compete normally with wt BM and display unaffected self-renewal and differentiation capacity. Moreover, even though BMP receptor expression is increased in fetal liver, Smad5 deficient fetal liver cells could still long-term reconstitute lethally irradiated recipients in a multi-lineage manner. Thus, we can conclude that canonical BMP signaling is not required to maintain adult hematopoiesis despite its crucial role in the initial patterning of hematopoiesis in early embryonic development.

ARTICLE III

Endoglin is not critical for hematopoietic stem cell engraftment and reconstitution but regulates adult erythroid development. Moody J.L, Singbrant S, Karlsson G, Blank U, Aspling M, Flygare J, Bryder D, Karlsson S. *Stem Cells* 25(11): 2809-19 (2007)

Endoglin is a TGF- β accessory receptor recently identified to define long-term repopulating HSC. However, little is known regarding its function in these cells. We have employed two complimentary approaches towards understanding endoglin's role in HSC biology; one that efficiently knocks down expression via lentiviral driven shRNA, and another utilizing retroviral-mediated over-expression. Altering endoglin expression had functional consequences for hematopoietic progenitors *in vitro* such that endoglin-suppressed myeloid progenitors display a higher degree of sensitivity to TGF- β -mediated growth inhibition, while endoglin over-expressing cells are partially resistant. However, transplantation of transduced BM enriched in primitive hematopoietic stem and progenitor cells reveals that neither endoglin suppression nor endoglin over-expression affect the ability of HSC to short-term or long-term repopulate recipient marrow. Furthermore, transplantation of cells altered in endoglin expression yields normal white blood cell proportions and PB platelets. Interestingly, decreasing endoglin expression increases the clonogenic capacity of early erythroid progenitors, while over-expression compromises erythroid differentiation at the basophilic erythroblast phase, suggesting a pivotal role for endoglin at key stages of adult erythropoietic development.

GENERAL DISCUSSION

LOSS OF FUNCTION

Conditional Knockout Mice

Complete deletion of a gene is probably the most stringent method to study its functional role *in vivo*. A limitation of conventional knockout models is that many genes are critical during embryonic development, and hence result in embryonic lethality if the gene is deleted. Although offering a good model to study development, this greatly aggravates the ability to study the role of several genes in an adult setting. Recent techniques have made it possible to conditionally knock out genes using Cre site-specific DNA recombinase (Sauer, 1998). This enzyme recognizes a specific short sequence, and efficiently deletes genes that are flanked by these so-called loxP sites (“floxed” genes) in a highly specific manner. By mating mice that carry a “floxed” gene of interest with a mouse strain having the Cre recombinase under an inducible tissue specific promoter, it is possible to control both when, and in which type of cells the gene will be deleted.

Because conventional knockouts of Smad1 and Smad5 both result in embryonic lethal phenotypes we used Cre-mediated conditional knockout mice in **Article I** and **Article II**, which have been previously described (Huang et al., 2002; Umans et al., 2003). By crossing mice with “floxed” Smad1 and Smad5 alleles respectively, we also generated double knockouts, thereby disrupting the entire canonical BMP signaling pathway. In the adult setting we utilized mice with the Cre-recombinase gene under control of the *Mx1-promoter* (*MxCre*) (Kuhn et al., 1995), which is an interferon-inducible promoter that has been shown in multiple studies to very efficiently delete “floxed” genes in hematopoietic stem and progenitor cells (Larsson et al., 2003; Singbrant et al., 2006; Wilson et al., 2004). Since deletion of Smad5 results in embryonic lethality at E10.5 due to defective angiogenesis and the *Mx1-promoter* is active also in endothelial cells, *MxCre* cannot be used to study fetal liver hematopoiesis at E14.5. We therefore generated homozygously “floxed” Smad1/5 mice with the Cre-recombinase gene under control of the *Vav-promoter* (*VavCre*). *Vav* is a pan-hematopoietic gene, and Cre-expression driven from the *Vav-promoter* has been reported to cause recombination in essentially all hematopoietic cells including HSCs with an efficiency of 93-96% in fetal liver, while leaving endothelial cells unaffected (Stadtfeld and Graf, 2005).

To confirm efficient deletion of Smad1 and Smad5 respectively, individual hematopoietic colonies were screened using PCR analysis. Consistent with previous reports testing *MxCre*-mediated deletion of single genes in hematopoietic colonies, exon 2 was deleted in 100 % of the colonies tested from Smad1 and Smad5 single knockout mice (Larsson et al., 2003; Singbrant et al., 2006). However, when concurrently knocking out Smad1 and Smad5, the deletion efficiency was sometimes slightly lower of one or both of the genes. Although the vast majority of the screened hematopoietic progenitors were completely lacking both Smad1 and Smad5, it can be argued that the lack of phenotype could be due to the very few cells expressing wt Smad1 or Smad5. Although we cannot entirely exclude this, we find it highly unlikely since we could not detect any differences in any hematopoietic parameters analyzed between mice having 100% deletion of both Smad1 and Smad5 and mice with slightly lower deletion efficiency. Additionally, Arnold et al recently demonstrated that concurrent heterozygous deletion of Smad1 and Smad5 is enough to result in embryonic lethality, even though single heterozygotes of Smad1 or Smad5 are normal (Arnold et al., 2006).

shRNA

One disadvantage of using conventional or conditional knockout mice is that the method is very time consuming and expensive. A much faster approach to reduce the expression of a gene is the usage of RNA interference (RNAi), which has emerged as a powerful tool to gain insight into gene function. In brief, RNAi is a sequence-specific post-transcriptional gene silencing mechanism, which is mediated by small interfering RNAs (siRNAs). Delivery of siRNAs into mammalian cells by transfection with synthetic siRNAs or DNA plasmids expressing short hairpin RNAs (shRNAs) has been shown to successfully mediate RNAi. Therefore, lentiviral vectors that express shRNA represent a powerful tool to achieve stable knock-down of gene expression in HSCs (reviewed in (Dykxhoorn et al., 2003; Shi, 2003)).

To knock down endoglin expression in **Article III**, BM enriched for stem and progenitor cells were transduced with lentivirus driving the expression of a specifically designed shRNA against endoglin (endoglin KD), or a control virus containing a scrambled shRNA (scrambled KD) that does not recognize any target in the mouse genome. The shRNA used knocks down both of the two reported isoforms of endoglin (Perez-Gomez et al., 2005). The degree of reduction in surface endoglin was typically 70-80 %. However, it should be noted that the majority of endoglin KD GFP⁺

cells were negative for surface expression, while cells that were “positive” expressed very low levels. Correspondingly, quantitative reverse transcriptase (QRT)-PCR analysis of RNA from GFP⁺ sorted cells demonstrated endoglin expression levels that averaged 20% of scrambled levels. We therefore estimated that we could achieve approximately 80% knockdown of endoglin expression using our shRNA strategy. Furthermore, protein suppression was sustained long-term throughout *in vivo* transplantation, thereby demonstrating that an shRNA strategy can efficiently suppress gene expression in studies of murine HSC.

GAIN OF FUNCTION

Retroviral Over-expression

As discussed under “Gene Therapy”, over-expression of genes can be accomplished using viral vectors. The ability of retroviral vectors to integrate into the genome, in combination with the capacity of HSCs to long-term reconstitute hematopoiesis following myeloablation, makes it possible to study the effect of genetically modified HSCs throughout life in transplanted recipients. Additionally, the transplantation-approach limits the over-expression to the hematopoietic system. Moreover, as opposed to genetic transfer into human cells, introduction of genes into murine HSCs using retroviral vectors has proven to be both efficient and stable, and has been widely used for the purpose of evaluating gene function at the stem cell level (Dick et al., 1985). It should be kept in mind that the high levels of gene expression accomplished using this method are non-physiological. Effects revealed might hence not be relevant for the normal function of the protein. Another adverse feature of retroviral over-expression is that efficient transduction of the gene of interest is accompanied with the risk of insertional mutagenesis in the transduced cells, as observed in the SCID trials. However, as evident by our study discussed in **Article III**, the very mild phenotype seen in HSCs over-expressing endoglin is unlikely to depend on any such effect. Furthermore, we did not detect any signs of malignant proliferation, strongly supporting that the vector has not been inserted into a proto-oncogene in our case.

In **Article III** we used the MIG vector, which is a murine stem cell-based vector (MSCV) containing the reporter gene Green Fluorescent Protein (GFP). To over-express endoglin we transduced cells with the murine cDNA corresponding to murine L-endoglin, a full-length splice variant that is predominantly expressed in mouse tissues (Perez-Gomez et

al., 2005). Sustained high levels of endoglin protein were evident by western analysis of lysates from MIG endoglin cells expanded in culture for 8 days post-transduction, while endogenous levels dropped below detectable levels in differentiating MIG cells. Furthermore, QRT-PCR analysis of MIG endoglin GFP⁺ cells assessed 48 hours post-transduction revealed an average 70-fold increase of endoglin RNA levels compared to MIG transduced cells. Two weeks post-transduction, at the point where MIG cells have lost endoglin surface expression in culture, FACS analysis revealed that MIG endoglin GFP⁺ cells had a mean fluorescent intensity (MFI) of endoglin expression 2-fold higher than that observed for control transduced cells. Taken together, these data established the feasibility of our approach to alter endoglin expression in transduced hematopoietic cells.

REDUNDANCY IN THE SMAD SIGNALING PATHWAY

In **Article I**, we demonstrate that Smad5 is dispensable for adult murine hematopoiesis, in sharp contrast to its role as a negative regulator of primitive hematopoietic cells in the developing embryo (Liu et al., 2003). A likely explanation for this lack of effect is that the related Smad1 may functionally compensate for the deficiency of Smad5 (**Figure 10**). This theory is supported by the fact that mutants lacking BMP2, BMP4, or the upstream ALK3 receptor display earlier and/or more severe phenotypes than the Smad1 or the Smad5 knockouts (Mishina et al., 1995; Winnier et al., 1995; Zhang and Bradley, 1996). Even though Smad1 and Smad5 possess inherent specificities, demonstrated by different expression and distribution patterns (Flanders et al., 2001; Monteiro et al., 2004; Tremblay et al., 2001) as well as dissimilar knockout phenotypes (Chang et al., 1999; Lechleider et al., 2001; Tremblay et al., 2001; Yang et al., 1999) it is conceivable that the absence of effects in our earlier study is due to redundancy with Smad1. Redundant mechanisms between Smad1 and Smad5 were recently demonstrated as Smad1^{+/-}; Smad5^{+/-} murine mutants, in contrast to Smad1 or Smad5 single heterozygotes, are embryonic lethal and display defects that closely resemble those seen in Smad1 or Smad5 homozygous mutants (Arnold et al., 2006). Additionally, Smad1 is able to rescue the Smad5^{-/-} phenotype in Zebrafish (McReynolds et al., 2007). Thus, Smad1 and Smad5 share equivalent functional activities in the early embryo.

To address the issue of functional redundancy between related Smads in adult hematopoiesis in **Article II**, we created a conditional double knockout mouse for Smad1 and Smad5, enabling us to analyze the distinct

versus overlapping roles of these related Smads. To our surprise, HSCs with disrupted BMP signaling could still long-term repopulate lethally irradiated mice in a multi-lineage manner in both primary and secondary recipients, demonstrating that BMP signaling is not required for HSC self-renewal, proliferation, differentiation or engraftment. Although Smad8 is not expressed in primitive hematopoietic cells in the BM (Bhatia et al., 1999; Utsugisawa et al., 2006) we examined whether the expression levels of Smad8 was altered when knocking out Smad1 and Smad5. QRT-PCR analysis on sorted LSK cells from induced *MxCre;Smad1^{fl/fl}Smad5^{fl/fl}* and wt mice demonstrated that Smad8 remained undetectable, suggesting that redundancy between related Smads is not accountable for the lack of phenotype observed in BMP signaling deficient adult hematopoiesis *in vivo*.

ONTOGENIC DIFFERENCES

Numerous publications have described the importance of BMP signaling in the formation of hematopoietic tissue in developing embryos (Snyder et al., 2004). Additionally, BMP4 has been shown to promote hematopoietic differentiation of ESCs (Chadwick et al., 2003), and to stimulate proliferation and colony formation of human primitive progenitors purified from CB *in vitro* (Bhatia et al., 1999). However, BMP4 does not have a stimulatory effect on either proliferation or colony formation of adult hematopoietic progenitors from murine BM (Utsugisawa et al., 2006). Accordingly, our results from **Article I** and **Article II** clearly demonstrates that BMP signaling is dispensable for adult hematopoiesis in the mouse, even when assessing the HSCs under stressed conditions, such as after serial transplantation. Conclusively, this indicates that the developmental context is an important factor and that this discrepancy in response to BMP may depend on ontogenic differences (**Figure 10**). In fact, Bhatia et al. demonstrated significant expression of ALK3 and ALK6 in HSCs derived from human CB, while the expression level of these BMP type I receptors in BM HSCs was very low to undetectable (Bhatia et al., 1999). The absence of these receptors has also been documented in murine BM (Utsugisawa et al., 2006).

Because targeted disruption of different components of the BMP signaling pathway all result in early death of the embryo (Beppu et al., 2000; Chang et al., 1999; Mishina et al., 1995; Winnier et al., 1995; Zhang and Bradley, 1996), the majority of the studies of BMP function in hematopoiesis are based on *in vitro* experiments using very primitive hematopoietic cells derived from murine or human ESC (Chadwick et al.,

2003; Johansson and Wiles, 1995), murine yolk sac or embryonic bodies (Liu et al., 2003; Yang et al., 1999). We were therefore interested in studying the role for BMP signaling in fetal liver hematopoiesis, a developmental phase in between the adult hematopoiesis in the BM and the primitive hematopoiesis found in yolk sac when the HSCs are massively expanded. To address the question of possible biological differences between these two ontogenic stages, we analyzed the expression level of receptors involved in BMP signaling by QRT-PCR in sorted primitive fetal liver cells (**Article II**). Intriguingly, the expression of ALK3 was markedly increased compared to levels in BM HSCs, suggesting that there may be a discrepancy in response to BMP signaling between BM and fetal liver HSCs. However, in spite of differential expression of BMP receptors, Smad5 remains dispensable in fetal liver hematopoiesis. Together this implies that cells of early ontogeny may reflect a unique population of HSCs with a distinct response to growth factors.

BMP SIGNALING IN THE COLON

Concurrent deletion of Smad1 and Smad5, but not of Smad1 or Smad5 alone, results in death due to pathology in the colon (**Article II**). Most of the BMP signaling deficient mice died within 4 weeks after induction, and all of them were anemic and tested positive for hemoglobin in the feces. Accordingly, histological examination of the gastrointestinal organs from these mice revealed pathological changes in the colon submucosa, including dilated crypts and occasional infiltration of inflammatory cells. Several studies have previously shown that BMP signaling is crucial for maintenance of normal intestinal function (He et al., 2004; Shroyer and Wong, 2007). Additionally, when we conditionally knocked out the common Smad4 in a previous study, this resulted in a dramatic colon phenotype and intestinal hemorrhage, which was hypothesized to be due to disrupted BMP signaling (Karlsson et al., 2007). Hence, the phenocopy we now see in the Smad1/5 knockout clearly confirms this hypothesis. Mice with disrupted BMP signaling also exhibit a compensatory enlargement of the spleen, and display a decrease in B-cells and increase in myeloid cells in the BM. The latter findings indicate that simultaneous deletion of Smad1 and Smad5 may affect the differentiation capacity of hematopoietic progenitors. However, the disturbed lineage distribution in the Smad1/5 knockout mice at steady state might also be explained by that these mice are moribund and are in a bad general condition. Accordingly, none of the mice transplanted with Smad1/5 deficient BM display any of the described

symptoms, supporting that the phenotype is of extra-hematopoietic origin. Interestingly, since knocking out only Smad1 or Smad5 did not result in disruption of the colon architecture, these related Smads seem to play a redundant role in maintaining colon homeostasis.




Figure 10. Ontogenic differences and redundancy in BMP signaling. ALK3, ALK6 and Smad8 (depicted in grey) are not expressed in BM derived HSCs. However, ALK3 expression is detected in fetal liver (*), and hence constitutes a possible ontogenic difference in BMP response between BM and fetal liver HSCs. Furthermore, it is possible that the related Smad1 might functionally compensate for deficiency of Smad5.

ENDOGLIN IN HEMATOPOIESIS

Endoglin is one of a number of genes expressed by endothelial cells that recently have been described as identifying markers for HSCs (Balazs et al., 2006; Chen et al., 2002; Matsubara et al., 2005). The expression of these molecules in endothelial and hematopoietic cells is intriguing given their intertwined origin (Jaffredo et al., 2005). While the role for endoglin in HSCs until now has been unknown, it is well defined in endothelial cells, where it balances TGF- β signals that promote stimulatory effects through the TGF- β RII/ALK1 complex, with inhibitory signals transduced by TGF- β RII in complex with ALK5 (Lebrin et al., 2004). Likewise, proliferation and quiescence must be carefully balanced in HSCs. However, QRT-PCR on purified LSKCD34⁺ cells revealed undetectable levels of ALK1 (Utsugisawa et al., 2006), suggesting that an analogous function for endoglin involving ALK1 in HSCs is unlikely. Accordingly, our results indicate that modulating endoglin expression has no impact on the proliferative response of hematopoietic stem and progenitor cells, as assessed *in vivo* by their reconstituting ability and *in vitro* using proliferation and colony forming assays.

In endothelial cells endoglin expression is in part regulated by hypoxia (Sanchez-Elsner et al., 2002), and endoglin has been implicated in the protection from hypoxia-induced apoptosis in these cells (Li et al., 2003). Interestingly, HSCs localize to the endosteal surface in the BM, an area that is also considered to be hypoxic. It was therefore a possibility that endoglin could play a role in protecting HSCs from factors in the niche. However, the sustained engraftment levels of HSC seen in our experiments suggest that endoglin suppression does not confer a disadvantage for cells in their microenvironment, nor does over-expression of endoglin afford any advantage to these cells. It is curious that altering expression of a marker that is relatively definitive for long-term repopulating stem cells does not affect any of the measured functions of transplanted HSCs. Endoglin is thought to modulate signaling initiated by the TGF- β signaling family. Of these, the TGF- β pathway is the most thoroughly characterized especially with respect to its negative regulation of murine HSC function *in vitro* (as previously described). However, *in vivo* its role is less important to HSC function, as proven by the normal HSC reconstitution kinetics and differentiation capacity when TGF- β signaling was abolished by deleting T β RI/ALK5 (Larsson et al., 2003). It remains a dilemma if these and our results indicate a lack of importance for TGF- β and endoglin signaling in

HSC regulation *in vivo*, or if compensatory mechanisms resulting from redundancy within the TGF- β superfamily are at play.

Several lines of evidence have suggested a potential role for endoglin in erythropoiesis. Endoglin expression has been described on various human erythroid populations (Rokhlin et al., 1995). Additionally, a study using hematopoietic differentiation of endoglin deficient ESC suggests that complete deficiency of endoglin allows for progression to the Flk1⁺ stage, representative of definitive hematopoiesis, but compromises differentiation towards the myeloid lineage 5-8 fold, and towards the erythroid lineage 16-fold (Cho et al., 2001). Furthermore, endoglin is found on primitive murine erythroid progenitors, and is down-regulated as cells progress from basophilic erythroblasts to polychromatophilic erythroblasts (D. Bryder, unpublished observations). Accordingly, our results suggest that endoglin negatively regulates the proliferation of primitive erythroid progenitors. Furthermore, our data reveal that differentiation through the basophilic erythroblast stage is negatively impacted by over-expression of endoglin, suggesting a critical role for its down-regulation in progression throughout this phase of maturation. The lack of altered red blood cell counts in the transplanted recipients is likely due to compensation by either untransduced cells and/or the 5-10 % of endogenous cells that remain. Our system does not allow us to track transduced cells past this stage, as vector-driven GFP becomes undetectable in later erythroid progeny (J. Moody and D. Bryder, unpublished observations).

CONCLUSIONS

From the work included in **Article I-III** we have drawn the following conclusions:

- Smad5 is not required for TGF- β 1 inhibition of hematopoietic progenitors from adult mice *in vitro* (I)
- **Smad5 deficient BM HSCs can long-term repopulate lethally irradiated mice in a multi-lineage fashion in both primary and secondary recipients. Hence, in contrast to its role in embryonic hematopoiesis, Smad5 is dispensable for hematopoiesis in the adult mouse (I)**
- **BMP signaling is not essential for HSC function in adult mice (II)**
- Redundancy between related Smads is not accountable for this lack of phenotype observed in BMP deficient adult hematopoiesis (II)
- **Smad5 remains dispensable in fetal liver hematopoiesis in spite of increased expression of BMP receptors (II)**
- Endoglin negatively regulates early erythroid proliferation, while persistence of endoglin expression at the basophilic erythroblast stage negatively impacts erythroid differentiation (III)
- **Neither inhibition, nor over-expression of Endoglin affects the ability of HSCs to engraftment and long-term reconstitute lethally irradiated recipients (III)**

FUTURE DIRECTIONS

Double Knockout for Smad1 and Smad5 in Fetal Liver Hematopoiesis

As previously described in this thesis, considerable amounts of data demonstrate that BMP signaling is crucial for the initial specification of hematopoiesis in the developing embryo. It was therefore surprising to discover that HSCs completely lacking BMP signaling display unperturbed ability to long-term reconstitute mice in a multi-lineage manner in the adult system. When comparing the expression profiles from HSCs derived from BM and fetal liver, we discovered that ALK3, which is missing in BM HSCs, is expressed in primitive fetal liver cells, suggesting that BMP may affect these cells in a different manner. Since Smad5 is the only Smad mediating BMP signals that has been implicated in regulating hematopoiesis in mammals, we investigated its role in fetal liver hematopoiesis using conditional knockout mice. Unexpectedly, Smad5 was shown to be dispensable for normal HSC function also in the fetal liver. Together this implies that cells of early ontogeny may reflect a unique population of HSCs with a distinct response to growth factors. However, it cannot be excluded that the related Smad1 is able to functionally compensate for the lack of Smad5 in the fetal liver. Therefore we have also created a Smad1/5 double knockout on *VavCre*-background, hence completely blocking canonical BMP signaling in these cells. Analysis of BMP deficient fetal liver hematopoiesis is in progress. The fact that HSCs in the fetal liver are greatly expanding, as compared to the mainly quiescent HSCs found in adult hematopoiesis, speaks in favor of that these cells might respond differently to various growth factors, such as BMP.

The Role of BMP Signaling in Human Cord Blood Hematopoiesis

As in the case of murine investigations, the majority of the human studies evaluating the role of BMP in hematopoiesis have also been carried out in embryonic cells, or in CB cells. CB represents a source of stem cells that is quite distinct from adult BM. In fact CB HSCs have been shown to be more readily cycling than the HSCs derived from BM (Lansdorp et al., 1993). Additionally, when kept in serum-free cytokine-supplemented long-term cultures *in vitro*, primitive CB cells were able to expand the number of CD34⁺ cells, while the number of CD34⁺ cells derived from primitive BM remained constant (Lansdorp et al., 1993), suggesting that these HSCs respond differentially to growth factors. In accordance, Bhatia et al.

demonstrate significant expression of ALK3 and ALK6 in CB HSCs, while the expression level of these BMP type I receptors in BM HSCs is very low to undetectable (Bhatia et al., 1999). The same group has also shown that a high dose of BMP4 is able to maintain human CB HSCs *in vitro* (Bhatia et al., 1999), and more importantly, that Shh is able to induce expansion of functional human CB HSCs *in vitro* in a BMP-dependent manner, as verified by transplanting the expanded cells into NOD/SCID mice (Bhardwaj et al., 2001). This strongly suggests that, although BMP signaling is not important for adult hematopoiesis, it may still play an essential role in *ex vivo* expansion of CB cells. Evaluation of human HSCs has been hampered by the lack of good functional assays. However, as discussed under “Assays & Methods”, technical advances during recent years including the new NOG-mouse and improved vector design have provided more reliable tools to functionally study these cells. As expansion of CB cells is of utmost clinical importance, being an upcoming source for HSC transplantations (further see “Clinical Use of Hematopoietic Stem Cells”), it would be interesting to further study the role of BMP signaling in CB cells using the new improved xenograft models available. One experiment would be to culture CB cells enriched for primitive stem and progenitor cells in serum-free medium with and without BMP4 in combination with maintaining cytokines (such as SCF, TPO, Flt3L and IL-6), and subsequently assess their long-term reconstitution ability in NOG-mice. In addition, it would be interesting to concurrently knock down the expression of Smad1 and Smad5 to get a total block of BMP signaling, using the shRNA approach described in Article III, to further delineate its role in these cells.

Interactions Between BMP Signaling and Other Regulatory Pathways

We have in Article II ruled out the possibility of redundancy within the Smad-signaling pathway by knocking out both Smad1 and Smad5, and controlling for that Smad8 is not expressed. It is however possible that crosstalk with other pathways might influence the readout of our experiments. The diverging result seen when blocking the entire TGF- β family signaling by over-expressing the inhibitory Smad7 (Blank et al., 2006) or knocking out the common Smad4 (Karlsson et al., 2007) suggests that this might be an option. It has for example been shown that crosstalk between BMP and Wnt signaling is vital during early embryonic development in *Xenopus* (Niehrs, 2004). To address this question it would be interesting to perform an expression profile analysis of Smad1/5 deficient LSK CD34- cells to look for changes in other regulatory pathways.

Complete Knockout of Endoglin

It is unexpected that altering expression of a marker that selectively marks long-term repopulating HSCs like endoglin does not affect any of the measured functions of transplanted HSCs. We are confident that our dual approach to both over-express and knock down endoglin expression, in combination with using stringent and correct assays to assess HSC self-renewal and differentiation ability, would have revealed a potential role for endoglin in regulating hematopoiesis if there was one. Using an shRNA strategy we achieved an approximate 80% knock-down of endoglin expression, which was sustained long-term throughout *in vivo* transplantations at the protein level. However, it could be argued that the remaining 20 % of normal endoglin expression potentially might rescue a hypothetical phenotype. To address this, one could repeat our study in an endoglin knockout mouse. A conditional knockout mouse for endoglin is available, and could be crossed onto the MxCre or VavCre background to study the role of complete endoglin deficiency in adult murine hematopoiesis.

PUBLICATIONS NOT INCLUDED IN THE THESIS

1. **Smad4 is critical for self-renewal of hematopoietic stem cells.**
Karlsson G, Blank U, Moody J.L, Ehinger M, Singbrant S, Deng CX, Karlsson S. *Journal of Experimental Medicine* 19;204 (3):467-74 (2007)
2. **Smad7 promotes self-renewal of hematopoietic stem cells in vivo.**
Blank U, Karlsson G, Moody J.L, Utsugisawa T, Magnusson M, Singbrant S, Larsson J, Karlsson S. *Blood* 15;108 (13):4246-54 (2006)

ACKNOWLEDGEMENTS

This work has been performed in the department of Molecular Medicine and Gene Therapy over the past five and a half years, and I would like to take this opportunity to thank all of the past and present members of the department for a wonderful time. Although I have loved working with science, no job in world is fun and inspiring every single day. But thanks to you my dear colleagues I can honestly say that I have truly enjoyed going to work. So thank you for all your help, the laughter, all weird expressions in foreign languages, and your friendship. It has been a pleasure working with you! There are some people I would especially like to thank...

First of all I would like to express my gratitude to my supervisor *Stefan Karlsson* for believing in me and giving me the opportunity to be a part of the interesting science that takes place in your lab. You have created a fantastic scientific environment where top science meets a friendly and relaxed atmosphere, creating a platform where people collaborate and learn from each other instead of competing. Thank you!

I would also like to direct a special thanks to the fantastic members of the Smad group. *Jennifer Moody*, my brilliant mentor and role model in science. I'm so grateful for all that you've taught me, and for your friendship. Article III obviously would not be a part of this thesis if it weren't for you. You have an impressive way of being realistically pessimistic with a smile on your face. I can only hope to become as good as you one day. *Göran Karlsson*, my time in the lab would not have been the same without you. Thank you for always taking the time to help me when I needed it, especially with critically reading this thesis and the manuscripts. Your brutal honesty is greatly appreciated (much more than your lies). You will become a great group leader in the future. *Ulrika Blank*, thank you for taking such good care of me during my first year in the lab, and for your contribution to my first paper. The lab is lucky to have you back. *Ronan Quere*, thank you for contributing to our excellent office spirit, but also for walking the streets of Manhattan with me for hours and hours and making our short trip to NY such a great stay. I would also like to thank Taiju Utsugisawa, *Pekka Jaako*, *Silja Andradottir*, and *Gudrun Eiriksdottir* for their contribution to this work.

Furthermore, I would like to show my appreciation to some additional co-workers. *Maria (Maarja) Askmyr*, for so many different things. You are a great friend, and I am very glad that we will soon be

colleagues again. Who knew?! I have a feeling that working in Melbourne will be a lot of fun! *Ida Berglin Enquist* for kindly taking the time to critically read this thesis, and giving me chocolate when I needed it the most. *Marianne Rissler*, for being a great roommate, always spreading light and positive thinking, as well as some highly unexpected comments. *Eva Nilsson* and *Karin Olsson*, you are the backbone of this lab. We all depend on your organization skills and your consideration about the wellbeing of us all. Thank you for taking care of us! *Ann Brun*, for sharing your knowledge in science and food with me, and for your encouraging messages from the dessert while writing this thesis. Additionally, I would like to thank *Johan Richter*, *Jonas Larsson*, och *Jörg Cammenga* for always answering my questions, and for bringing your terrific groups members to the department.

I would also like to thank our collaborators for their contribution to this work; *David Bryder* for your brilliant FACS skills, *Mats Ehinger* for the histopathology, and *An Zwijsen*, *Thomas Graf*, and *Anita Roberts* for sharing your mice with me. Moreover, thank you *Eva Gynnstam* and the rest of the staff in the animal facility for taking care of our mice, as well as *Zhi Ma* and *Anna Fossum* for technical support. I would also like to direct a special thanks to *Anders Malmström* for accepting me to the Biomedical Research School back in 2002 and sharing your enthusiasm for science. If it weren't for you I wouldn't be defending this thesis now.

Although these last months have not been a good example, life is more than just work. So I would also like to express my gratitude to those of you who bright up my life by just being there. My amazing *childhood friends*! With you I never have to explain, and we can talk about anything. I'm so happy to be a part of us. "*TURN-tjejerna*", thank you all for taking me in when I moved to Helsingborg. You are so considerate, kind, and a lot of fun to be with. I couldn't have met better friends. Moreover I want to thank the wonderful people I met during my studies in Kalmar. Those were the days! Although some of us don't meet as often anymore, you still mean a lot to me. A special thanks to *Ruben and Anna Linton*, *Susie Hjorthagen*, *Jenny Kastberg* and *Åsa Odenbring* for helping me out with the defense-party. Also, thank you *Ola Bruno*, for so generously sharing your home with me so that I had somewhere to write during the weekends.

Last, but not the least, I turn to my wonderful family. Mum and Dad, *Eva and Owe Singbrant*, the way you have guided and supported me with your love and advice through my many choices in life has made me who I am today. You always make me feel loved, and that I'm good enough as I am. Thank you so much for everything, I could not have asked for better

parents! My beautiful sisters, *Therése and Christine Singbrant*, you mean the world to me. No one knows me like you do, and no one can make me smile like you. You are the best sisters I've got =) I would also like to thank my bonus family *Maj, Göran, Kristina, Andreas* and your families, for taking me to your hearts and always being there for Simon, Tilde and me whenever we need you.

Above all, I would like to express my deepest appreciation to my wonderful husband *Simon Söderberg* and our lovely daughter *Tilde*. Simon, not only are you an amazing husband, but you are also a fantastic dad. I'm so lucky to have met you. Tilde, you can turn the worst day around just by smiling that incredible smile of yours. I love you both with all of my heart!

REFERENCES

- Adolfsson, J., Borge, O. J., Bryder, D., Theilgaard-Monch, K., Astrand-Grundstrom, I., Sitnicka, E., Sasaki, Y., and Jacobsen, S. E. (2001). Upregulation of Flt3 expression within the bone marrow Lin(-)Sca1(+)c-kit(+) stem cell compartment is accompanied by loss of self-renewal capacity. *Immunity* *15*, 659-669.
- Adolfsson, J., Mansson, R., Buza-Vidas, N., Hultquist, A., Liuba, K., Jensen, C. T., Bryder, D., Yang, L., Borge, O. J., Thoren, L. A., *et al.* (2005). Identification of Flt3+ lymphomyeloid stem cells lacking erythro-megakaryocytic potential a revised road map for adult blood lineage commitment. *Cell* *121*, 295-306.
- Afan, A. M., Broome, C. S., Nicholls, S. E., Whetton, A. D., and Miyazawa, J. A. (1997). Bone marrow innervation regulates cellular retention in the murine haemopoietic system. *Br J Haematol* *98*, 569-577.
- Akala, O. O., and Clarke, M. F. (2006). Hematopoietic stem cell self-renewal. *Curr Opin Genet Dev* *16*, 496-501.
- Akashi, K., Traver, D., Miyamoto, T., and Weissman, I. L. (2000). A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. *Nature* *404*, 193-197.
- Akira, S., Uematsu, S., and Takeuchi, O. (2006). Pathogen recognition and innate immunity. *Cell* *124*, 783-801.
- Alvarez-Silva, M., Belo-Diabangouaya, P., Salaun, J., and Dieterlen-Lievre, F. (2003). Mouse placenta is a major hematopoietic organ. *Development* *130*, 5437-5444.
- Antonchuk, J., Sauvageau, G., and Humphries, R. K. (2002). HOXB4-induced expansion of adult hematopoietic stem cells ex vivo. *Cell* *109*, 39-45.
- Ara, T., Tokoyoda, K., Sugiyama, T., Egawa, T., Kawabata, K., and Nagasawa, T. (2003). Long-term hematopoietic stem cells require stromal cell-derived factor-1 for colonizing bone marrow during ontogeny. *Immunity* *19*, 257-267.
- Arai, F., Hirao, A., Ohmura, M., Sato, H., Matsuoka, S., Takubo, K., Ito, K., Koh, G. Y., and Suda, T. (2004). Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. *Cell* *118*, 149-161.
- Arnold, S. J., Maretto, S., Islam, A., Bikoff, E. K., and Robertson, E. J. (2006). Dose-dependent Smad1, Smad5 and Smad8 signaling in the early mouse embryo. *Dev Biol*.
- Arthur, H. M., Ure, J., Smith, A. J., Renforth, G., Wilson, D. I., Torsney, E., Charlton, R., Parums, D. V., Jowett, T., Marchuk, D. A., *et al.* (2000). Endoglin, an ancillary TGFbeta receptor, is required for extraembryonic angiogenesis and plays a key role in heart development. *Dev Biol* *217*, 42-53.
- Askmyr, M. K., Fasth, A., and Richter, J. (2008). Towards a better understanding and new therapeutics of osteopetrosis. *Br J Haematol* *140*, 597-609.

- Audet, J., Miller, C. L., Rose-John, S., Piret, J. M., and Eaves, C. J. (2001). Distinct role of gp130 activation in promoting self-renewal divisions by mitogenically stimulated murine hematopoietic stem cells. *Proc Natl Acad Sci U S A* *98*, 1757-1762.
- Balazs, A. B., Fabian, A. J., Esmon, C. T., and Mulligan, R. C. (2006). Endothelial protein C receptor (CD201) explicitly identifies hematopoietic stem cells in murine bone marrow. *Blood* *107*, 2317-2321.
- Barker, J. N., and Wagner, J. E. (2003). Umbilical cord blood transplantation: current practice and future innovations. *Crit Rev Oncol Hematol* *48*, 35-43.
- Batard, P., Monier, M. N., Fortunel, N., Ducos, K., Sansilvestri-Morel, P., Phan, T., Hatzfeld, A., and Hatzfeld, J. A. (2000). TGF-(beta)1 maintains hematopoietic immaturity by a reversible negative control of cell cycle and induces CD34 antigen up-modulation. *J Cell Sci* *113 (Pt 3)*, 383-390.
- Becker, A. J., Mc, C. E., and Till, J. E. (1963). Cytological demonstration of the clonal nature of spleen colonies derived from transplanted mouse marrow cells. *Nature* *197*, 452-454.
- Beilhack, G. F., Landa, R. R., Masek, M. A., and Shizuru, J. A. (2005). Prevention of type 1 diabetes with major histocompatibility complex-compatible and nonmarrow ablative hematopoietic stem cell transplants. *Diabetes* *54*, 1770-1779.
- Benestad, H. B., Strom-Gundersen, I., Iversen, P. O., Haug, E., and Nja, A. (1998). No neuronal regulation of murine bone marrow function. *Blood* *91*, 1280-1287.
- Benveniste, P., Cantin, C., Hyam, D., and Iscove, N. N. (2003). Hematopoietic stem cells engraft in mice with absolute efficiency. *Nat Immunol* *4*, 708-713.
- Beppu, H., Kawabata, M., Hamamoto, T., Chytil, A., Minowa, O., Noda, T., and Miyazono, K. (2000). BMP type II receptor is required for gastrulation and early development of mouse embryos. *Dev Biol* *221*, 249-258.
- Bhardwaj, G., Murdoch, B., Wu, D., Baker, D. P., Williams, K. P., Chadwick, K., Ling, L. E., Karanu, F. N., and Bhatia, M. (2001). Sonic hedgehog induces the proliferation of primitive human hematopoietic cells via BMP regulation. *Nat Immunol* *2*, 172-180.
- Bhatia, M., Bonnet, D., Wu, D., Murdoch, B., Wrana, J., Gallacher, L., and Dick, J. E. (1999). Bone morphogenetic proteins regulate the developmental program of human hematopoietic stem cells. *J Exp Med* *189*, 1139-1148.
- Bhattacharya, D., Rossi, D. J., Bryder, D., and Weissman, I. L. (2006). Purified hematopoietic stem cell engraftment of rare niches corrects severe lymphoid deficiencies without host conditioning. *J Exp Med* *203*, 73-85.
- Blanco, F. J., Santibanez, J. F., Guerrero-Esteo, M., Langa, C., Vary, C. P., and Bernabeu, C. (2005). Interaction and functional interplay between endoglin and ALK-1, two components of the endothelial transforming growth factor-beta receptor complex. *J Cell Physiol* *204*, 574-584.
- Blank, U., Karlsson, G., and Karlsson, S. (2008). Signaling pathways governing stem-cell fate. *Blood* *111*, 492-503.

Blank, U., Karlsson, G., Moody, J. L., Utsugisawa, T., Magnusson, M., Singbrant, S., Larsson, J., and Karlsson, S. (2006). Smad7 promotes self-renewal of hematopoietic stem cells. *Blood* 108, 4246-4254.

Bourdeau, A., Dumont, D. J., and Letarte, M. (1999). A murine model of hereditary hemorrhagic telangiectasia. *J Clin Invest* 104, 1343-1351.

Bowie, M. B., McKnight, K. D., Kent, D. G., McCaffrey, L., Hoodless, P. A., and Eaves, C. J. (2006). Hematopoietic stem cells proliferate until after birth and show a reversible phase-specific engraftment defect. *J Clin Invest* 116, 2808-2816.

Bradford, G. B., Williams, B., Rossi, R., and Bertoncello, I. (1997). Quiescence, cycling, and turnover in the primitive hematopoietic stem cell compartment. *Exp Hematol* 25, 445-453.
Bradley, T. R., and Metcalf, D. (1966). The growth of mouse bone marrow cells in vitro. *Aust J Exp Biol Med Sci* 44, 287-299.

Broxmeyer, H. E., Douglas, G. W., Hangoc, G., Cooper, S., Bard, J., English, D., Arny, M., Thomas, L., and Boyse, E. A. (1989). Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells. *Proc Natl Acad Sci U S A* 86, 3828-3832.

Brun, A. C., Bjornsson, J. M., Magnusson, M., Larsson, N., Leveen, P., Ehinger, M., Nilsson, E., and Karlsson, S. (2004). Hoxb4-deficient mice undergo normal hematopoietic development but exhibit a mild proliferation defect in hematopoietic stem cells. *Blood* 103, 4126-4133.

Bruno, E., Horrigan, S. K., Van Den Berg, D., Rozler, E., Fitting, P. R., Moss, S. T., Westbrook, C., and Hoffman, R. (1998). The Smad5 gene is involved in the intracellular signaling pathways that mediate the inhibitory effects of transforming growth factor-beta on human hematopoiesis. *Blood* 91, 1917-1923.

Bryder, D., and Jacobsen, S. E. (2000). Interleukin-3 supports expansion of long-term multilineage repopulating activity after multiple stem cell divisions in vitro. *Blood* 96, 1748-1755.

Bryder, D., Ramsfjell, V., Dybedal, I., Theilgaard-Monch, K., Hogerkorp, C. M., Adolfsson, J., Borge, O. J., and Jacobsen, S. E. (2001). Self-renewal of multipotent long-term repopulating hematopoietic stem cells is negatively regulated by Fas and tumor necrosis factor receptor activation. *J Exp Med* 194, 941-952.

Buhring, H. J., Muller, C. A., Letarte, M., Gougos, A., Saalmuller, A., van Agthoven, A. J., and Busch, F. W. (1991). Endoglin is expressed on a subpopulation of immature erythroid cells of normal human bone marrow. *Leukemia* 5, 841-847.

Buza-Vidas, N., Antonchuk, J., Qian, H., Mansson, R., Luc, S., Zandi, S., Anderson, K., Takaki, S., Nygren, J. M., Jensen, C. T., and Jacobsen, S. E. (2006). Cytokines regulate postnatal hematopoietic stem cell expansion: opposing roles of thrombopoietin and LNK. *Genes Dev* 20, 2018-2023.

Calabro, L., Fonsatti, E., Bellomo, G., Alonci, A., Colizzi, F., Sigalotti, L., Altomonte, M., Musolino, C., and Maio, M. (2003). Differential levels of soluble endoglin (CD105) in myeloid malignancies. *J Cell Physiol* 194, 171-175.

- Calvi, L. M., Adams, G. B., Weibrecht, K. W., Weber, J. M., Olson, D. P., Knight, M. C., Martin, R. P., Schipani, E., Divieti, P., Bringham, F. R., *et al.* (2003). Osteoblastic cells regulate the haematopoietic stem cell niche. *Nature* 425, 841-846.
- Camargo, F. D., Chambers, S. M., Drew, E., McNagny, K. M., and Goodell, M. A. (2006). Hematopoietic stem cells do not engraft with absolute efficiencies. *Blood* 107, 501-507.
- Cavazzana-Calvo, M., and Fischer, A. (2007). Gene therapy for severe combined immunodeficiency: are we there yet? *J Clin Invest* 117, 1456-1465.
- Cavazzana-Calvo, M., Hacein-Bey, S., de Saint Basile, G., Gross, F., Yvon, E., Nusbaum, P., Selz, F., Hue, C., Certain, S., Casanova, J. L., *et al.* (2000). Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. *Science* 288, 669-672.
- Chadwick, K., Wang, L., Li, L., Menendez, P., Murdoch, B., Rouleau, A., and Bhatia, M. (2003). Cytokines and BMP-4 promote hematopoietic differentiation of human embryonic stem cells. *Blood* 102, 906-915.
- Chang, H., Huylebroeck, D., Verschueren, K., Guo, Q., Matzuk, M. M., and Zwijsen, A. (1999). Smad5 knockout mice die at mid-gestation due to multiple embryonic and extraembryonic defects. *Development* 126, 1631-1642.
- Chen, C. Z., Li, L., Li, M., and Lodish, H. F. (2003). The endoglin(positive) sca-1(positive) rhodamine(low) phenotype defines a near-homogeneous population of long-term repopulating hematopoietic stem cells. *Immunity* 19, 525-533.
- Chen, C. Z., Li, M., de Graaf, D., Monti, S., Gottgens, B., Sanchez, M. J., Lander, E. S., Golub, T. R., Green, A. R., and Lodish, H. F. (2002). Identification of endoglin as a functional marker that defines long-term repopulating hematopoietic stem cells. *Proc Natl Acad Sci U S A* 99, 15468-15473.
- Cheng, T. (2004). Cell cycle inhibitors in normal and tumor stem cells. *Oncogene* 23, 7256-7266.
- Cheng, T., Rodrigues, N., Dombkowski, D., Stier, S., and Scadden, D. T. (2000a). Stem cell repopulation efficiency but not pool size is governed by p27(kip1). *Nat Med* 6, 1235-1240.
- Cheng, T., Rodrigues, N., Shen, H., Yang, Y., Dombkowski, D., Sykes, M., and Scadden, D. T. (2000b). Hematopoietic stem cell quiescence maintained by p21cip1/waf1. *Science* 287, 1804-1808.
- Cheng, T., Shen, H., Rodrigues, N., Stier, S., and Scadden, D. T. (2001). Transforming growth factor beta 1 mediates cell-cycle arrest of primitive hematopoietic cells independent of p21(Cip1/Waf1) or p27(Kip1). *Blood* 98, 3643-3649.
- Cheshier, S. H., Morrison, S. J., Liao, X., and Weissman, I. L. (1999). In vivo proliferation and cell cycle kinetics of long-term self-renewing hematopoietic stem cells. *Proc Natl Acad Sci U S A* 96, 3120-3125.
- Cho, S. K., Bourdeau, A., Letarte, M., and Zuniga-Pflucker, J. C. (2001). Expression and function of CD105 during the onset of hematopoiesis from Flk1(+) precursors. *Blood* 98, 3635-3642.

- Cobas, M., Wilson, A., Ernst, B., Mancini, S. J., MacDonald, H. R., Kemler, R., and Radtke, F. (2004). Beta-catenin is dispensable for hematopoiesis and lymphopoiesis. *J Exp Med* 199, 221-229.
- Congdon, K. L., and Reya, T. (2008). Divide and conquer: how asymmetric division shapes cell fate in the hematopoietic system. *Curr Opin Immunol* 20, 302-307.
- Copelan, E. A. (2006). Hematopoietic stem-cell transplantation. *N Engl J Med* 354, 1813-1826.
- Cottler-Fox, M. H., Lapidot, T., Petit, I., Kollet, O., DiPersio, J. F., Link, D., and Devine, S. (2003). Stem cell mobilization. *Hematology Am Soc Hematol Educ Program*, 419-437.
- Cumano, A., Dieterlen-Lievre, F., and Godin, I. (1996). Lymphoid potential, probed before circulation in mouse, is restricted to caudal intraembryonic splanchnopleura. *Cell* 86, 907-916.
- Cumano, A., Ferraz, J. C., Klaine, M., Di Santo, J. P., and Godin, I. (2001). Intraembryonic, but not yolk sac hematopoietic precursors, isolated before circulation, provide long-term multilineage reconstitution. *Immunity* 15, 477-485.
- Dale, L., Howes, G., Price, B. M., and Smith, J. C. (1992). Bone morphogenetic protein 4: a ventralizing factor in early *Xenopus* development. *Development* 115, 573-585.
- Daley, G. Q., and Scadden, D. T. (2008). Prospects for stem cell-based therapy. *Cell* 132, 544-548.
- de Bruijn, M. F., Speck, N. A., Peeters, M. C., and Dzierzak, E. (2000). Definitive hematopoietic stem cells first develop within the major arterial regions of the mouse embryo. *Embo J* 19, 2465-2474.
- de Haan, G., Weersing, E., Dontje, B., van Os, R., Bystrykh, L. V., Vellenga, E., and Miller, G. (2003). In vitro generation of long-term repopulating hematopoietic stem cells by fibroblast growth factor-1. *Dev Cell* 4, 241-251.
- de Martin, R., Haendler, B., Hofer-Warbinek, R., Gaugitsch, H., Wrann, M., Schlusener, H., Seifert, J. M., Bodmer, S., Fontana, A., and Hofer, E. (1987). Complementary DNA for human glioblastoma-derived T cell suppressor factor, a novel member of the transforming growth factor-beta gene family. *Embo J* 6, 3673-3677.
- Delassus, S., and Cumano, A. (1996). Circulation of hematopoietic progenitors in the mouse embryo. *Immunity* 4, 97-106.
- Dennler, S., Itoh, S., Vivien, D., ten Dijke, P., Huet, S., and Gauthier, J. M. (1998). Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. *Embo J* 17, 3091-3100.
- Derynck, R., Jarrett, J. A., Chen, E. Y., Eaton, D. H., Bell, J. R., Assoian, R. K., Roberts, A. B., Sporn, M. B., and Goeddel, D. V. (1985). Human transforming growth factor-beta complementary DNA sequence and expression in normal and transformed cells. *Nature* 316, 701-705.

Derynck, R., Lindquist, P. B., Lee, A., Wen, D., Tamm, J., Graycar, J. L., Rhee, L., Mason, A. J., Miller, D. A., Coffey, R. J., and et al. (1988). A new type of transforming growth factor-beta, TGF-beta 3. *Embo J* 7, 3737-3743.

Derynck, R., and Zhang, Y. E. (2003). Smad-dependent and Smad-independent pathways in TGF-beta family signalling. *Nature* 425, 577-584.

Detmer, K., and Walker, A. N. (2002). Bone morphogenetic proteins act synergistically with haematopoietic cytokines in the differentiation of haematopoietic progenitors. *Cytokine* 17, 36-42.

Di Santo, J. P. (2006). Natural killer cell developmental pathways: a question of balance. *Annu Rev Immunol* 24, 257-286.

Dick, J. E., Guenechea, G., Gan, O. I., and Dorrell, C. (2001). In vivo dynamics of human stem cell repopulation in NOD/SCID mice. *Ann N Y Acad Sci* 938, 184-190.

Dick, J. E., Magli, M. C., Huszar, D., Phillips, R. A., and Bernstein, A. (1985). Introduction of a selectable gene into primitive stem cells capable of long-term reconstitution of the hemopoietic system of W/W^v mice. *Cell* 42, 71-79.

Dickson, M. C., Martin, J. S., Cousins, F. M., Kulkarni, A. B., Karlsson, S., and Akhurst, R. J. (1995). Defective haematopoiesis and vasculogenesis in transforming growth factor-beta 1 knock out mice. *Development* 121, 1845-1854.

Dieterlen-Lievre, F. (1998). Hematopoiesis: progenitors and their genetic program. *Curr Biol* 8, R727-730.

Domen, J., Cheshier, S. H., and Weissman, I. L. (2000). The role of apoptosis in the regulation of hematopoietic stem cells: Overexpression of Bcl-2 increases both their number and repopulation potential. *J Exp Med* 191, 253-264.

Domen, J., and Weissman, I. L. (2000). Hematopoietic stem cells need two signals to prevent apoptosis; BCL-2 can provide one of these, Kitl/c-Kit signaling the other. *J Exp Med* 192, 1707-1718.

Domen, J., and Weissman, I. L. (2003). Hematopoietic stem cells and other hematopoietic cells show broad resistance to chemotherapeutic agents in vivo when overexpressing bcl-2. *Exp Hematol* 31, 631-639.

Donahue, R. E., Kirby, M. R., Metzger, M. E., Agricola, B. A., Sellers, S. E., and Cullis, H. M. (1996). Peripheral blood CD34⁺ cells differ from bone marrow CD34⁺ cells in Thy-1 expression and cell cycle status in nonhuman primates mobilized or not mobilized with granulocyte colony-stimulating factor and/or stem cell factor. *Blood* 87, 1644-1653.

Driessen, R. L., Johnston, H. M., and Nilsson, S. K. (2003). Membrane-bound stem cell factor is a key regulator in the initial lodgment of stem cells within the endosteal marrow region. *Exp Hematol* 31, 1284-1291.

Dubois, C. M., Ruscetti, F. W., Palaszynski, E. W., Falk, L. A., Oppenheim, J. J., and Keller, J. R. (1990). Transforming growth factor beta is a potent inhibitor of interleukin 1 (IL-1) receptor expression: proposed mechanism of inhibition of IL-1 action. *J Exp Med* 172, 737-744.

- Dubois, C. M., Ruscetti, F. W., Stankova, J., and Keller, J. R. (1994). Transforming growth factor-beta regulates c-kit message stability and cell-surface protein expression in hematopoietic progenitors. *Blood* 83, 3138-3145.
- Duff, S. E., Li, C., Garland, J. M., and Kumar, S. (2003). CD105 is important for angiogenesis: evidence and potential applications. *Faseb J* 17, 984-992.
- Duncan, A. W., Rattis, F. M., DiMascio, L. N., Congdon, K. L., Pazianos, G., Zhao, C., Yoon, K., Cook, J. M., Willert, K., Gaiano, N., and Reya, T. (2005). Integration of Notch and Wnt signaling in hematopoietic stem cell maintenance. *Nat Immunol* 6, 314-322.
- Dykxhoorn, D. M., Novina, C. D., and Sharp, P. A. (2003). Killing the messenger: short RNAs that silence gene expression. *Nat Rev Mol Cell Biol* 4, 457-467.
- Dzierzak, E., and Speck, N. A. (2008). Of lineage and legacy: the development of mammalian hematopoietic stem cells. *Nat Immunol* 9, 129-136.
- Eilers, M., Schirm, S., and Bishop, J. M. (1991). The MYC protein activates transcription of the alpha-prothymosin gene. *Embo J* 10, 133-141.
- Ema, H., and Nakauchi, H. (2000). Expansion of hematopoietic stem cells in the developing liver of a mouse embryo. *Blood* 95, 2284-2288.
- Ema, H., Sudo, K., Seita, J., Matsubara, A., Morita, Y., Osawa, M., Takatsu, K., Takaki, S., and Nakauchi, H. (2005). Quantification of self-renewal capacity in single hematopoietic stem cells from normal and Lnk-deficient mice. *Dev Cell* 8, 907-914.
- Ema, H., Takano, H., Sudo, K., and Nakauchi, H. (2000). In vitro self-renewal division of hematopoietic stem cells. *J Exp Med* 192, 1281-1288.
- Enver, T., Heyworth, C. M., and Dexter, T. M. (1998). Do stem cells play dice? *Blood* 92, 348-351; discussion 352.
- Fan, X., Valdimarsdottir, G., Larsson, J., Brun, A., Magnusson, M., Jacobsen, S. E., ten Dijke, P., and Karlsson, S. (2002). Transient disruption of autocrine TGF-beta signaling leads to enhanced survival and proliferation potential in single primitive human hemopoietic progenitor cells. *J Immunol* 168, 755-762.
- Ficara, F., Murphy, M. J., Lin, M., and Cleary, M. L. (2008). Pbx1 regulates self-renewal of long-term hematopoietic stem cells by maintaining their quiescence. *Cell Stem Cell* 2, 484-496.
- Flanders, K. C., Kim, E. S., and Roberts, A. B. (2001). Immunohistochemical expression of Smads 1-6 in the 15-day gestation mouse embryo: signaling by BMPs and TGF-betas. *Dev Dyn* 220, 141-154.
- Fonsatti, E., Del Vecchio, L., Altomonte, M., Sigalotti, L., Nicotra, M. R., Coral, S., Natali, P. G., and Maio, M. (2001). Endoglin: An accessory component of the TGF-beta-binding receptor-complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies. *J Cell Physiol* 188, 1-7.
- Fonsatti, E., and Maio, M. (2004). Highlights on endoglin (CD105): from basic findings towards clinical applications in human cancer. *J Transl Med* 2, 18.

- Ford, C. E., Hamerton, J. L., Barnes, D. W., and Loutit, J. F. (1956). Cytological identification of radiation-chimaeras. *Nature* 177, 452-454.
- Fortunel, N. O., Hatzfeld, A., and Hatzfeld, J. A. (2000). Transforming growth factor-beta: pleiotropic role in the regulation of hematopoiesis. *Blood* 96, 2022-2036.
- Fuchs, O., Simakova, O., Klener, P., Cmejlova, J., Zivny, J., Zavadil, J., and Stopka, T. (2002). Inhibition of Smad5 in human hematopoietic progenitors blocks erythroid differentiation induced by BMP4. *Blood Cells Mol Dis* 28, 221-233.
- Gekas, C., Dieterlen-Lievre, F., Orkin, S. H., and Mikkola, H. K. (2005). The placenta is a niche for hematopoietic stem cells. *Dev Cell* 8, 365-375.
- Gering, M., Rodaway, A. R., Gottgens, B., Patient, R. K., and Green, A. R. (1998). The SCL gene specifies haemangioblast development from early mesoderm. *Embo J* 17, 4029-4045.
- Germain, R. N. (2001). The art of the probable: system control in the adaptive immune system. *Science* 293, 240-245.
- Glimm, H., Oh, I. H., and Eaves, C. J. (2000). Human hematopoietic stem cells stimulated to proliferate in vitro lose engraftment potential during their S/G(2)/M transit and do not reenter G(0). *Blood* 96, 4185-4193.
- Goey, H., Keller, J. R., Back, T., Longo, D. L., Ruscetti, F. W., and Wiltout, R. H. (1989). Inhibition of early murine hemopoietic progenitor cell proliferation after in vivo locoregional administration of transforming growth factor-beta 1. *J Immunol* 143, 877-880.
- Goff, J. P., Shields, D. S., and Greenberger, J. S. (1998). Influence of cytokines on the growth kinetics and immunophenotype of daughter cells resulting from the first division of single CD34(+)Thy-1(+)lin- cells. *Blood* 92, 4098-4107.
- Golub, T. R., McLean, T., Stegmaier, K., Carroll, M., Tomasson, M., and Gilliland, D. G. (1996). The TEL gene and human leukemia. *Biochim Biophys Acta* 1288, M7-10.
- Goodell, M. A., Brose, K., Paradis, G., Conner, A. S., and Mulligan, R. C. (1996). Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. *J Exp Med* 183, 1797-1806.
- Goumans, M. J., Valdimarsdottir, G., Itoh, S., Lebrin, F., Larsson, J., Mummery, C., Karlsson, S., and ten Dijke, P. (2003). Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFbeta/ALK5 signaling. *Mol Cell* 12, 817-828.
- Goumans, M. J., Valdimarsdottir, G., Itoh, S., Rosendahl, A., Sideras, P., and ten Dijke, P. (2002). Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. *Embo J* 21, 1743-1753.
- Gu, Y., Filippi, M. D., Cancelas, J. A., Siefring, J. E., Williams, E. P., Jasti, A. C., Harris, C. E., Lee, A. W., Prabhakar, R., Atkinson, S. J., *et al.* (2003). Hematopoietic cell regulation by Rac1 and Rac2 guanosine triphosphatases. *Science* 302, 445-449.
- Guo, X., and Wang, X. F. (2008). Signaling cross-talk between TGF-beta/BMP and other pathways. *Cell Res.*

Gupta, S., Zhu, H., Zon, L. I., and Evans, T. (2006). BMP signaling restricts hemato-vascular development from lateral mesoderm during somitogenesis. *Development* 133, 2177-2187.

Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., *et al.* (2003). LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. *Science* 302, 415-419.

Harrison, D. E., Astle, C. M., and Delaittre, J. A. (1978). Loss of proliferative capacity in immunohemopoietic stem cells caused by serial transplantation rather than aging. *J Exp Med* 147, 1526-1531.

Harrison, D. E., Jordan, C. T., Zhong, R. K., and Astle, C. M. (1993). Primitive hemopoietic stem cells: direct assay of most productive populations by competitive repopulation with simple binomial, correlation and covariance calculations. *Exp Hematol* 21, 206-219.

Haylock, D. N., and Nilsson, S. K. (2005). Stem cell regulation by the hematopoietic stem cell niche. *Cell Cycle* 4, 1353-1355.

Haylock, D. N., and Nilsson, S. K. (2006). Osteopontin: a bridge between bone and blood. *Br J Haematol* 134, 467-474.

Haylock, D. N., Williams, B., Johnston, H. M., Liu, M. C., Rutherford, K. E., Whitty, G. A., Simmons, P. J., Bertoncello, I., and Nilsson, S. K. (2007). Hemopoietic stem cells with higher hemopoietic potential reside at the bone marrow endosteum. *Stem Cells* 25, 1062-1069.

He, W., Dorn, D. C., Erdjument-Bromage, H., Tempst, P., Moore, M. A., and Massague, J. (2006). Hematopoiesis controlled by distinct TIF1gamma and Smad4 branches of the TGFbeta pathway. *Cell* 125, 929-941.

He, X. C., Zhang, J., Tong, W. G., Tawfik, O., Ross, J., Scoville, D. H., Tian, Q., Zeng, X., He, X., Wiedemann, L. M., *et al.* (2004). BMP signaling inhibits intestinal stem cell self-renewal through suppression of Wnt-beta-catenin signaling. *Nat Genet* 36, 1117-1121.

Hirao, A., Arai, F., and Suda, T. (2004). Regulation of cell cycle in hematopoietic stem cells by the niche. *Cell Cycle* 3, 1481-1483.

Hock, H., Hamblen, M. J., Rooke, H. M., Schindler, J. W., Saleque, S., Fujiwara, Y., and Orkin, S. H. (2004a). Gfi-1 restricts proliferation and preserves functional integrity of haematopoietic stem cells. *Nature* 431, 1002-1007.

Hock, H., Meade, E., Medeiros, S., Schindler, J. W., Valk, P. J., Fujiwara, Y., and Orkin, S. H. (2004b). Tel/Etv6 is an essential and selective regulator of adult hematopoietic stem cell survival. *Genes Dev* 18, 2336-2341.

Hofmeister, C. C., Zhang, J., Knight, K. L., Le, P., and Stiff, P. J. (2007). Ex vivo expansion of umbilical cord blood stem cells for transplantation: growing knowledge from the hematopoietic niche. *Bone Marrow Transplant* 39, 11-23.

Hogan, B. L. (1996). Bone morphogenetic proteins in development. *Curr Opin Genet Dev* 6, 432-438.

- Hsu, H. C., Ema, H., Osawa, M., Nakamura, Y., Suda, T., and Nakauchi, H. (2000). Hematopoietic stem cells express Tie-2 receptor in the murine fetal liver. *Blood* 96, 3757-3762.
- Hu, M., Krause, D., Greaves, M., Sharkis, S., Dexter, M., Heyworth, C., and Enver, T. (1997). Multilineage gene expression precedes commitment in the hemopoietic system. *Genes Dev* 11, 774-785.
- Huang, S., Tang, B., Usoskin, D., Lechleider, R. J., Jamin, S. P., Li, C., Anzano, M. A., Ebendal, T., Deng, C., and Roberts, A. B. (2002). Conditional knockout of the Smad1 gene. *Genesis* 32, 76-79.
- Huber, T. L., Zhou, Y., Mead, P. E., and Zon, L. I. (1998). Cooperative effects of growth factors involved in the induction of hematopoietic mesoderm. *Blood* 92, 4128-4137.
- Ichikawa, M., Asai, T., Saito, T., Seo, S., Yamazaki, I., Yamagata, T., Mitani, K., Chiba, S., Ogawa, S., Kurokawa, M., and Hirai, H. (2004). AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis. *Nat Med* 10, 299-304.
- Ikuta, K., and Weissman, I. L. (1992). Evidence that hematopoietic stem cells express mouse c-kit but do not depend on steel factor for their generation. *Proc Natl Acad Sci U S A* 89, 1502-1506.
- Ito, M., Kobayashi, K., and Nakahata, T. (2008). NOD/Shi-scid IL2rgamma(null) (NOG) mice more appropriate for humanized mouse models. *Curr Top Microbiol Immunol* 324, 53-76.
- Iwama, A., Oguro, H., Negishi, M., Kato, Y., Morita, Y., Tsukui, H., Ema, H., Kamijo, T., Katoh-Fukui, Y., Koseki, H., *et al.* (2004). Enhanced self-renewal of hematopoietic stem cells mediated by the polycomb gene product Bmi-1. *Immunity* 21, 843-851.
- Jacobsen, F. W., Stokke, T., and Jacobsen, S. E. (1995). Transforming growth factor-beta potently inhibits the viability-promoting activity of stem cell factor and other cytokines and induces apoptosis of primitive murine hematopoietic progenitor cells. *Blood* 86, 2957-2966.
- Jacobsen, S. E., Keller, J. R., Ruscetti, F. W., Kondaiah, P., Roberts, A. B., and Falk, L. A. (1991a). Bidirectional effects of transforming growth factor beta (TGF-beta) on colony-stimulating factor-induced human myelopoiesis in vitro: differential effects of distinct TGF-beta isoforms. *Blood* 78, 2239-2247.
- Jacobsen, S. E., Ruscetti, F. W., Dubois, C. M., Lee, J., Boone, T. C., and Keller, J. R. (1991b). Transforming growth factor-beta trans-modulates the expression of colony stimulating factor receptors on murine hematopoietic progenitor cell lines. *Blood* 77, 1706-1716.
- Jaffredo, T., Bollerot, K., Sugiyama, D., Gautier, R., and Drevon, C. (2005). Tracing the hemangioblast during embryogenesis: developmental relationships between endothelial and hematopoietic cells. *Int J Dev Biol* 49, 269-277.
- Johansson, B. M., and Wiles, M. V. (1995). Evidence for involvement of activin A and bone morphogenetic protein 4 in mammalian mesoderm and hematopoietic development. *Mol Cell Biol* 15, 141-151.

- Johnson, K., Kirkpatrick, H., Comer, A., Hoffmann, F. M., and Laughon, A. (1999). Interaction of Smad complexes with tripartite DNA-binding sites. *J Biol Chem* *274*, 20709-20716.
- Jordan, C. T., Astle, C. M., Zawadzki, J., Mackarechtschian, K., Lemischka, I. R., and Harrison, D. E. (1995). Long-term repopulating abilities of enriched fetal liver stem cells measured by competitive repopulation. *Exp Hematol* *23*, 1011-1015.
- Karlsson, G., Blank, U., Moody, J. L., Ehinger, M., Singbrant, S., Deng, C. X., and Karlsson, S. (2007). Smad4 is critical for self-renewal of hematopoietic stem cells. *J Exp Med* *204*, 467-474.
- Karlsson, S., Ooka, A., and Woods, N. B. (2002). Development of gene therapy for blood disorders by gene transfer into haematopoietic stem cells. *Haemophilia* *8*, 255-260.
- Katayama, Y., Battista, M., Kao, W. M., Hidalgo, A., Peired, A. J., Thomas, S. A., and Frenette, P. S. (2006). Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow. *Cell* *124*, 407-421.
- Kaushansky, K. (2005). Thrombopoietin and the hematopoietic stem cell. *Ann N Y Acad Sci* *1044*, 139-141.
- Kawabata, M., Imamura, T., and Miyazono, K. (1998). Signal transduction by bone morphogenetic proteins. *Cytokine Growth Factor Rev* *9*, 49-61.
- Kay, M. A., Glorioso, J. C., and Naldini, L. (2001). Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. *Nat Med* *7*, 33-40.
- Keller, J. R., McNiece, I. K., Sill, K. T., Ellingsworth, L. R., Quesenberry, P. J., Sing, G. K., and Ruscetti, F. W. (1990). Transforming growth factor beta directly regulates primitive murine hematopoietic cell proliferation. *Blood* *75*, 596-602.
- Kiel, M. J., Yilmaz, O. H., Iwashita, T., Yilmaz, O. H., Terhorst, C., and Morrison, S. J. (2005). SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. *Cell* *121*, 1109-1121.
- Kim, I., He, S., Yilmaz, O. H., Kiel, M. J., and Morrison, S. J. (2006). Enhanced purification of fetal liver hematopoietic stem cells using SLAM family receptors. *Blood* *108*, 737-744.
- Kim, S. J., and Letterio, J. (2003). Transforming growth factor-beta signaling in normal and malignant hematopoiesis. *Leukemia* *17*, 1731-1737.
- Kimura, N., Matsuo, R., Shibuya, H., Nakashima, K., and Taga, T. (2000). BMP2-induced apoptosis is mediated by activation of the TAK1-p38 kinase pathway that is negatively regulated by Smad6. *J Biol Chem* *275*, 17647-17652.
- Kimura, S., Roberts, A. W., Metcalf, D., and Alexander, W. S. (1998). Hematopoietic stem cell deficiencies in mice lacking c-Mpl, the receptor for thrombopoietin. *Proc Natl Acad Sci U S A* *95*, 1195-1200.
- Kirstetter, P., Anderson, K., Porse, B. T., Jacobsen, S. E., and Nerlov, C. (2006). Activation of the canonical Wnt pathway leads to loss of hematopoietic stem cell repopulation and multilineage differentiation block. *Nat Immunol* *7*, 1048-1056.

Kondo, M., Scherer, D. C., Miyamoto, T., King, A. G., Akashi, K., Sugamura, K., and Weissman, I. L. (2000). Cell-fate conversion of lymphoid-committed progenitors by instructive actions of cytokines. *Nature* 407, 383-386.

Kondo, M., Wagers, A. J., Manz, M. G., Prohaska, S. S., Scherer, D. C., Beilhack, G. F., Shizuru, J. A., and Weissman, I. L. (2003). Biology of hematopoietic stem cells and progenitors: implications for clinical application. *Annu Rev Immunol* 21, 759-806.

Kondo, M., Weissman, I. L., and Akashi, K. (1997). Identification of clonogenic common lymphoid progenitors in mouse bone marrow. *Cell* 91, 661-672.

Kuhn, R., Schwenk, F., Aguet, M., and Rajewsky, K. (1995). Inducible gene targeting in mice. *Science* 269, 1427-1429.

Kulkarni, A. B., Huh, C. G., Becker, D., Geiser, A., Lyght, M., Flanders, K. C., Roberts, A. B., Sporn, M. B., Ward, J. M., and Karlsson, S. (1993). Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. *Proc Natl Acad Sci U S A* 90, 770-774.

Kumaravelu, P., Hook, L., Morrison, A. M., Ure, J., Zhao, S., Zuyev, S., Ansell, J., and Medvinsky, A. (2002). Quantitative developmental anatomy of definitive haematopoietic stem cells/long-term repopulating units (HSC/RUs): role of the aorta-gonad-mesonephros (AGM) region and the yolk sac in colonisation of the mouse embryonic liver. *Development* 129, 4891-4899.

Kunisato, A., Chiba, S., Saito, T., Kumano, K., Nakagami-Yamaguchi, E., Yamaguchi, T., and Hirai, H. (2004). Stem cell leukemia protein directs hematopoietic stem cell fate. *Blood* 103, 3336-3341.

Langer, J. C., Henckaerts, E., Orenstein, J., and Snoeck, H. W. (2004). Quantitative trait analysis reveals transforming growth factor-beta2 as a positive regulator of early hematopoietic progenitor and stem cell function. *J Exp Med* 199, 5-14.

Lansdorp, P. M., Dragowska, W., and Mayani, H. (1993). Ontogeny-related changes in proliferative potential of human hematopoietic cells. *J Exp Med* 178, 787-791.

Lapidot, T., Dar, A., and Kollet, O. (2005). How do stem cells find their way home? *Blood* 106, 1901-1910.

Larsson, J., Blank, U., Helgadottir, H., Bjornsson, J. M., Ehinger, M., Goumans, M. J., Fan, X., Leveen, P., and Karlsson, S. (2003). TGF-beta signaling-deficient hematopoietic stem cells have normal self-renewal and regenerative ability in vivo despite increased proliferative capacity in vitro. *Blood* 102, 3129-3135.

Larsson, J., Blank, U., Klintman, J., Magnusson, M., and Karlsson, S. (2005). Quiescence of hematopoietic stem cells and maintenance of the stem cell pool is not dependent on TGF-beta signaling in vivo. *Exp Hematol* 33, 592-596.

Larsson, J., Goumans, M. J., Sjostrand, L. J., van Rooijen, M. A., Ward, D., Leveen, P., Xu, X., ten Dijke, P., Mummery, C. L., and Karlsson, S. (2001). Abnormal angiogenesis but intact hematopoietic potential in TGF-beta type I receptor-deficient mice. *Embo J* 20, 1663-1673.

- Larsson, J., and Karlsson, S. (2005). The role of Smad signaling in hematopoiesis. *Oncogene* 24, 5676-5692.
- Lastres, P., Bellon, T., Cabanas, C., Sanchez-Madrid, F., Acevedo, A., Gougos, A., Letarte, M., and Bernabeu, C. (1992). Regulated expression on human macrophages of endoglin, an Arg-Gly-Asp-containing surface antigen. *Eur J Immunol* 22, 393-397.
- Lawrence, H. J., Christensen, J., Fong, S., Hu, Y. L., Weissman, I., Sauvageau, G., Humphries, R. K., and Largman, C. (2005). Loss of expression of the Hoxa-9 homeobox gene impairs the proliferation and repopulating ability of hematopoietic stem cells. *Blood* 106, 3988-3994.
- Lebrin, F., Goumans, M. J., Jonker, L., Carvalho, R. L., Valdimarsdottir, G., Thorikay, M., Mummery, C., Arthur, H. M., and ten Dijke, P. (2004). Endoglin promotes endothelial cell proliferation and TGF-beta/ALK1 signal transduction. *Embo J* 23, 4018-4028.
- Lechleider, R. J., Ryan, J. L., Garrett, L., Eng, C., Deng, C., Wynshaw-Boris, A., and Roberts, A. B. (2001). Targeted mutagenesis of Smad1 reveals an essential role in chorioallantoic fusion. *Dev Biol* 240, 157-167.
- Lenox, L. E., Perry, J. M., and Paulson, R. F. (2005). BMP4 and Madh5 regulate the erythroid response to acute anemia. *Blood* 105, 2741-2748.
- Lerner, C., and Harrison, D. E. (1990). 5-Fluorouracil spares hemopoietic stem cells responsible for long-term repopulation. *Exp Hematol* 18, 114-118.
- Letterio, J. J., Geiser, A. G., Kulkarni, A. B., Roche, N. S., Sporn, M. B., and Roberts, A. B. (1994). Maternal rescue of transforming growth factor-beta 1 null mice. *Science* 264, 1936-1938.
- Leveen, P., Larsson, J., Ehinger, M., Cilio, C. M., Sundler, M., Sjostrand, L. J., Holmdahl, R., and Karlsson, S. (2002). Induced disruption of the transforming growth factor beta type II receptor gene in mice causes a lethal inflammatory disorder that is transplantable. *Blood* 100, 560-568.
- Li, C., Issa, R., Kumar, P., Hampson, I. N., Lopez-Novoa, J. M., Bernabeu, C., and Kumar, S. (2003). CD105 prevents apoptosis in hypoxic endothelial cells. *J Cell Sci* 116, 2677-2685.
- Li, C. L., and Johnson, G. R. (1994). Stem cell factor enhances the survival but not the self-renewal of murine hematopoietic long-term repopulating cells. *Blood* 84, 408-414.
- Li, D. Y., Sorensen, L. K., Brooke, B. S., Urness, L. D., Davis, E. C., Taylor, D. G., Boak, B. B., and Wendel, D. P. (1999). Defective angiogenesis in mice lacking endoglin. *Science* 284, 1534-1537.
- Li, W., Chen, F., Nagarajan, R. P., Liu, X., and Chen, Y. (2001). Characterization of the DNA-binding property of Smad5. *Biochem Biophys Res Commun* 286, 1163-1169.
- Liu, B., Sun, Y., Jiang, F., Zhang, S., Wu, Y., Lan, Y., Yang, X., and Mao, N. (2003). Disruption of Smad5 gene leads to enhanced proliferation of high-proliferative potential precursors during embryonic hematopoiesis. *Blood* 101, 124-133.

- Lu, L., Xiao, M., Grigsby, S., Wang, W. X., Wu, B., Shen, R. N., and Broxmeyer, H. E. (1993). Comparative effects of suppressive cytokines on isolated single CD34(3+) stem/progenitor cells from human bone marrow and umbilical cord blood plated with and without serum. *Exp Hematol* 21, 1442-1446.
- Luis, T. C., Weerkamp, F., Naber, B. A., Baert, M. R., de Haas, E. F., Nikolic, T., Heuvelmans, S., De Krijger, R. R., van Dongen, J. J., and Staal, F. J. (2008). Wnt3a deficiency irreversibly impairs hematopoietic stem cell self-renewal and leads to defects in progenitor cell differentiation. *Blood*.
- Lux, C. T., Yoshimoto, M., McGrath, K., Conway, S. J., Palis, J., and Yoder, M. C. (2008). All primitive and definitive hematopoietic progenitor cells emerging before E10 in the mouse embryo are products of the yolk sac. *Blood* 111, 3435-3438.
- Madisen, L., Webb, N. R., Rose, T. M., Marquardt, H., Ikeda, T., Twardzik, D., Seyedin, S., and Purchio, A. F. (1988). Transforming growth factor-beta 2: cDNA cloning and sequence analysis. *DNA* 7, 1-8.
- Maeno, M., Mead, P. E., Kelley, C., Xu, R. H., Kung, H. F., Suzuki, A., Ueno, N., and Zon, L. I. (1996). The role of BMP-4 and GATA-2 in the induction and differentiation of hematopoietic mesoderm in *Xenopus laevis*. *Blood* 88, 1965-1972.
- Maestroni, G. J. (1998). Catecholaminergic regulation of hematopoiesis in mice. *Blood* 92, 2971; author reply 2972-2973.
- Magli, M. C., Iscove, N. N., and Odartchenko, N. (1982). Transient nature of early haematopoietic spleen colonies. *Nature* 295, 527-529.
- Magnusson, M., Brun, A. C., Lawrence, H. J., and Karlsson, S. (2007). Hoxa9/hoxb3/hoxb4 compound null mice display severe hematopoietic defects. *Exp Hematol* 35, 1421-1428.
- Maguer-Satta, V., Bartholin, L., Jeanpierre, S., Ffrench, M., Martel, S., Magaud, J. P., and Rimokh, R. (2003). Regulation of human erythropoiesis by activin A, BMP2, and BMP4, members of the TGFbeta family. *Exp Cell Res* 282, 110-120.
- Maguer-Satta, V., Bartholin, L., Jeanpierre, S., Gadoux, M., Bertrand, S., Martel, S., Magaud, J. P., and Rimokh, R. (2001). Expression of FLRG, a novel activin A ligand, is regulated by TGF-beta and during hematopoiesis [corrected]. *Exp Hematol* 29, 301-308.
- Majeti, R., Park, C. Y., and Weissman, I. L. (2007). Identification of a hierarchy of multipotent hematopoietic progenitors in human cord blood. *Cell Stem Cell* 1, 635-645.
- Mancini, S. J., Mantei, N., Dumortier, A., Suter, U., MacDonald, H. R., and Radtke, F. (2005). Jagged1-dependent Notch signaling is dispensable for hematopoietic stem cell self-renewal and differentiation. *Blood* 105, 2340-2342.
- Manz, M. G., Traver, D., Miyamoto, T., Weissman, I. L., and Akashi, K. (2001). Dendritic cell potentials of early lymphoid and myeloid progenitors. *Blood* 97, 3333-3341.
- Markoulaki, S., Meissner, A., and Jaenisch, R. (2008). Somatic cell nuclear transfer and derivation of embryonic stem cells in the mouse. *Methods* 45, 101-114.

- Martin, M. A., and Bhatia, M. (2005). Analysis of the human fetal liver hematopoietic microenvironment. *Stem Cells Dev* 14, 493-504.
- Massague, J. (2000). How cells read TGF-beta signals. *Nat Rev Mol Cell Biol* 1, 169-178.
- Massague, J., Blain, S. W., and Lo, R. S. (2000). TGFbeta signaling in growth control, cancer, and heritable disorders. *Cell* 103, 295-309.
- Massague, J., Seoane, J., and Wotton, D. (2005). Smad transcription factors. *Genes Dev* 19, 2783-2810.
- Matsubara, A., Iwama, A., Yamazaki, S., Furuta, C., Hirasawa, R., Morita, Y., Osawa, M., Motohashi, T., Eto, K., Ema, H., *et al.* (2005). Endomucin, a CD34-like sialomucin, marks hematopoietic stem cells throughout development. *J Exp Med* 202, 1483-1492.
- Matsuzaki, Y., Kinjo, K., Mulligan, R. C., and Okano, H. (2004). Unexpectedly efficient homing capacity of purified murine hematopoietic stem cells. *Immunity* 20, 87-93.
- Matsuzaki, Y., Nakayama, K., Tomita, T., Isoda, M., Loh, D. Y., and Nakauchi, H. (1997). Role of bcl-2 in the development of lymphoid cells from the hematopoietic stem cell. *Blood* 89, 853-862.
- McAllister, K. A., Grogg, K. M., Johnson, D. W., Gallione, C. J., Baldwin, M. A., Jackson, C. E., Helmbold, E. A., Markel, D. S., McKinnon, W. C., Murrell, J., and *et al.* (1994). Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. *Nat Genet* 8, 345-351.
- McReynolds, L. J., Gupta, S., Figueroa, M. E., Mullins, M. C., and Evans, T. (2007). Smad1 and Smad5 differentially regulate embryonic hematopoiesis. *Blood* 110, 3881-3890.
- Medvinsky, A., and Dzierzak, E. (1996). Definitive hematopoiesis is autonomously initiated by the AGM region. *Cell* 86, 897-906.
- Mikkola, H. K., Klintman, J., Yang, H., Hock, H., Schlaeger, T. M., Fujiwara, Y., and Orkin, S. H. (2003). Haematopoietic stem cells retain long-term repopulating activity and multipotency in the absence of stem-cell leukaemia SCL/tal-1 gene. *Nature* 421, 547-551.
- Mikkola, H. K., and Orkin, S. H. (2006). The journey of developing hematopoietic stem cells. *Development* 133, 3733-3744.
- Miller, C. L., and Eaves, C. J. (1997). Expansion in vitro of adult murine hematopoietic stem cells with transplantable lympho-myeloid reconstituting ability. *Proc Natl Acad Sci U S A* 94, 13648-13653.
- Mishina, Y., Suzuki, A., Ueno, N., and Behringer, R. R. (1995). Bmpr encodes a type I bone morphogenetic protein receptor that is essential for gastrulation during mouse embryogenesis. *Genes Dev* 9, 3027-3037.
- Miyake, N., Brun, A. C., Magnusson, M., Miyake, K., Scadden, D. T., and Karlsson, S. (2006). HOXB4-induced self-renewal of hematopoietic stem cells is significantly enhanced by p21 deficiency. *Stem Cells* 24, 653-661.

- Miyamoto, K., Araki, K. Y., Naka, K., Arai, F., Takubo, K., Yamazaki, S., Matsuoka, S., Miyamoto, T., Ito, K., Ohmura, M., *et al.* (2007). Foxo3a is essential for maintenance of the hematopoietic stem cell pool. *Cell Stem Cell* 1, 101-112.
- Miyamoto, T., Iwasaki, H., Reizis, B., Ye, M., Graf, T., Weissman, I. L., and Akashi, K. (2002). Myeloid or lymphoid promiscuity as a critical step in hematopoietic lineage commitment. *Dev Cell* 3, 137-147.
- Miyan, J. A., Broome, C. S., and Whetton, A. D. (1998). Neural regulation of bone marrow. *Blood* 92, 2971-2973.
- Miyazawa, K., Williams, D. A., Gotoh, A., Nishimaki, J., Broxmeyer, H. E., and Toyama, K. (1995). Membrane-bound Steel factor induces more persistent tyrosine kinase activation and longer life span of c-kit gene-encoded protein than its soluble form. *Blood* 85, 641-649.
- Monteiro, R. M., de Sousa Lopes, S. M., Korchynskyi, O., ten Dijke, P., and Mummery, C. L. (2004). Spatio-temporal activation of Smad1 and Smad5 in vivo: monitoring transcriptional activity of Smad proteins. *J Cell Sci* 117, 4653-4663.
- Moody, J. L., Singbrant, S., Karlsson, G., Blank, U., Aspling, M., Flygare, J., Bryder, D., and Karlsson, S. (2007). Endoglin is not critical for hematopoietic stem cell engraftment and reconstitution but regulates adult erythroid development. *Stem Cells* 25, 2809-2819.
- Morrison, S. J., Hemmati, H. D., Wandycz, A. M., and Weissman, I. L. (1995). The purification and characterization of fetal liver hematopoietic stem cells. *Proc Natl Acad Sci U S A* 92, 10302-10306.
- Morrison, S. J., and Kimble, J. (2006). Asymmetric and symmetric stem-cell divisions in development and cancer. *Nature* 441, 1068-1074.
- Morrison, S. J., Wandycz, A. M., Hemmati, H. D., Wright, D. E., and Weissman, I. L. (1997a). Identification of a lineage of multipotent hematopoietic progenitors. *Development* 124, 1929-1939.
- Morrison, S. J., and Weissman, I. L. (1994). The long-term repopulating subset of hematopoietic stem cells is deterministic and isolatable by phenotype. *Immunity* 1, 661-673.
- Morrison, S. J., Wright, D. E., and Weissman, I. L. (1997b). Cyclophosphamide/granulocyte colony-stimulating factor induces hematopoietic stem cells to proliferate prior to mobilization. *Proc Natl Acad Sci U S A* 94, 1908-1913.
- Muller-Sieburg, C. E., and Sieburg, H. B. (2006). The GOD of hematopoietic stem cells: a clonal diversity model of the stem cell compartment. *Cell Cycle* 5, 394-398.
- Neff, T., Beard, B. C., and Kiem, H. P. (2006). Survival of the fittest: in vivo selection and stem cell gene therapy. *Blood* 107, 1751-1760.
- Neschadim, A., McCart, J. A., Keating, A., and Medin, J. A. (2007). A roadmap to safe, efficient, and stable lentivirus-mediated gene therapy with hematopoietic cell transplantation. *Biol Blood Marrow Transplant* 13, 1407-1416.
- Niehrs, C. (2004). Regionally specific induction by the Spemann-Mangold organizer. *Nat Rev Genet* 5, 425-434.

Nilsson, S. K., Dooner, M. S., Tiarks, C. Y., Weier, H. U., and Quesenberry, P. J. (1997). Potential and distribution of transplanted hematopoietic stem cells in a nonablated mouse model. *Blood* 89, 4013-4020.

Nilsson, S. K., Haylock, D. N., Johnston, H. M., Occhiodoro, T., Brown, T. J., and Simmons, P. J. (2003). Hyaluronan is synthesized by primitive hemopoietic cells, participates in their lodgment at the endosteum following transplantation, and is involved in the regulation of their proliferation and differentiation in vitro. *Blood* 101, 856-862.

Nilsson, S. K., Johnston, H. M., and Coverdale, J. A. (2001). Spatial localization of transplanted hemopoietic stem cells: inferences for the localization of stem cell niches. *Blood* 97, 2293-2299.

Nilsson, S. K., Johnston, H. M., Whitty, G. A., Williams, B., Webb, R. J., Denhardt, D. T., Bertoncello, I., Bendall, L. J., Simmons, P. J., and Haylock, D. N. (2005). Osteopontin, a key component of the hematopoietic stem cell niche and regulator of primitive hematopoietic progenitor cells. *Blood* 106, 1232-1239.

Nygren, J. M., Bryder, D., and Jacobsen, S. E. (2006). Prolonged cell cycle transit is a defining and developmentally conserved hemopoietic stem cell property. *J Immunol* 177, 201-208.

Ogawa, M. (1993). Differentiation and proliferation of hematopoietic stem cells. *Blood* 81, 2844-2853.

Ogawa, M. (2002). Changing phenotypes of hematopoietic stem cells. *Exp Hematol* 30, 3-6.
Ogawa, M., Tajima, F., Ito, T., Sato, T., Laver, J. H., and Deguchi, T. (2001). CD34 expression by murine hematopoietic stem cells. Developmental changes and kinetic alterations. *Ann N Y Acad Sci* 938, 139-145.

Oguro, H., Iwama, A., Morita, Y., Kamijo, T., van Lohuizen, M., and Nakauchi, H. (2006). Differential impact of Ink4a and Arf on hematopoietic stem cells and their bone marrow microenvironment in Bmi1-deficient mice. *J Exp Med* 203, 2247-2253.

Ohneda, O., Fennie, C., Zheng, Z., Donahue, C., La, H., Villacorta, R., Cairns, B., and Lasky, L. A. (1998). Hematopoietic stem cell maintenance and differentiation are supported by embryonic aorta-gonad-mesonephros region-derived endothelium. *Blood* 92, 908-919.

Okada, S., Nakauchi, H., Nagayoshi, K., Nishikawa, S., Miura, Y., and Suda, T. (1992). In vivo and in vitro stem cell function of c-kit- and Sca-1-positive murine hematopoietic cells. *Blood* 80, 3044-3050.

Okada, S., Nakauchi, H., Nagayoshi, K., Nishikawa, S., Nishikawa, S., Miura, Y., and Suda, T. (1991). Enrichment and characterization of murine hematopoietic stem cells that express c-kit molecule. *Blood* 78, 1706-1712.

Okuda, T., van Deursen, J., Hiebert, S. W., Grosveld, G., and Downing, J. R. (1996). AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. *Cell* 84, 321-330.

Opferman, J. T., Iwasaki, H., Ong, C. C., Suh, H., Mizuno, S., Akashi, K., and Korsmeyer, S. J. (2005). Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells. *Science* 307, 1101-1104.

Orkin, S. H. (2000). Diversification of haematopoietic stem cells to specific lineages. *Nat Rev Genet* 1, 57-64.

Osawa, M., Hanada, K., Hamada, H., and Nakauchi, H. (1996). Long-term lymphohematopoietic reconstitution by a single CD34-low/negative hematopoietic stem cell. *Science* 273, 242-245.

Oshima, M., Oshima, H., and Taketo, M. M. (1996). TGF-beta receptor type II deficiency results in defects of yolk sac hematopoiesis and vasculogenesis. *Dev Biol* 179, 297-302.

Ottersbach, K., and Dzierzak, E. (2005). The murine placenta contains hematopoietic stem cells within the vascular labyrinth region. *Dev Cell* 8, 377-387.

Palis, J., and Yoder, M. C. (2001). Yolk-sac hematopoiesis: the first blood cells of mouse and man. *Exp Hematol* 29, 927-936.

Papayannopoulou, T., Craddock, C., Nakamoto, B., Priestley, G. V., and Wolf, N. S. (1995). The VLA4/VCAM-1 adhesion pathway defines contrasting mechanisms of lodgement of transplanted murine hemopoietic progenitors between bone marrow and spleen. *Proc Natl Acad Sci U S A* 92, 9647-9651.

Park, C., Afrikanova, I., Chung, Y. S., Zhang, W. J., Arentson, E., Fong Gh, G., Rosendahl, A., and Choi, K. (2004). A hierarchical order of factors in the generation of FLK1- and SCL-expressing hematopoietic and endothelial progenitors from embryonic stem cells. *Development* 131, 2749-2762.

Park, I. K., Qian, D., Kiel, M., Becker, M. W., Pihalja, M., Weissman, I. L., Morrison, S. J., and Clarke, M. F. (2003). Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. *Nature* 423, 302-305.

Passegue, E., Wagers, A. J., Giuriato, S., Anderson, W. C., and Weissman, I. L. (2005). Global analysis of proliferation and cell cycle gene expression in the regulation of hematopoietic stem and progenitor cell fates. *J Exp Med* 202, 1599-1611.

Pearson, S., Sroczynska, P., Lacaud, G., and Kouskoff, V. (2008). The stepwise specification of embryonic stem cells to hematopoietic fate is driven by sequential exposure to Bmp4, activin A, bFGF and VEGF. *Development* 135, 1525-1535.

Pece-Barbara, N., Vera, S., Kathirkamathamby, K., Liebner, S., Di Guglielmo, G. M., Dejana, E., Wrana, J. L., and Letarte, M. (2005). Endoglin null endothelial cells proliferate faster and are more responsive to transforming growth factor beta1 with higher affinity receptors and an activated Alk1 pathway. *J Biol Chem* 280, 27800-27808.

Perez-Gomez, E., Eleno, N., Lopez-Novoa, J. M., Ramirez, J. R., Velasco, B., Letarte, M., Bernabeu, C., and Quintanilla, M. (2005). Characterization of murine S-endoglin isoform and its effects on tumor development. *Oncogene* 24, 4450-4461.

Perlingeiro, R. C. (2007). Endoglin is required for hemangioblast and early hematopoietic development. *Development* 134, 3041-3048.

Petit, I., Szyper-Kravitz, M., Nagler, A., Lahav, M., Peled, A., Habler, L., Ponomaryov, T., Taichman, R. S., Arenzana-Seisdedos, F., Fujii, N., *et al.* (2002). G-CSF induces stem cell

mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. *Nat Immunol* 3, 687-694.

Pierelli, L., Scambia, G., Bonanno, G., Rutella, S., Puggioni, P., Battaglia, A., Mozzetti, S., Marone, M., Menichella, G., Rumi, C., *et al.* (2000). CD34⁺/CD105⁺ cells are enriched in primitive circulating progenitors residing in the G0 phase of the cell cycle and contain all bone marrow and cord blood CD34⁺/CD38^{low/-} precursors. *Br J Haematol* 108, 610-620.

Pronk, C. J., Rossi, D. J., Mansson, R., Attema, J. L., Norddahl, G. L., Chan, C. K., Sigvardsson, M., Weissman, I. L., and Bryder, D. (2007). Elucidation of the phenotypic, functional, and molecular topography of a myeloerythroid progenitor cell hierarchy. *Cell Stem Cell* 1, 428-442.

Purton, L. E., and Scadden, D. T. (2007). Limiting factors in murine hematopoietic stem cell assays. *Cell Stem Cell* 1, 263-270.

Rampon, C., and Huber, P. (2003). Multilineage hematopoietic progenitor activity generated autonomously in the mouse yolk sac: analysis using angiogenesis-defective embryos. *Int J Dev Biol* 47, 273-280.

Randall, T. D., and Weissman, I. L. (1997). Phenotypic and functional changes induced at the clonal level in hematopoietic stem cells after 5-fluorouracil treatment. *Blood* 89, 3596-3606.

Reya, T., Duncan, A. W., Ailles, L., Domen, J., Scherer, D. C., Willert, K., Hintz, L., Nusse, R., and Weissman, I. L. (2003). A role for Wnt signalling in self-renewal of haematopoietic stem cells. *Nature* 423, 409-414.

Reya, T., Morrison, S. J., Clarke, M. F., and Weissman, I. L. (2001). Stem cells, cancer, and cancer stem cells. *Nature* 414, 105-111.

Robb, L., Lyons, I., Li, R., Hartley, L., Kontgen, F., Harvey, R. P., Metcalf, D., and Begley, C. G. (1995). Absence of yolk sac hematopoiesis from mice with a targeted disruption of the *scl* gene. *Proc Natl Acad Sci U S A* 92, 7075-7079.

Roberts, A. W., and Metcalf, D. (1995). Noncycling state of peripheral blood progenitor cells mobilized by granulocyte colony-stimulating factor and other cytokines. *Blood* 86, 1600-1605.

Rokhlin, O. W., Cohen, M. B., Kubagawa, H., Letarte, M., and Cooper, M. D. (1995). Differential expression of endoglin on fetal and adult hematopoietic cells in human bone marrow. *J Immunol* 154, 4456-4465.

Ruscetti, F. W., Akel, S., and Bartelmez, S. H. (2005). Autocrine transforming growth factor-beta regulation of hematopoiesis: many outcomes that depend on the context. *Oncogene* 24, 5751-5763.

Ruscetti, F. W., and Bartelmez, S. H. (2001). Transforming growth factor beta, pleiotropic regulator of hematopoietic stem cells: potential physiological and clinical relevance. *Int J Hematol* 74, 18-25.

Sabin, F. R. (2002). Preliminary note on the differentiation of angioblasts and the method by which they produce blood-vessels, blood-plasma and red blood-cells as seen in the living chick. 1917. *J Hematother Stem Cell Res* 11, 5-7.

Sacchetti, B., Funari, A., Michienzi, S., Di Cesare, S., Piersanti, S., Saggio, I., Tagliafico, E., Ferrari, S., Robey, P. G., Riminucci, M., and Bianco, P. (2007). Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. *Cell* 131, 324-336.

Sadlon, T. J., Lewis, I. D., and D'Andrea, R. J. (2004). BMP4: its role in development of the hematopoietic system and potential as a hematopoietic growth factor. *Stem Cells* 22, 457-474.

Samokhvalov, I. M., Samokhvalova, N. I., and Nishikawa, S. (2007). Cell tracing shows the contribution of the yolk sac to adult haematopoiesis. *Nature* 446, 1056-1061.

Sanchez-Elsner, T., Botella, L. M., Velasco, B., Langa, C., and Bernabeu, C. (2002). Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-beta pathways. *J Biol Chem* 277, 43799-43808.

Sato, T., Selleri, C., Young, N. S., and Maciejewski, J. P. (1995). Hematopoietic inhibition by interferon-gamma is partially mediated through interferon regulatory factor-1. *Blood* 86, 3373-3380.

Satoh, Y., Matsumura, I., Tanaka, H., Ezoe, S., Sugahara, H., Mizuki, M., Shibayama, H., Ishiko, E., Ishiko, J., Nakajima, K., and Kanakura, Y. (2004). Roles for c-Myc in self-renewal of hematopoietic stem cells. *J Biol Chem* 279, 24986-24993.

Sauer, B. (1998). Inducible gene targeting in mice using the Cre/lox system. *Methods* 14, 381-392.

Sauvageau, G., Thorsteinsdottir, U., Eaves, C. J., Lawrence, H. J., Largman, C., Lansdorp, P. M., and Humphries, R. K. (1995). Overexpression of HOXB4 in hematopoietic cells causes the selective expansion of more primitive populations in vitro and in vivo. *Genes Dev* 9, 1753-1765.

Scandura, J. M., Bocconi, P., Massague, J., and Nimer, S. D. (2004). Transforming growth factor beta-induced cell cycle arrest of human hematopoietic cells requires p57KIP2 up-regulation. *Proc Natl Acad Sci U S A* 101, 15231-15236.

Schmidt-Weber, C. B., Letarte, M., Kunzmann, S., Ruckert, B., Bernabeu, C., and Blaser, K. (2005). TGF- β signaling of human T cells is modulated by the ancillary TGF- β receptor endoglin. *Int Immunol* 17, 921-930.

Schofield, R. (1978). The relationship between the spleen colony-forming cell and the haemopoietic stem cell. *Blood Cells* 4, 7-25.

Shav-Tal, Y., and Zipori, D. (2002). The role of activin a in regulation of hemopoiesis. *Stem Cells* 20, 493-500.

Shi, Y. (2003). Mammalian RNAi for the masses. *Trends Genet* 19, 9-12.

Shi, Y., and Massague, J. (2003). Mechanisms of TGF-beta signaling from cell membrane to the nucleus. *Cell* 113, 685-700.

Shoham, T., Parameswaran, R., Shav-Tal, Y., Barda-Saad, M., and Zipori, D. (2003). The mesenchymal stroma negatively regulates B cell lymphopoiesis through the expression of activin A. *Ann N Y Acad Sci* 996, 245-260.

Shroyer, N. F., and Wong, M. H. (2007). BMP signaling in the intestine: cross-talk is key. *Gastroenterology* 133, 1035-1038.

Shull, M. M., Ormsby, I., Kier, A. B., Pawlowski, S., Diebold, R. J., Yin, M., Allen, R., Sidman, C., Proetzel, G., Calvin, D., and et al. (1992). Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. *Nature* 359, 693-699.

Siminovitch, L., McCulloch, E. A., and Till, J. E. (1963). The Distribution of Colony-Forming Cells among Spleen Colonies. *J Cell Physiol* 62, 327-336.

Singbrant, S., Moody, J. L., Blank, U., Karlsson, G., Umans, L., Zwijsen, A., and Karlsson, S. (2006). Smad5 is dispensable for adult murine hematopoiesis. *Blood* 108, 3707-3712.

Sitnicka, E., Ruscetti, F. W., Priestley, G. V., Wolf, N. S., and Bartelmez, S. H. (1996). Transforming growth factor beta 1 directly and reversibly inhibits the initial cell divisions of long-term repopulating hematopoietic stem cells. *Blood* 88, 82-88.

Snyder, A., Fraser, S. T., and Baron, M. H. (2004). Bone morphogenetic proteins in vertebrate hematopoietic development. *J Cell Biochem* 93, 224-232.

Spangrude, G. J., Heimfeld, S., and Weissman, I. L. (1988). Purification and characterization of mouse hematopoietic stem cells. *Science* 241, 58-62.

Staal, F. J., and Clevers, H. C. (2005). WNT signalling and haematopoiesis: a WNT-WNT situation. *Nat Rev Immunol* 5, 21-30.

Stadtfeld, M., and Graf, T. (2005). Assessing the role of hematopoietic plasticity for endothelial and hepatocyte development by non-invasive lineage tracing. *Development* 132, 203-213.

Stier, S., Cheng, T., Dombkowski, D., Carlesso, N., and Scadden, D. T. (2002). Notch1 activation increases hematopoietic stem cell self-renewal in vivo and favors lymphoid over myeloid lineage outcome. *Blood* 99, 2369-2378.

Stier, S., Ko, Y., Forkert, R., Lutz, C., Neuhaus, T., Grunewald, E., Cheng, T., Dombkowski, D., Calvi, L. M., Rittling, S. R., and Scadden, D. T. (2005). Osteopontin is a hematopoietic stem cell niche component that negatively regulates stem cell pool size. *J Exp Med* 201, 1781-1791.

Stiles, B., Groszer, M., Wang, S., Jiao, J., and Wu, H. (2004). PTENless means more. *Dev Biol* 273, 175-184.

Sugiyama, T., Kohara, H., Noda, M., and Nagasawa, T. (2006). Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. *Immunity* 25, 977-988.

Szilvassy, S. J., Humphries, R. K., Lansdorp, P. M., Eaves, A. C., and Eaves, C. J. (1990). Quantitative assay for totipotent reconstituting hematopoietic stem cells by a competitive repopulation strategy. *Proc Natl Acad Sci U S A* 87, 8736-8740.

Taichman, R. S., and Emerson, S. G. (1994). Human osteoblasts support hematopoiesis through the production of granulocyte colony-stimulating factor. *J Exp Med* 179, 1677-1682.

Taichman, R. S., Reilly, M. J., Verma, R. S., and Emerson, S. G. (1997). Augmented production of interleukin-6 by normal human osteoblasts in response to CD34+ hematopoietic bone marrow cells in vitro. *Blood* 89, 1165-1172.

Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., and Yamanaka, S. (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell* 131, 861-872.

Takahashi, K., and Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell* 126, 663-676.

ten Dijke, P., Hansen, P., Iwata, K. K., Pieler, C., and Foulkes, J. G. (1988). Identification of another member of the transforming growth factor type beta gene family. *Proc Natl Acad Sci U S A* 85, 4715-4719.

ten Dijke, P., and Hill, C. S. (2004). New insights into TGF-beta-Smad signalling. *Trends Biochem Sci* 29, 265-273.

Thomas, E. D., Lochte, H. L., Jr., Cannon, J. H., Sahler, O. D., and Ferrebee, J. W. (1959). Supralethal whole body irradiation and isologous marrow transplantation in man. *J Clin Invest* 38, 1709-1716.

Thoren, L. A., Liuba, K., Bryder, D., Nygren, J. M., Jensen, C. T., Qian, H., Antonchuk, J., and Jacobsen, S. E. (2008). Kit regulates maintenance of quiescent hematopoietic stem cells. *J Immunol* 180, 2045-2053.

Till, J. E., and McCulloch, E. A. (1961). A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. *Radiat Res* 14, 213-222.

Tremblay, K. D., Dunn, N. R., and Robertson, E. J. (2001). Mouse embryos lacking Smad1 signals display defects in extra-embryonic tissues and germ cell formation. *Development* 128, 3609-3621.

Uchida, N., He, D., Frier, A. M., Reitsma, M., Sasaki, D., Chen, B., and Tsukamoto, A. (1997). The unexpected G0/G1 cell cycle status of mobilized hematopoietic stem cells from peripheral blood. *Blood* 89, 465-472.

Umans, L., Vermeire, L., Francis, A., Chang, H., Huylebroeck, D., and Zwijsen, A. (2003). Generation of a floxed allele of Smad5 for cre-mediated conditional knockout in the mouse. *Genesis* 37, 5-11.

Urist, M. R. (1965). Bone: formation by autoinduction. *Science* 150, 893-899.

Utsugisawa, T., Moody, J. L., Aspling, M., Nilsson, E., Carlsson, L., and Karlsson, S. (2006). A road map toward defining the role of Smad signaling in hematopoietic stem cells. *Stem Cells* 24, 1128-1136.

Walkley, C. R., Fero, M. L., Chien, W. M., Purton, L. E., and McArthur, G. A. (2005). Negative cell-cycle regulators cooperatively control self-renewal and differentiation of haematopoietic stem cells. *Nat Cell Biol* 7, 172-178.

Walkley, C. R., and Orkin, S. H. (2006). Rb is dispensable for self-renewal and multilineage differentiation of adult hematopoietic stem cells. *Proc Natl Acad Sci U S A* 103, 9057-9062.

van Os, R., Kamminga, L. M., and de Haan, G. (2004). Stem cell assays: something old, something new, something borrowed. *Stem Cells* 22, 1181-1190.

Wang, L. C., Kuo, F., Fujiwara, Y., Gilliland, D. G., Golub, T. R., and Orkin, S. H. (1997). Yolk sac angiogenic defect and intra-embryonic apoptosis in mice lacking the Ets-related factor TEL. *Embo J* 16, 4374-4383.

Watchman, C. J., Bourke, V. A., Lyon, J. R., Knowlton, A. E., Butler, S. L., Grier, D. D., Wingard, J. R., Braylan, R. C., and Bolch, W. E. (2007). Spatial distribution of blood vessels and CD34+ hematopoietic stem and progenitor cells within the marrow cavities of human cancellous bone. *J Nucl Med* 48, 645-654.

Weekx, S. F., Plum, J., Van Cauwelaert, P., Lenjou, M., Nijs, G., De Smedt, M., Vanhove, M., Muylaert, P., Van Bockstaele, D. R., Berneman, Z. N., and Snoeck, H. W. (1999). Developmentally regulated responsiveness to transforming growth factor-beta is correlated with functional differences between human adult and fetal primitive hematopoietic progenitor cells. *Leukemia* 13, 1266-1272.

Willert, K., Brown, J. D., Danenberg, E., Duncan, A. W., Weissman, I. L., Reya, T., Yates, J. R., 3rd, and Nusse, R. (2003). Wnt proteins are lipid-modified and can act as stem cell growth factors. *Nature* 423, 448-452.

Wilson, A., Laurenti, E., Oser, G., van der Wath, R. C., Blanco-Bose, W., Jaworski, M., Offner, S., Dunant, C. F., Eshkind, L., Bockamp, E., *et al.* (2008). Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair. *Cell* 135, 1118-1129.

Wilson, A., Murphy, M. J., Oskarsson, T., Kaloulis, K., Bettess, M. D., Oser, G. M., Pasche, A. C., Knabenhans, C., Macdonald, H. R., and Trumpp, A. (2004). c-Myc controls the balance between hematopoietic stem cell self-renewal and differentiation. *Genes Dev* 18, 2747-2763.

Wilson, A., Oser, G. M., Jaworski, M., Blanco-Bose, W. E., Laurenti, E., Adolphe, C., Essers, M. A., Macdonald, H. R., and Trumpp, A. (2007). Dormant and self-renewing hematopoietic stem cells and their niches. *Ann N Y Acad Sci* 1106, 64-75.

Wilson, A., and Trumpp, A. (2006). Bone-marrow haematopoietic-stem-cell niches. *Nat Rev Immunol* 6, 93-106.

Winnier, G., Blessing, M., Labosky, P. A., and Hogan, B. L. (1995). Bone morphogenetic protein-4 is required for mesoderm formation and patterning in the mouse. *Genes Dev* 9, 2105-2116.

Viswanathan, S., and Zandstra, P. W. (2003). Towards predictive models of stem cell fate. *Cytotechnology* 41, 75-92.

Wozney, J. M. (2002). Overview of bone morphogenetic proteins. *Spine* 27, S2-8.

- Wrana, J. L., Attisano, L., Wieser, R., Ventura, F., and Massague, J. (1994). Mechanism of activation of the TGF-beta receptor. *Nature* 370, 341-347.
- Wright, D. E., Wagers, A. J., Gulati, A. P., Johnson, F. L., and Weissman, I. L. (2001). Physiological migration of hematopoietic stem and progenitor cells. *Science* 294, 1933-1936.
- Wu, A. M., Siminovitch, L., Till, J. E., and McCulloch, E. A. (1968). Evidence for a relationship between mouse hemopoietic stem cells and cells forming colonies in culture. *Proc Natl Acad Sci U S A* 59, 1209-1215.
- Yagi, M., Ritchie, K. A., Sitnicka, E., Storey, C., Roth, G. J., and Bartelmez, S. (1999). Sustained ex vivo expansion of hematopoietic stem cells mediated by thrombopoietin. *Proc Natl Acad Sci U S A* 96, 8126-8131.
- Yamazaki, K., and Allen, T. D. (1990). Ultrastructural morphometric study of efferent nerve terminals on murine bone marrow stromal cells, and the recognition of a novel anatomical unit: the "neuro-reticular complex". *Am J Anat* 187, 261-276.
- Yang, L., Bryder, D., Adolfsson, J., Nygren, J., Mansson, R., Sigvardsson, M., and Jacobsen, S. E. (2005). Identification of Lin(-)Sca1(+)kit(+)CD34(+)Flt3- short-term hematopoietic stem cells capable of rapidly reconstituting and rescuing myeloablated transplant recipients. *Blood* 105, 2717-2723.
- Yang, X., Castilla, L. H., Xu, X., Li, C., Gotay, J., Weinstein, M., Liu, P. P., and Deng, C. X. (1999). Angiogenesis defects and mesenchymal apoptosis in mice lacking SMAD5. *Development* 126, 1571-1580.
- Yilmaz, O. H., Kiel, M. J., and Morrison, S. J. (2006a). SLAM family markers are conserved among hematopoietic stem cells from old and reconstituted mice and markedly increase their purity. *Blood* 107, 924-930.
- Yilmaz, O. H., Valdez, R., Theisen, B. K., Guo, W., Ferguson, D. O., Wu, H., and Morrison, S. J. (2006b). Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. *Nature* 441, 475-482.
- Yoder, M. C., and Hiatt, K. (1997). Engraftment of embryonic hematopoietic cells in conditioned newborn recipients. *Blood* 89, 2176-2183.
- Yu, H., Yuan, Y., Shen, H., and Cheng, T. (2006). Hematopoietic stem cell exhaustion impacted by p18 INK4C and p21 Cip1/Waf1 in opposite manners. *Blood* 107, 1200-1206.
- Yuan, Y., Shen, H., Franklin, D. S., Scadden, D. T., and Cheng, T. (2004). In vivo self-renewing divisions of haematopoietic stem cells are increased in the absence of the early G1-phase inhibitor, p18INK4C. *Nat Cell Biol* 6, 436-442.
- Zeng, H., Yucel, R., Kosan, C., Klein-Hitpass, L., and Moroy, T. (2004). Transcription factor Gfi1 regulates self-renewal and engraftment of hematopoietic stem cells. *Embo J* 23, 4116-4125.
- Zhang, C. C., Kaba, M., Ge, G., Xie, K., Tong, W., Hug, C., and Lodish, H. F. (2006a). Angiopoietin-like proteins stimulate ex vivo expansion of hematopoietic stem cells. *Nat Med* 12, 240-245.

Zhang, C. C., and Lodish, H. F. (2005). Murine hematopoietic stem cells change their surface phenotype during ex vivo expansion. *Blood* *105*, 4314-4320.

Zhang, H., and Bradley, A. (1996). Mice deficient for BMP2 are nonviable and have defects in amnion/chorion and cardiac development. *Development* *122*, 2977-2986.

Zhang, J., Grindley, J. C., Yin, T., Jayasinghe, S., He, X. C., Ross, J. T., Haug, J. S., Rupp, D., Porter-Westpfahl, K. S., Wiedemann, L. M., *et al.* (2006b). PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. *Nature* *441*, 518-522.

Zhang, J., Niu, C., Ye, L., Huang, H., He, X., Tong, W. G., Ross, J., Haug, J., Johnson, T., Feng, J. Q., *et al.* (2003). Identification of the haematopoietic stem cell niche and control of the niche size. *Nature* *425*, 836-841.

